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ABSTRACT
Hepatitis C VIruS (HCY) infection is characterized by a broad spectrum of clinical
outcomes. An estimated 14%-46% of individuals exposed to HCY are able to clear the
virus, while the other portion develops chronic (persistent) infections. Among the
individuals with chronic HCY who are treated with interferon-based therapies, only a
portion are able experience sustained virological suppression. Similarly, a number of
chronically infected individuals have autoimmune extrahepatic manifestations such as the
presence of autoantibodies. The pathological mechanisms behind these phenomena are not
known, but it is believed that host genetic factors may playa role. This thesis examines the
hypothesis that host genetic factors may contribute to the diverse spectrum of HCY clinical
outcomes. In addition, it examines the pathogenesis of antinuclear antibodies (ANA) in
chronic HCY, and the effect of ANA positivity on the natural history of HCY. Correlations
were observed between female gender and geographic location and ANA positivity. No
relationships were observed for an effect of ANA positivity on response rates to interferon
therapy. We observed a trend of ANA positivity with faster progression of HCY-related
fibrosis, although t his failed to achieve statistical significance. ANA-positive individuals
tended to have more plasma cells in their liver than ANA-negative individuals. This study
also observed a number of correlations between genotypes of the interferon induced genes
encoding the myxovirus resistance 1 protein (MxA), 2'-5'0Iigo-adenylate synthase 1 (OAS-
I), and protein kinase (PKR), as well as genes encoding cytotoxic T-lymphocyte antigen-s
(CTLA4), and inducible nitric oxide synthase (iNOS) (encoded by the NOS2A gene) with
several outcomes including self-limiting versus chronic HCY infection, along with the
response to interferon therapy. This study identified several factors to be correlated with
ANA positivity in HCY. These factors may serve as future points for investigation by basic
scientists understanding the mechanisms ofHCY-mediated autoimmunity. Importantly, this
study suggests that low titre ANA positivity should not be a contraindication to therapy.
This study also highlighted the importance of several genetic pathways in HCY infection.
These may serve as targets for future pharmacologic interventions or genetic tests designed
to screen for those who will not benefit from interferon therapies.
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Chapter 1
Chapter 1
Background: Hepatitis C Epidemiology
and Natural History
1.1 The Hepatitis C Virus
Isolated in 1989, the Hepatitis e virus (HeV) accounts for the majority of cases of non-
A, non B hepatitis.' HeV is a member of the flaviviridae family and is the sole member of
the genus hepacivirus.v' HeV is separated into 6 major genotypes, with several
subtypes.Y
The hepatitis C virus has a single-stranded RNA genome of approximately 9.6
kilobases that encodes a single, large polyprotein of about 3,000 amino acids.' Proteins
encoded by the HeV genome are cleaved post-translationally into multiple structural and
non structural polypeptides (Figure 1.1.1). Structural components include: the nucleocapsid
core (e) and the envelope glycoproteins, El and E2. Nonstructural proteins (NS) include
NS2 through NS5. While it is believed that NS3 has helicase and protease properties, and
that NS5 has polymerase properties that aid in viral replication, the specific functions of the
NS proteins have not been fully elucidated." The 5' and 3' untranslated regions are highly
conserved. The 5' untranslated region has an internal ribosomal entry site for the initiation
20
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Chapter 1
of viral protein translation. The 3' untranslated region has RNA elements that are crucial
for translation and viral replication.i
The study of HCV virology has to an extent, been hampered by the lack of a viable
culture system that allows for the long-term propagation of virus. Furthermore, there are no
simple small animal models of HCV infection. Consequently, the replicative cycle of HCV
has been largely deduced from that of other flaviviruses.i HCV replicates predominantly in
the cytoplasm of hepatocytes.' Recent research, however, has identified the presence of
HCV in other parts of the body, suggesting that while the liver is the main site of viral
replication, there are other parts of the body that may serve as a reservoir. Virion
production in HCV infection is quite high, ranging from 1010 to 1012 virions produced per
day.8 Studies of serum from HCV-infected individuals also suggests that there is a rapid
turn-over of virus, with the predicted half-life of virions being only 2 to 3 hours.t The low
fidelity of HCV viral replication and the rapidity of the production of new virions leads to
the formation of multiple quasispecies within an infected individual. Studies have suggested
that viral genomes may differ by as much as 5% within an individual." 10
HCV may be divided into several genotypes," Differences exist with the global
distribution of these subtypes. HCV subtype 1a and 1b are prevalent in the United States,
Europe and Japan (mainly Ib). Subtypes 2a and 2b are common in North America, Europe
and Japan, with subtype 2c common to northern Italy. Subtype 3a is common among
intravenous drug users (IVDU) in Europe and the United States. Genotype 4 is prevalent in
North Africa and the Middle East. Genotype 5 seems to be confmed to South Africa, and
genotype 6 to Hong Kong. Genotypes 7, 8 and 9 have been seen only in Vietnamese
patients and genotypes 10 and 11 only in Indonesian patients. Debates exist regarding the
classification of genotypes 7-11. Some feel that these should be classified as variants of
genotype 6.3 Figure 1.1.2 summarises the distribution ofHCV genotypes in regions around
the world. Because of the debate surrounding the classification of genotypes 7-11, the
figure is restricted to depicting only genotypes 1-6.
22
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1.2 The Epidemiology of Hepatitis C Virus Infection
Hepatitis e virus infection (HeV) is recognised as a major global public health burden
m the world today, with an estimated 170 million individuals chronically infected
worldwide. Approximately 10 million individuals are chronically infected in Europe
alone.II-13 In the United States (US), HeV is currently the most common chronic blood-
borne disease and the leading indication for a liver transplant.14-16 Population-based
estimates of HeV prevalence based on referral clinic, hospital and blood donor populations
in the United Kingdom suggest that HeV prevalence in the UK is between 0.08% and
0.72%.17-20
The highest prevalence of HeV has been observed in Egypt, where approximately
20% of the population is infected_2I-23The propagation of this epidemic is believed to have
been facilitated by iatrogenic transmission from mass population-based attempts to
eradicate schistosomiasis.f Figure 1.2.1 presents a map with the estimations of HeV
prevalence across the world.
1.3 Risk Factors for the Acquisition of Hepatitis C Virus Infection
Hepatitis e virus (Hey) infection is predominantly transmitted via parenteral
routes. The facility of parenteral transmission is reflected in the high number of infected
individuals who have either injected drugs or who have received blood or blood/products
prior to the development and introduction of routine screening employing the more
sensitive second generation assays for detection of anti-HCV antibodies for hepatitis C in
1992. Similarly, other sources of transmission involving contact with infected blood, such
as haemodialysis was also common prior to the introduction of He V screening.
24
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Subsequent to the introduction of the screening of blood and blood products, injection drug
use has become the major source of HCV transmission. Because the UK does not have a
network for the surveillance of acute hepatitis, I will refer to data on risk factors for HCV
transmission from the Centres for Disease Control and Prevention's (CDC) Sentinel
Counties Surveillance system in the US. This surveillance system examines incident cases
of viral hepatitis in 6 counties throughout the country, and provides an opportunity to
examine the distribution of reported Hev risk factors. Figure 1.3.1 summarises surveillance
data from this surveillance system.
Aside from blood products and injection drug use, other less common routes of
HeV transmission have also been reported. Some of the other routes include, for example,
tattooing or the sharing of equipment for intranasal cocaine use, where blood may be
transmitted from one person to another through tears in the passages of the nasal septum"
It is also possible that self-reported cocaine use may be a surrogate marker for other high
risk behaviours such as past experimentation with injection drugs. In a study by Vee et al.,
over 90% of individuals who reported intranasal cocaine use also used injection drugs at
least once in their life.26 It is quite possible that stigmatisation of "harder drugs" such as
those that are taken intravenously, makes individuals more likely to report the use of
"softer" drugs like cocaine, which are usually not taken intravenously. Other reported
sources of HCV include the sharing of household items such as razors or toothbrushes with
HCV-infected individuals, acupuncture, body piercing, and occupational exposure to
blood-for example, a doctor or nurse working in the medical field. Table 1.3.1
summarises these reported routes of He V transmission.
Vertical transmission of HCV from mother to child appears is likely dependent upon
the level of HeV viraemia. Transmission via this route occurs to infants born to viraemic
mothers.27 Vertical HCV transmission is more common among children born to mothers
coinfected with the human immunodeficiency virus
26
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Chapter 1
(HIV), and increased HeV viraemia among HIVlHeV coinfected individuals likely
accounts for this observancn."
Perhaps the most controversial risk factor is that of sexual transmission.P In a recent
population-based study of HeV, a number of individuals reported sex as the sole risk factor
for hepatitis e.16 Several case reports also document sexual transmission.i" 30 These studies
document HeV transmission in individuals at risk in temporal relationships with an HeV-
infected partner. High levels of viral sequence homology also support the notion of
transmission in these studies.29• 30 In contrast, Hollinger and colleagues studied 18 couples
(36 persons) recruited from 430 HeV-infected persons.i' After screening for risk factors,
all but only one of the 36 individuals reported exposure to parenteral risk factors. In half of
the couples sexual transmission was immediately ruled-out, as the couples were infected
with different Hev viral genotypes. In the remaining individuals, analysis of viral
sequences suggested that transmission could have occurred in only 1 couple, and this
couple later admitted to sharing equipment with each other for injection drug use.3l Other
studies, have also suggested low sexual transmission of HeV.32-34 All sexual acts do not
carry the same level of risk. Future studies must not only address these differences in risk,
but also evaluate the role of comorbidities such as concomitant infection with HIV in HeV
transmission via sex. Large prospective studies specifically designed to evaluate the risk of
sexual exposure in HeV transmission must be conducted before this issue will be resolved.
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Table 1.3.1. Summary of commonly recognised risk factors for
HCV acquisition.
RISK FACTOR REFERENCES
Receiving blood/blood products
prior to 1992
Injection drug use
Intranasal cocaine use
Sharing of razors or toothbrushes
Piercing
Sexual exposure
Occupational exposure to blood
Vertical transmission
Tattooing
Haemodialysis
Acupuncture
Aach,199135
Conroy-Cantilena, 199625
Alter, 198936
Conroy-Cantilena, 199625
Alter, 199916
Alter, 199037 JAMA
Conroy-Cantilena, 199625
Mele, 1995 38
Tumminelli,199539
Conroy-Cantilena, 199625
Mele, 199538
Alter, 199916
Alter, 198936
Alter, 199037
Ohto, 199440
Mele, 199538
Sun, 199641
Kaldor, 1992 42
Alter. 199037
Sandhu, 199943
Kioysawa. 1994 44
Mansell, 199511
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Individuals are often exposed to more than one risk factor. Surveillance of Hev risk
factors often involves the use of hierarchical algorithms, where risk factors are placed in a
hierarchical order based on probability of transmission. For example, sharing of equipment
for injection drug use is placed higher on the algorithm than sexual exposure, because the
probability of transmission via injection drugs is much higher. "Lower risk" routes of
transmission may be masked by "higher risk" routes of transmission. While such a
hierarchical system facilitates the surveillance of hepatitis e acquisition, it may not
necessarily provide an accurate picture of HeV acquisition. Future studies of HeV
transmission will have to address these factors as new studies are designed to assess the role
of lower risk behaviours, such as sexual exposure, in the transmission of Hev. Figure 1.3.2
summarises the distribution of risk factors for HeV acquisition. A cohort effect is present,
where older individuals tend to have exposure to blood and blood products, while younger
individuals tend to report exposure to injection drug use. Some individuals report exposure
to both blood products and drugs. Individuals in both age categories also report exposure to
multiple other risk factors.
1.4 The Natural History of Hepatitis C Virus Infection: Progression and
Therapy
The acute phase of HCV infection
Hev infection results in a diverse spectrum of possible outcomes. To begin with, an
estimated 14% - 46% of individuals exposed to HeV are able to naturally clear the virus
(self-limiting infections). While chronicity was traditionally defined as the persistence of
elevated amino transferase levels for 6 months or more, it is now commonly defined as the
persistence of HeV-RNA levels beyond 6 months or more. Unfortunately, the majority
(54% - 86%) of individuals exposed to HeV develop persistent (chronic) HeV infections.
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Chapter 1
Infection with Hev is asymptomatic in the vast majority of individuals, with the
transition from acute to chronic infection usually occurring without notice." Retrospective
studies have suggested varied rates in the development of chronicity (Table 1.4.1).
Interestingly, studies have also suggested much lower rates of HeV chronicity among
women and younger individuals. Studies conducted among young women who received
contaminated anti-Rh-immunglobulin in both Ireland and the former East Germany
suggested that chronicity occurs in approximately 55% of individuals. In one study, Vogt
and colleagues tested for the presence of antibodies to Hev in stored sera from 458
children who had undergone cardiac surgery prior to the introduction of anti-Hf'V
screening. The mean age of the patients was 2.8 years.47
Table 1.4.1. Table illustrating some of the variation
in reported rates of HeV chronicity.
Author (year) Chronicity
Alter, MJ 199248 74%
Locasciulli, 199749 71%
Alter, HJ 199750 86%
Vogt, 199947 55%
Kenny-Walsh, 199951 55%
Rodger, 200052 54%
Thomas, 200053 86%
Wiese, 200054 55%
Seeff 200155 76%
Among the samples tested, 67 (14.6%) were found to be anti-HflV positive." Follow-up of
these samples 20 years later revealed that HeV-RNA was detectable in 37 (55%) of the
antibody positive individuals. None had been treated for HeV. Differences in the rates of
natural clearance of virus may occur by race as well. In a study in Baltimore, Maryland,
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USA, Thomas and colleagues observed that individuals who were most likely to naturally
clear HCV viraemia were non-black (Odds ratio (OR)=4.66; 95% Confidence Interval
(95%C.I.): 2.44-8.90) and female (OR=1.58; 95%C.I.: 0.98 - 2.54).56
Progression of chronic HCV
The clinical outcome of chronic HeV infection is varied as well. Among individuals
with chronic infections, a portion progress to develop I iver cirrhosis, while a portion 0 f
these cirrhotics continue to progress and develop the complications of end-stage liver
disease, with some developing hepatocellular carcinoma. Just how many individuals
progress to cirrhosis, develop end stage liver disease, or primary liver cancer is currently a
matter of debate. Early studies of Hev natural history suggested that as many 20% of
individuals progress to cirrhosis. However, recent studies involving individuals who were
young and otherwise healthy at the time of infection, suggest that the occurrence of
cirrhosis is less than 5%.46
It is also important to bear in mind several limitations regarding natural history
studies. First, follow up of infected individuals has rarely exceeded two decades, so that
outcome beyond this point is not yet known. Second, primary infection with Hev is usually
asymptomatic. Aside from some unique incidents such as groups of women being infected
with contaminated anti-Rh immunoglobulin in Ireland and Germany.i!' 54 estimates of
durations of infection have been largely conducted on a retrospective basis by patient
interview for risk factors for HeV acquisition. Consequently, problems such as recall bias
come into play. In addition, HCV is a slowly-progressive disease. Many individuals
experience other factors during the decades following infection, such as ingestion of large
amounts of alcohol, or infection with other viruses such as the hepatitis B virus, so as to
obscure "true HeV natural history."
The progression of fibrosis in chronic HCV infection is measured semi-
quantitatively, commonly using either the METAVIR system, which has a scale of 0 to 4
for degrees of fibrosis (0 is no fibrosis and 4 is cirrhosisj." or the Knodell score, which has
a scale of 0 to 6 for fibrosis (0 is no fibrosis and 6 is cirrhosis). 58 A characteristic feature of
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chronic HCV infection is the presence of lymphoid aggregates. Figure 1.4.1. Part A.
presents an example of lymphoid aggregates in a liver biopsy specimen stained with
haematoxilin and eosin. Figure 1.4.1. Part B. presents a reticulin stain of a lymphoid
follicle. Figure 1.4.2. illustrates some of the key clinical features of HeV -related end stage
liver disease (ESLD). The computerised tomography (CT) scan presents a patient with a
cirrhotic liver that is shrunken in size, covered with the nodules characteristic of cirrhosis,
an enlarged spleen, and the presence of ascites. In addition, there is the presence of a
notable hypervascular tumour in the liver. Figure 1.4.3. Part A. is a fme-needle biopsy of a
cirrhotic liver. Figure 1.4.3. Part B. is a laparoscopic view of a cirrhotic liver. The nodular
surface characteristic of cirrhosis may be clearly seen in this picture. Whether progression
to cirrhosis is linear in these individuals is also a matter of debate. 59 Large cross-sectional
studies have suggested that progression is linear, while follow-up studies have suggested
varied progression." More research is needed before this issue can be resolved.
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A.
B.
Figure 1.4.1. Lymphoid follicles in chronic hepatitis C virus infection. Part A.
presents a haematoxylin and eosin stain of a liver biopsy specimen. The dark
area is a lmyphoid follicle. Part B. is a reticulin stain of a lymphoid follicle.
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Figure 1.4.2. Computerised tomography (CT) scan of a patient with chronic
hepatitis C virus (HCV) infection that depicts many of the characteristics of end-
stage liver disease. The patient has an enlarged spleen and a cirrhotic liver with a
nodular surface. There is also a sizeable tumour in the liver. Note the presence of
ascites as well.
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A.
B.
Figure 1.4.3. The cirrhotic liver. Part A. presents a haematoxylin and eosin
stain of a liver biopsy specimen. The white arrow depicts the boundaries
wh re a cirrhotic nodule has formed. Part B. is a cirrhotic liver as viewed
by laparoscopy.
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1.5 Therapy for hepatitis C virus infection
Interferon monotherapy
One of the first successful agents to be used against HeV infection was interferon-
a. Interferons are cytokines with potent immunological effects that include anti-viral
activity, and are divided into two main groups.": 62Type I interferons include interferon-a
(with at least 12 different subtypes), an interferon-B subtype, and an interferon-eo subtype.
Type II interferons include interferon-yo Type I interferons are released during a host
response to an invading virus and bind to cell surface receptors and initiate the transcription
of several proteins with potent anti-viral activities, such as protein kinase (PKR), 2'-5'
oligo-adenylate synthase (OAS), and rnxyovirus resistance-l (MxA).63 Type II interferons
are produced by antigenic ally stimulated immunocytes and modulate the developing,
specific immune reponse." Interferons are released by the body within hours of any viral
infection and inhibit viral replication in a non-specific manner.63. 64 The importance of
interferons in the host defense against viral infections are illustrated with transgenic animal
models lacking type-l interferon receptors. Following inoculation with small doses of
viruses with low pathogenicity, these animals die rapidly.6s
Trials of the use of recombinant interferon-a (3 million units administered by
subcutaneous injection three times p er week) for the treatment of chronic Hev showed
promise. Treatment for 24 weeks resulted in a sustained response in 10-15% of
individuals.66.67.68Subsequently, interferon-a became the first approved regimen for the
treatment of chronic hepatitis e.
Interferon and Ribavirin combination therapy
In 1998, two landmark studies demonstrated higher response rates with the use of
interferon-a in combination with ribavirin, than therapy with interferon-a alone.69. 70
Ribavirin, a purine nucleoside analogue, is ineffective in lowering HeV-RNA levels when
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used as mono therapy for HCY, although it did lower serum alanine transaminase levels in a
significant number of patients.7l-73 In combination with interferon, however, addition of
ribavirin results in increased end of treatment response rates. Combination interferon-a. and
ribavirin therapy results in sustained virologic response in approximately 25% of
individuals with genotype-l infections and about 40% of individuals with non-l infections.
It is worth noting that the exact mechanisms of action of ribavirin are not known.
There a re 4 proposed mechanisms 0 faction at present: 1) that r ibavirin enhances T-cell
responses by encouraging the expression of a THI cell phenotype over that of a TH2
phenotype;74-76 2) that it inhibits the enzyme inosine monophosphate dehydrogenase
(IMPDH), which produces GTP-a critical ingredient for successful RNA synthesis. By
decreasing the net GTP pool, it is hypothesised that viral replication may be inhibited;77.78
3) that it directly inhibits HCY via the NS5B region-encoded RNA dependent
polymeraser" and 4) that it inhibits successful HCY replication as a mutagen that pushes
the already error-prone RNA virus replication process to that of such immense proportions
that viable virions can no longer be produced." Further research into the pharmacology of
ribavirin is needed to fully understand its mechanisms of action.
Another important feature resulting from these clinical trials was the demonstration
that patients infected with genotype-l viruses, which are more resilient to these interferon-
based regimens, benefit from longer durations of therapy. Standard combination therapy
consists of 3 million units of interferon-a.- 2b administered by subcutaneous injection three
times per week. In conjunction, 1200 mg of ribavirin is taken orally every day by
individuals> 75 kg, or 1000 mg of ribavirin is taken orally every day for individuals ~
75kg. Those with genotype-l infections are now generally treated for a full year, while
those with non-l infections are treated for 6 months.
Pegylated interferons as monotherapy and combination therapy with ribavirin
Standard interferons have two important I iabilities. First, the pharmacokinetics of
standard interferons peak following administration and wane soon after, consequently
limiting the amount of interferon available to fight virus during the troughs (Figure 1.5.1.
Part A). Second, the need to administer three doses p er week b y subcutaneous i njection
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increases the possibility for non-compliance. Addition of a polyethylene glycol (PEG)
moiety to the interferon molecule has greatly reduced its excretion, and increased the half-
life of the protein (Figure 1.5.1 Part B).79Addition of the PEG molecule to interferon has
resulted in higher sustained response rates in HeV patients
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Figure 1.5.1 Pharmacokinetics of standard IFN and PEG-IFN. Levels
of standard IFN peak and wane after each administration, while PEG-
IFN maintains more steady levels over the entire week. (Adapted from
Kozlowski 2001)79
compared to standard interferons (69% with PEG-interferon and 28% with standard
interferon at 48 weeks of treatment; and 39% for PEG-interferon and 19% for standard
interferon at 72 weeks of treatmentj.i" Trails combining pegylated interferon with ribavirin
observed sustained response in approximately 40 - 46%% of those with genotype-I
infections and 76% - 80% of those with non-I infections.81•82
Outcomes of anti-HeV therapy
Three main outcomes are observed in therapy for chronic HCV infection: (Lindsay
2002) 1) sustained response-this is now commonly defined virologically as having
undetectable serum HCV-RNA levels at 6 months after the discontinuation of treatment.
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Older studies have defined response biochemically a san ormalisation 0 f A LT levels; 2)
initial response-this is a disappearance in serum levels of HCV-RNA at the end of the
initial phase of treatment-commonly 12 weeks after the inception of the regimen. A
portion of these individuals who have achieved initial response may also experience a
virological relapse later on, so they are not true responders; and finally, 3) non-
responders-these are individuals who have detectable viraemia at week 12 of therapy.
They are distinct from initial responders because they never achieved any sort of virological
decline to undetectable levels, even during the initial course (first 12 weeks) of therapy.
Figure 1.5.2 graphically illustrates these response phenotypes.
Side effects of therapy
Interferon therapy is associated with a number of side-effects, some of which may
be debilitating and necessitate discontinuation of therapy. Common side effects include
fatigue, influenza-like symptoms, haematologic abnormalities including haemolytic
anaemia and neutropaenia, as well as neuropsychiatric symptoms including suicidal
ideation.t'
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Table 1.5.1 lists the frequency of the most commonly reported side effects for standard
interferon-a plus ribavirin and pegylated interferon-a plus ribavirin.
Table 1.5.1. Frequency of some of the common side effects for interferon as mono-therapy,
standard interferon with ribavirin (IFN+R) and pegylated interferon with ribavirin (PEG-IFN+R)
during clinical trials.
Factor IFN monotherapy (%) IFN+R (%) PEG-IFN+R (%)
Fatigue 78 55 54
Headache 53 52 47
Pyrexia 48 56 43
Myalgia 55 50 42
Rigors NR 35 24
Insomnia NR 39 37
Nausea 36 33 29
Alopecia 24 34 28
Irritability 28 28 24
Arthralgia 16 25 27
Anorexia NR 22 21
Dermatitis NR 18 21
Diarrhoea 34 NR NR
Depression 14 30 22
Abbreviations: NR=Not Reported
Adapted from Davis 1989, Fried 2002 and Fried 2002.66,82,83
Predictors of response to therapy
The multiple, often debilitating side effects accompanying interferon-based
therapies has prompted a search for predictors of w ho w ill most 1ikely respond tot hese
interferon-based therapies. Currently, commonly employed predictors of response involve
viral factors. Non-l viral genotype and low pre-treatment viral levels are all favorable
prognosticators.t=" More recently, there has been an interest in the role of viral dynamics
during the period immediately following the inception of treatment in predicting therapeutic
response. Early rapid decline in viral levels is a favorable indicator. The drop in viral levels
following the start of treatment is biphasic. The initial drop is believed to reflect the
clearance of free virions. The slope of this drop is dependent upon the dose of interferon.
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The second slope reflects the clearance of virally infected cells.8 Figures 1.5.3. and 1.5.4.
illustrate these concepts. Figure 1.5.3 presents data from the Consensus interferon trials.
Among those individuals who achieve sustained virologic response, the majority
experienced viral disappearance within the first 4 weeks following initiation of therapy/"
Figure 1.5.4. is a schematic diagram that illustrates the biphasic nature of viral dynamics in
the period immediately following treatment of HCV infection with interferon.
The search for host factors that predict therapeutic response has also examined host
demographic factors as well as host genetics. Women have been observed to respond better
to treatment with interferon.i" 70, 81, 82, 85 Race may also affect response to therapy." In
particular, blacks in the United States have also been observed to have a poor response to
treatment.87,88 Other factors such as body weight and obesity have also been explored.89
There has also been a search for genetic factors that predict outcome of therapy. This is
reviewed in Chapter 2.
1.6 Comorbid Conditions in Hepatitis C Virus Infection
Chronic HCV infection is associated with a number of clinicallbiological
extrahepatic manifestations. Table 1.6.1 lists some of these comorbid conditions associated
with HCV infection. Extrahepatic comorbidities include the presence of autoimmunity (non
organ-specific autoantibodies) to more autoimmune disease-like manifestations, such as the
Sicca syndrome, presence of cryoglobulins, or Raynaud's phenomena.Y' 91Other conditions
include peripheral blood count abnorrnalities.f or the presence of Type II diabetes
mellitus.93-98 More recently, reports have suggested an association between chronic HCV
infection and cognitive dysfunction including memory impairment {"brain fog,,).99
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Hev is also associated with a number of non-clinicallbiological comorbidities. Perhaps the
most important non-clinicallbiological co-morbidity is that of substance abuse (injection
drugs and alcohol).IOO-I03The prevalence of antibodies to Hev has been reported to be
higher in alcoholic patients with clinically apparent liver disease than those without
clinically apparent liver disease in France, Germany, the United States, Italy, Japan, and
Sweden.104-110Strong correlations between behavioural patterns such as alcohol use and
past or current drug abuse are likely to account for this strong connection. Given the
observed synergistic effect of concurrent alcohol abuse and infection with chronic HeV in
accelerating disease progression, this c omorbidity is a factor with important clinical and
public health ramifications.
1.7 Autoimmunity in hepatitis C virus infection
Many of the comorbidities associated with HeV infection are autoimmune in
nature.III-114 In this section I will highlight a few of the most common and important
autoimmune comorbidities. Perhaps the most common autoimmune manifestation is the
presence of non organ-specific autoantibodies (NOSA).1l4-116Table 1.7.1 highlights some
of the autoantibodies associated with chronic HeV infection. The prevalence of these
autoantibodies varies greatly, depending upon the population studied.i'" Differences in
methodologies used to assess the presence of autoantibodies as well as choice of cut-off
titres may also account for some differences. HeV -associated autoantibodies may differ
from those seen in patients with primary rheumatic disorders. For example, Hey-
associated anti-cardiolipin antibodies (AeA) generally exist in low titres and are not
associated with lupus anticoagulants, anti-beta-2 glycoprotein 1, antithrombin antibodies, or
clinical manifestations such as thrombocytopaenia.lF While the prevalence of some of
these autoantibodies in HeV-infected individuals is high, there are little data examining
correlates of autoantibody positivity and the effect of positivity on HeV clinical outcome.
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Table 1.7.1. Autoantibodies associated with
chronic HCV infection.
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Autoantibody
Reported
prevalence
Rheumatoid factor
Cryoglobulins
Antinuclear antibody
Antithyroid antibodies
Anticardiolipin antibodies
Anti-smooth muscle antibodies
Anti-liver kidney microsomal-1 antibodies
Anti-neutrophil cytoplasmic antibodies
60%
40%
4% -41%
10%
20%
7% -20%
1%-3%
10%
Adapted from LOvy 2000.114
There have been reports associating chronic HeV infection with other clinical
manifestations including cryoglobulinaemia, thyroid dysfunction and Sjogren's syndrome.
The presence of cryoglobulins was the initial and most widely recognised extrahepatic
manifestation of HeV infection. IIS.119Cryglobulins are immunoglobulins directed against
immunoglobulins that reversibly precipitate at cold temperatures and consist of two types.
Type I cryoglobulins are monoclonal, while type II cryoglobulins are polyclonal and
typically contain a mixture of IgG and IgM molecules.'" Immune complex formation and
cryoprecipitation may occur and result in glomerulonephritis or vasculitis. " Arthralgias,
peripheral neuropathy, hepatosplenomegaly, and lymphadenopathy may occur, and
cutaneous lesions are common and may include palpable purpura and urticaria.t" Treatment
with interferon-a has generally been reported to mitigate HeV-induced cryoglobulinaemic
symptoms. IIS.119
Thyroid dysfunction has also been reported in HeV infection. Although the association
of HeV with autoimmune thyroid disease is controversial,120-122the presence of thyroid
autoantibodies is relatively common.123-127 Interferon therapy for Hev has also been shown
to induce the formation of anti-thyroid autoantibodies de novo in some patients.12S-131
Exacerbation of thyroid autoimmunity may occur in some individuals with preexisting
di hesi h th f anti . l antib di 129-131at esis, sue as e presence 0 antrmicrosoma anti 0 res.
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Associations of Sjogren's syndrome and HeV has been reported to be as high as 10%-
20%.132-135Other studies, however, have refuted these findings.136-140If primary Sjogren's
syndrome is defined as sicca syndrome in the presence of anti-Ro (SSA) and anti-La (SSB)
antibodies, then the prevalence is quite low.9o HeV infection, however, is more commonly
associated with sialoadenitis (in the absence of anti-Ro (SSA) and anti-La (SSB)
antibodies) and occasionally Sicca symptorns.l'" 141-144The cause of this association is not
clear, although in one study transgenic mice expressing HeV-envelope proteins developed
an sialoadenitis-like exocrinopathy.l'"
Table 1.7.2 outlines some of the extrahepatic manifestations reported among
individuals with chronic HeV infection. There are many other autoimmune associations
reported with HeV infection, including autoimmune haemolysis and
thrombocytopaenia, 146-148Becher's syndrome.l'" and myasthenia gravis. ISO Many of these
reports await further evidence to confirm a true association with Hev.
Table 1.7.2. Some of the extrahepatic manifestations
reported in individuals with chronic HCV infection.
Extrahepatic manifestations
Fatigue
Arthalgia
Paresthesia
Myalgia
Pruritis
Diabetes
Raynaud's phenomena
Thyroid abnormalitites
Psoriasis
Non organ-specific autoantibodies
Peripheral blood count abnormalities
Cognitive dysfunction
Adapted from: Poynard and Gumber SC.81, 151
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1.8 Viral Factors and the Outcome of Hepatitis C Virus Infection
The association of the various HCV genotypes with differences in pathogenicity has
not been clearly established." IS2.IS3 Some reports have suggested that infection with
genotype 1b is associated with more severe disease and a more aggressive course than other
genotypes.l" IS4-161and is more prone to chronicity.162 In contrast, there are a number of
studies that have found no such associations.P': 163-166An explanation for this discrepancy
centres on a possible cohort effect. Zein et al found that individuals with genotype 1b
tended to be older than those infected with other genotypes and that genotype 1b may have
been present before the other genotypes, and thus patients with genotype 1b infection may
have just been infected for longer durations of time.161 Similar observations have been
made in France and Spain.167.I68In short, this explanation suggests that genotype 1b is a
surrogate for more severe disease because people with this strain of virus are most likely to
have been infected for longer durations of time and that the genotype 1b strain, per se, is
not more pathogenic than others.
Infection with any HCV genotype may lead to cirrhosis, end-stage liver disease and
hepatocellular carcinoma, and the frequency of these outcomes appear to be similar with
each of the different viral genotypes.' However, there are two major differences with
respect to v iral genotypes. First, it i s clear t hat genotype 1 v iruses are more resistant to
therapeutic intervention with interferon-based regimens.i?' 70Unfortunately, in developed
countries such as those of Western Europe, genotype 1 virus is the predominant viral
subtype.l" 164.169Second, infection with genotype 3 has been associated with a greater
likelihood of developing steatosis on liver biopsy.170 Interestingly, clearance of genotype 3
has been associated with a resolution of this steatosls.!"
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1.9 The Immune Response to Hepatitis C Virus Infection
The Immune Response in Self-limiting Infections
In addition to the generation of anti-HeV antibodies, individuals who are able to
experience self-limiting H ev infections a ppear to mount strong e D4+ and eD8+ T-cell
responses against multiple epitopes on HeV structural as well as non-structural proteins.V':
172 T cells are likely to playa major role in the clearance of virally-infected cells. Lack of
such a strong T-cell response during the initial phase following HeV infection is likely to
result in persistent infection.172• 173 A chimpanzee model of HeV infection has also
demonstrated a strong intrahepatic T-cell response among animals with self-limiting
infection than in those with chronically evolving infections.I"
A strong THI cytokine response is likely important in self-limiting infections as
well.17S-178 In a prospective study of the immune response in acute HeV infection, Kamal
and colleagues examined eD4+ T-cell responses in individuals with and without co-
infection with Schistosoma mansoni,179 and organism that is known to elicit a strong TH2-
type cytokine response.180-182This group observed one-third (5 of 15) patients with acute
Hev mono-infection to experience self-limiting infections, while all individuals with HeV
and S. mansoni co-infection progressed to chronic hepatitis.!" Using interferon-y
production as a measure of the THI cytokine profile and interleukin-l0 as a measure of the
TH2 cytokine profile, co-infected patients were observed to exhibit a low THI cytokine
profile.179 In addition, proliferation assays were used to assess CD4+ T-cell responses to
HCV (Core, NS3, NS4 and NS5 antigens).179 Patients with self-limited HCV mono-
infection exhibited CD4+ T-cell responses that were significantly greater in vigour,
frequency, and breadth than in those with chronic HeV mono-infection or in those with
chronic HCV and S. mansoni co-infection, thereby providing further evidence supporting
the notion that a strong THI profile is important in self-limiting HeV infection.179There is a
similar correlation with strong CD8+ T-cell responses in self-limiting infections. Gruner
and colleagues examined CD8+ T-cell responses among patients with self-limiting and
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chronic Hey infection.183 They observed that individuals with self-limiting Hey infection
had higher numbers of interferon-y-producing Hey -specific eD8+ T_cells.183
The importance of a strong cell-mediated immune response has also been
demonstrated in several studies that have documented cellular immune responses to Hey-
antigens in the peripheral blood of individuals who were both anti-Hey and Hey -RNA
negative. 184, 18S In a study following a cohort of women who were exposed to the same
strain of Hey via a contaminated batch of human Rhesus immunoglobulin approximately 2
decades earlier, circulating HeY-specific T-cells persisted in peripheral blood
approximately 20 years after resolving Hey infection, while anti-Hey antibodies were not
detectable in many of the individuals.178 This study not only underscores the importance of
strong cellular immune responses to Hey, but suggests that the occurrence of self-limiting
infections in the general population may be underestimated, because documentation of
initial infection is often not available and surveys of Hey only measure Hey exposure via
humoral parameters rather than cellular ones.178 Another study by Wedemeyer and
colleagues suggested that the presence of HeY-specific T cell responses in the absence of
HeY-infection may be the result of the induction of cross-reactive T-cells by heterologous
viruses.186 In a database search, a high degree of sequence homology was observed between
the HeY-NS3 peptide epitope and a sequence of the influenza A virus neuraminidase
protein. The researchers observed a high degree of cross-reactivity between the two viruses
in both in vitro assays and in vivo animal models, suggesting that host responses to an
infectious agent may be influenced by cross-reactive memory cells that are induced by past
exposure to heterologous viruses.i"
These observations elicit the question as to whether individuals who have cleared
Hey infection are protected from viral recrudescence upon reinfection with Hey. Bassett
and colleagues rechallenged chimpanzees with homologous and heterologous Hey and did
not observe sterilising immunity.l'" However, the clinical course of HeV reinfection was
less severe in these animals.187 Similar observations for the lack of protective immunity
were observed by Farci and colleagues.P''
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Immune-Mediated Liver Injury in Chronic HCV Infections
HCY is not directly cytopathic. Consequently, it is believed that liver injury in
chronic HCY infection is likely to result from immune-mediated clearance of infected
hepatocytes.l'" Murine models have provided evidence of the role of antigen-specific T-
cells in hepatocyte damage. For example, hepatitis C virus transgenic mice develop acute
hepatitis upon transfer of syngeneic hepatitis C virus-specific CD8+ T-cell clones.l'"
Similarly, a hepatotropic isolate of lymphocytic choriomeningitis virus induced liver cell
injury mediated by class I-restricted CD8+ T cells.!"
On the human level, several observations also support the role of immune-mediated
liver damage: 1) liver cell damage coincides with the development of the host immune
response and not the initiation of viral replication during primary HCY infection.l" 2) viral
replication in chronic HCY occurs in some individuals with the absence of liver damage.l'"
3) liver-infiltrating HCY immune effector cells have been recovered in several studies.I94-
196,and 4) immunosuppression of HCY patients is generally associated with a transient
surge in viraemia and a temporary normalisation of transaminases, while removal of
immunosuppression may lead to exacerbation ofhepatitis,197.198
Immune Response in the Context of Interferon-Based Therapies
A strong a nd robust T-cell response is also associated with sustained response to
interferon-based regimens for HCY. Cramp and colleagues prospectively studied the role of
virus-specific T-helper lymphocyte responses along with interferon-y and interleukin-IO
(ILIO) production before, during and after treatment with interferon alone or in
combination with ribavirin. They observed that T -cell reactivity was uncommon prior to
therapy, but increased with therapy, with peak activity occurring between weeks 4-8. Those
who cleared virus were patients who developed HCY-specific T-cell proliferation with
increased interferon-y production. In addition, patients treated with combination interferon
plus ribavirin had markedly lower levels of ILl 0 production, with lymphocyte proliferation
being similar in both treatment groups. These observations suggest that those who are able
to mount strong CD4+ T-cell responses with strong type I cytokine production (i.e.,
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interferon-s) and lower type II cytokine production (i.e., ILIO) are more likely to achieve
sustained virologic response.
1.10 Host Genetic Factors and the Natural History of Hepatitis C Virus
Infection
Studies of twins suggest that genetic factors may play a significant role in
modulating the immune response to infectious agents. Twin heritability studies have found
a high genetic contribution for the immune response to several infectious diseases.199-203
This is in contrast to many autoimmune diseases, where concordance among monozygotic
twins is a lmost a lways under 50%, suggesting a m ore significant role for environmental
factors in autoimmune disease pathogenesis.F'" 205 For this reason, much interest has been
focused in recent years 0n the possible contributions of host genetic factors to the often
diverse clinical manifestations seen in many infectious diseases.
With the discovery of the major histocompatability complex and its role in
immunity, there has been historically, a great interest in the potential role of HLA antigens
in the natural history of infectious diseases. More recently, however, there has been an
interest in the role single base-pair exchanges, termed single nucleotide polymorphisms
(SNP), in the regulatory regions of genes of key immunomodulatory proteins, or proteins
involved in drug or metabolic pathways. The human genome project has facilitated the
exploration of the role of these polymorphisms in disease outcomes. A systematic review of
the scientific literature regarding the potential role of host genetic diversity on the outcome
of HCV infection is provided in Chapter 2.
1.11 External Factors and the Natural History of Hepatitis C Virus
Infection
One of the most important external modulators ofHCV natural history is that of
alcohol consumption. Several studies have shown an association between increased alcohol
consumption and more advanced liver disease among individuals with chronic HCV
infection. 53, 60, 206-210
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In a retrospective study conducted by the HeV National Steering Group in the
United Kingdom, 923 individuals were identified as having become infected with Hev
following a blood transfusion, along with 475 transfusion-recipient controls. Study
participants were asked to complete a validated questionnaire on alcohol consumption.i'!
Individuals who drank more were at increased risk for cirrhosis (RR=2.84). The Dionysus
Study, a population-based study of 6,917 unselected residents of two cities in Italy, found
that among the 2.3% of individuals positive for the HeV virus, those who drank more than
30g of alcohol per day for more than 10 years had a 3-fold higher risk of cirrhosis
(95%e.I.: 1.2- 7.4; p=O.OI)_2!O
Several other studies have also suggested that increased alcohol consumption may
adversely affect the outcome of interferon therapy as well. In a study by Loguercio,
response of patients to interferon was inversely proportional to the amount of alcohol
ingested_212A study by Tabone an colleagues observed lowered rates of sustained virologic
response among individuals who drank alcohol: 33% of non-drinkers responded, 20% of
those who drank 25g - 50g of alcohol per day, and 9% in those who drank more than 75g
per day.213No differences were detected with respect to non-response suggesting that those
who consumed more alcohol and failed to respond were relapse-responders.i'? The
biological mechanisms behind these epidemiologic observations have not yet been fully
elucidated.
Co-infection
Another important external factor affecting the natural history of Hev infection is
co-infection with other infectious agents. The most important of these is co-infection with
the human immunodeficiency virus (HIV). Because HeV and HIV are both parenterally
transmitted infections, concomitant infection with the two agents may be common among
specific populations such as injection drug users. It is estimated that in the United States
alone, 25% of HlV-infected persons are co-infected with HeV.56 With rapid improvements
in HIV therapies, liver disease has emerged as an important medical problem in co-infected
individuals.
55
Chapter 1
HIV -infection adversely impacts the outcome of HeV infection at all stages."
While self-limiting infection occurs in approximately 14%- 46% of Hev mono-infected
patients, only 5% - 10% of individuals co-infected with HIV experience self-limiting
infections.": 53. 214.215 Among those with chronic HeV infections, co-infection with HIV
has been associated with higher HeV-RNA levels, an accelerated progression of liver
fibrosis, and an increased likelihood of developing liver failure and hepatocellular
carcinoma. 53. 216-223
1.12 Hepatitis C Virus Infection: The Burden of Disease
Sequelae of persistent HeV infection remain a major public health burden
worldwide. HeV, along with hepatitis B, are the main causes of primary liver cancer
worldwide. Liver cancer is currently the fifth most common cancer in the world, with
437,000 incident cases annually.224Developing countries are affected more than developed
countries by liver cancer (Table 1.12.1.)
Table 1.12.1. Cancer cases attributable to viral hepatitis C and hepatitis B in
1990 in developed and developing countries.
Developing
Developed Countries Countries
Males Females Males Females
Hepatitis C 11,300 5,700 68,200 24,500
Hepatitis B 12,400 6,200 154,800 55.500
World Total
Male Female Both
Hepatitis C 79,500 30,200 109,700
He atitis B 167,200 61.700 228.900
(Adapted from Parkin OM et al., Cancer Surveys, Vol. 33, 1999)225
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Random estimates of HeV prevalence have not been conducted in the United
Kingdom. While populations like blood donors groups, clinic populations, analyses of
stored sera or patient databases have been employed, probability cluster sample analyses
have not been conducted on the general population. Table 1.12.2. presents data on HeV
prevalence in England and Wales. These data were based on an epidemiologic survey of
residual sera collected from specimens submitted to the Public Health Laboratory Service
Laboratories in England and Wales for routine examination.F"
Table 1.12.3. presents estimates of HeV incidence and prevalence from a study
conducted in Tayside, Scotland. This study studied the liver disease virology dataset from
Ninewells Hospita1.227
Table 1.12.2. Number of individuals who tested positive out
of the total number of sera tested and the percent positive
for antibodies to hepatitis C from England and Wales.
Birth cohort
A. Males
Total
B. Females
Total
1976-1980
1971-1975
1966-1970
1961-1965
1956-1960
1951-1955
1946-1950
1936-1945
1926-1935
1880-1925
5/424 (1.18%)
41748 (0.53%)
11/1045 (1.05%)
21/1043 (2.01%)
10/854 (1.17%)
11/617 (1.78%)
7/426 (1.64%)
3/646 (0.46%)
3/609 (0.49%)
2/973 (0.21 %)
0/457 (0%)
1/853 (0.12%)
7/1152 (0.61%)
7/1190 (0.59%)
8/1063 (0.75%)
21789 (0.25%)
3/474 (0.63%)
1/705 (0.14%)
4/518 (0.77%)
5/1096 (0.46%)
Total 77/7385 (1.04%) 38/8297 (0.46%)
(Adapted from Balogun MA J Infect. 2002.)226
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Table 1.12.3. Incidenceand prevalence
of HCV in Tayside, Scotland (per 100,000
population).
Year Incidence Prevalence
1991 1.02
1992 6.60 7.11
1993 9.36 14.93
1994 9.87 22.50
1995 20.98 41.96
1996 27.44 65.80
1997 23.96 86.65
1998 20.01 103.64
(Adapted from: Steinke DT, et al. Gut, 2002)227
Random surveys of HCV prevalence in the general population have been conducted
in t he United States (US).16 Models estimating disease burden and economic costs have
been subsequently calculated based on these data. While it is difficult to extrapolate
estimates of costs from studies conducted in the US to the UK because of the different
healthcare systems, the estimates ofHCV disease burden provide a glimpse of the impact of
HCV on the healthcare system in a developed country. Accordingly, Iwill summarise some
important findings below.
While the introduction of screening the blood supply for hepatitis C has greatly
reduced transmission via that route, transmission via injection drug use remains an
important route of transmission. Although the number of incident cases has greatly
declined, the prevalent pool continues to rise. This is mainly a result of the fact that there is
generally a large lag between the acquisition of infection and the onset of symptoms
(sometimes a decade or two). Using United States-based estimates, the Centres for Disease
Control project a 4-fold increase in the numbers of individuals with long-standing infection
from 1990 to 2015.228 A recent study by Davis and colleagues projected the burden ofliver
disease based on existing incident and prevalent HCV cases. They found that if the
incidence of new infections remains stable, the prevalent pool will rise 4% annually and
plateau at 2008. The maturation of existing cases will cause increases in cirrhosis by 61%,
decompensated 1iver d isease by 279%, hepatocellular carcinoma b y 68%, the need for a
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liver transplant by 528% and the occurrence of liver-related deaths by 223%.229 The
majority (77%) 0 fl iver-related deaths in the United States during 1999 were a result 0 f
Hey infection.l" 230
A recent study from the United States by Wong and colleagues estimated that from
2010-2019, Hey may lead to the loss of 1.83 million years of life among those under 65, at
a societal cost of billions of dollars.r" The impact of Hey on liver transplantation is
highlighted in Table 1.12.4. These data from the United States United Network for Organ
Sharing (UNOS) show that both the number of patients registered on the liver transplant
waiting list and the number of transplants conducted as a result of HeY-related liver
disease have risen dramatically over the past few years.230
Table 1.12.4. Impact of HeV on liver transplantation over time.
A. Number of patients on the liver transplant waiting list in the United States
as a result of HeV infection and those on the list as a result of other causes.
1995 1996 1997 1998 1999 2000
Hev
Other causes
%from HeV
2086
5251
28%
2354
5704
29%
2798 3225
5832 6318
32% 34%
3670
6848
35%
3886
7007
36%
B. Number of liver transplants as a result of HeV in the United States and those
transplanted as a result of other causes.
1991 1992 1993 1994 1995 1996
HeV 343 565 796 930 1129 1190
Other causes 2588 2464 2608 2661 2750 2825
%from HeV 12% 19% 23% 26% 29% 30%
1997 1998 1999 2000
HeV 1268 1517 1625 1679
Other causes 2832 2899 2856 2900
%from Hev 31% 34% 36% 37%
Data from the United Network for Organ Sharing (UNOS) and excerpted from
Kim R. Hepatology 36 (5, Suppl. 1), 2002.230
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The burden of disease resulting from hepatitis C infection is severe in both
developing countries, as evidenced by the statistics concerning liver cancer, and developed
countries, as reflected in studies estimating HeV disease burden.
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Chapter 2
Host Genetic Diversity and the Outcome of
Hepatitis C Virus Infection:
A Systematic Literature Review
2.1 Genetic Heterogeneity and the Outcome of Hepatitis C
As mentioned in Chapter 1, the natural history of hepatitis C virus (HCV) infection
is characterised by diverse clinical outcomes. Some individuals infected with HCV are able
to clear the virus, while others develop persistent (chronic) infections. There is some
evidence to suggest that if people are infected at a younger age or if they are female then
the risk of persistent infection is reduced, but other factors which determine whether the
infection is self limiting or persistent have not been identified. It is unlikely that viral
sequence variation is a major determinant of the outcome at this stage as any viral strain
with a reduced capacity to establish persistent infection would rapidly disappear.
Treatment of persistent HCV infection has enjoyed a remarkable increase in success
rates over a relatively short period, but even with pegylated interferons in combination with
Ribavirin, about 50% of individuals with HCV genotype 1 and 30% with non-I HCV
genotypes will fail to achieve sustained virological responses.': 2 Viral genotype is clearly a
major determinant of the outcome of treatment along with gender and ethnic background.
However, these variables do not account for all of the variability in the outcome of HCV
infection or of treatment.
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It is clear that the outcomes of infectious diseases are determined by a number of
factors which can be broadly classified as host, organism and environment. Under the
category of host some of the most important factors are genetic. Studies amongst
monozygotic twins suggest that host genetic factors account for 50% or more of the
variability in the major outcomes in infectious disease.' Infection of siblings is rare with
HCY so it is unlikely that confirmatory twin studies will be reported, as has been done with
hepatitis B virus infection.l' " To date, genetic studies have not been conducted employing
siblings with vertically-acquired HCY. However, the emergence of reproducible genetic
associations with the outcomes of Hey, along with the parallels from other infectious
diseases such as malaria and hepatitis B,4. 5 provide strong circumstantial if not direct
evidence of the importance of genetics in the natural history of infectious diseases.
Identification of disease susceptibility genes is usually achieved using three
approaches: 1) linkage analysis in affected sibling pairs, 2) linkage analysis in rodent
models of the infection, and 3) disease association studies," There are examples suggesting
that some outcomes of Hey infection run in families," However, this situation is
sufficiently rare to preclude the use of linkage analysis to identify susceptibility genes. As
suitable small animal models of Hey infection are not available, disease association studies
are the principal approach used to identify disease susceptibility genes in Hey. This
approach has the advantage of statistical power but is limited by the need to select
candidate genes. Candidate genes are chosen by the investigator based on their knowledge
of Hey or infectious disease pathophysiology.
To examine the extent of the literature examining correlations between host genetic
markers and the outcome of hepatitis e virus infection, I conducted a systematic review of
the literature. In addition, I have attempted to highlight a ny consistent observations and
trends in the literature. Meta-analyses are also presented to further explore observed trends.
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2.2 Systematic Review Methods
Search strategy
A series of subject and keyword searches were conducted first using the 1966-15
April 2003 Medline and then repeated using the 1980-15 April 2003 EMBASE database.
First, "hepatitis C" was used as a subject heading, with the subgroup "genetics." Next, a
series of keyword searches were used to first identify articles related to "hepatitis C'' and
then combined with the following keywords using the "and" statement: "polymorphism,
HLA, MHC, and genetics." In addition, the citations of the bibliographies of these articles
were reviewed for additional references. Finally, the search was repeated in the 1980-15
April 2003 PubMed database. Articles were restricted to those in the English language. All
articles were evaluated for study design, technical aspects such as genotyping methods
(serological versus molecular) and statistical rigour.
Meta-analysis
All meta-analyses were conducted using the STATA ® software. Forest plots, tests of
heterogeneity and pooled estimates with weighted adjustments for sample size were
calculated using this software.'
2.3 Systematic Review Results
Among papers identified in the literature search, 88 were disease association studies
that directly pertained to the topic of genetics and the susceptibility to HeV infection, the
progression of Hev infection, the response to therapy, or extra-hepatic manifestations in
HeV. Table 2.3.1 lists the papers and the major findings for studies concerning genetics
and the susceptibility to Hev infection. Table 2.3.2 lists the studies and their findings on
the association of genetics with the response to anti-Hey therapies. Table 2.3.3 concerns
those studies ofgenetics and the progression ofHCV. Major fmdings are listed as well.
80
Chapter 2
Table 2.3.4lists studies concerning genetics and comorbid conditions in HeV. The relevant
findings of these studies are shown. Tables 2.3.1 through 2.3.4 are located at the end of the
chapter.
2.4 Systematic Review of Genetics and HeV Outcome: Data Synthesis
Susceptibility to persistent HeV infection
Early candidate gene studies focused on the genes of the major histocompatibility
complex (MHe) and the outcome of H'Cv, Given that MHe gene products encode key
components of the antigen presentation and processing pathways, it is not surprising that
these early studies focused on this region of the human genome. More recently, however,
the body of literature on genetic factors in HeV infection has grown to include many non-
MHC candidate genes as well. There are no estimates of the relative contribution of MHC
versus non-MHC genes to clinical outcome in HeV, but in other infections, such as
hepatitis B, the contributions appear to be well balanced or supportive of a greater effect
from non MHe genes."
A total of 34 studies address susceptibility to Hev infection (Table 2.3.1).9-42
Several consistent associations have been observed with specific alleles and the
susceptibility to HeV, and are highlighted in Table 2.4.1. A number of studies in several
populations have reported an association between DQBl *0301 with viral clearance." 10,17,
24.27.30.32.42.43One study, however, reported an opposite effect for DQBl *0301.38 Several
of these studies on susceptibility to HeV compared individuals with chronic HeV infection
to healthy controls. The use of healthy individuals poses a study design problem as an
estimated 54% - 86% of these controls, if exposed to the hepatitis C virus, would develop
chronic infections, while the others experience viral clearance.
Another allele that has been correlated with self-limiting HeV is DRBI *1101.9.10.
27.30.40 It is also worth noting that in one Italian study, a protective role was found for the
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DR5 serogroup against HeV infection." The molecularly-defmed DRB1*1100 and
DRBI *1200 group of alleles are part of the serologically-defmed DR5 group. In one study,
the DRB 1* 1101 allele was correlated with susceptibility to vertically transmitted HeV
infection."
These two DR and DQ alleles are in linkage disequilibrium with each other and this
makes it difficult to establish which allele is truly responsible for influencing the outcome
of HeV infection. However, the strength and patterns of linkage disequilibrium vary in
different ethnic groups and the replication of the association of DQB 1*0301 in multiple and
diverse populations suggests that this allele may exert a stronger effect on viral clearance
than DRBI *11.44
Table 2.4.1. Summary of replicated correlations of particular
alleles and self-limiting HCV infection.
Allele Studies
0081*0301 Alric, 1997
Alric,2000
Cramp, 1998
Mangia, 1999
Minton, 1998
Thursz, 1999
Thio,2001
Zavaglia, 1998
ORB1*1101 Alric, 1997
Alric,2000
Minton, 1998
Thursz, 1999
Yenigun, 2002
To examine the associations between DRBI *0301 and the DRBI *1101 alleles and
self-limiting HeV more closely, I conducted a meta-analysis employing data from the
published literature. To ensure that similar studies were pooled, only studies that employed
molecular g enotyping techniques and compared those with self-limiting infections (HeV
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antibody positive, but PCR negative) to those with chronic infections (HCV antibody
positive and PCR positive) were employed. Only data involving Caucasian individuals were
utilised in the analysis of DQB 1*0301. Because many studies involving the DR locus only
reported alleles to their 2-digit specificities, studies reporting 4-digit allele specificities
were collapsed into their respective 2-digit categories and all meta-analyses were conducted
with these data. In other words, all alleles such as DRBI *1101, DRBI *1103, etc. were
grouped together as DRBI *11. Similar to the analysis of DQBl *0301 above, only those
studies of Caucasian individuals employing molecular genotyping techniques that
compared those with self-limiting infections to those with chronic infection were included.
Figure 2.4.1. presents the results of these meta-analyses. Part A. presents the data for
DQB 1*0301, while Part B. presents the data for DRB 1*11. In addition, the identification of
individuals with self-limiting infections has largely been retrospective in nature.
Quantification of possible confounding factors such as viral genotypes, dose of virus, etc.
has been impossible in most cases.
The analysis of DQB 1*0301 and self-limiting infection shows a pooled estimate of
2.4 (95%C.I.: 1.8-4.8) (Figure 2.4.1. Part A.), Considerable heterogeneity exists with
respect to the studies of DQB 1*0301 and viral clearance (Q=21.1; p=0.004). Latent ethnic
differences may explain some of this variability. While this analysis was restricted to
Caucasian individuals, a wide range 0 f sub-ethnic groups a re i neluded, from northern to
southern Europeans. In contrast, studies of D RB 1*11 and self-limiting infection a re less
heterogeneous (Q=6.9; p=0.503). The pooled estimate for the effect of DRBI *11 on self-
limiting infection is 2.5 (95%C.I.: 1.7 - 3.7). The studies involving DRBI *11 are also
much smaller in size and have less precision (Figure 2.4.1. Part B.). These meta analyses
must be interpreted with caution. Considerable publication as well as and investigator-
submission biases exist. Many studies showing no association between class II alleles and
self-limiting infection may not be in the published literature both because journals tend to
dislike publication 0 fn egative studies or investigators do not bother writing-up negative
results. Alternatively, negative results may eventually be published in non-English journals.
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A. DQB1*0301
Thio, 2001 *
Thursz, 1999
Minton, 1998
Cramp, 1998
Fanning,2000 D
Alric, 2000 D
Alric,1997
B o
D
Combined ~
.380125 38.8389
or
Pooled estimate: 3.0 (95%C.I.: 1.8- 4.8) Test for heterogeneity:Q=21.1; p=O.002
B. DRB1*11
Alric,1997
Alric,2000
Thursz, 1999
Minton, 1998
Fanning, 2000
Cramp, 1998
Barrett, 1999
Lechmann, 1999
GJ
:0
D
Combined ~~-----------------------.----~~~
.08208 14.8522
or
Pooledestimate: 2.5 (95%C.I.: 1.7- 3.7) Test for heterogeneity: Q=6.9; p=0.503
Figure 2.4.1. Meta analyses. Summary estimates of studies showing an
association between OQB 1*030 1 and self limiting HCV infection (Part A.).
Summary of estimates of studies showing an association between ORB 1*11
and self-limiting HCV infection (Part B). Only data pertaining to Caucasian
individuals in comparisons between individuals with self-limiting versus
persistent HCV infections are employed in this analysis.
*This paper presented data on Caucasians only for DQB 1*0301 and not
DRB*11
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There is an unusual situation in Ireland where a large number of women were
infected with HCV by contaminated RhD immunoglobulin." The viral strain of the
infecting inoculum and the dose were consistent in this outbreak and associations has been
reported for HLA-DRB1*0101 with self limiting infection.P: 18 Outside this unique
population, however, HLA-DRBl*0101 has not been shown to influence the outcome of
HCV infection. This population provides an interesting opportunity for the study of
immunogenetic determinants of HCV susceptibility. To begin with, this cohort is quite
homogenous. It is comprised of younger child-bearing age women of a similar ethnic
background. Second, all individuals were infected with the same strain of virus with similar
doses. Variations in viral strain, size of viral inoculum and host racial heterogeneity that
may potentially mask genetic effects are eliminated in this situation. At the same time, these
attributes pose problems with respect to generalisability. It is unclear whether fmdings in
this cohort may be extrapolated to both genders or to other ethnic groups. This population is
a very homogenous group of Irish women, and correlations may not be readily extracted to
other ethnic groups. It is also possible that the dose and strain of HCV that infected these
women makes this cohort unique. Different immunodominant epitopes may exist on
different strains of HCV. It is possible that the strain of HCV found in the Irish outbreak
elicits immune responses from specific alleles such as ORB I*0101. This may explain why
the association of DRBI *0101 with self-limiting infection has only been reported in this
population.
It is difficult to dismiss the possibility that MHC class I genes influence the outcome
of HCV infection. There have been very few reports of disease association studies using
these loci as candidate genes. Thio et al. reported associations of MHC class I alleles with
viral clearance: HLA-B*57 (Odds ratio (OR)=0.62; 95% Cl, 0.39 to 1.00), and HLA-
Cw*0102 (OR= 0.43; 95% Cl, 0.21 to 0.89) as well as persistence: HLA-A*2301 (OR=
1.78; 95% Cl, 1.01 to 3.11) and HLA-Cw*04 (OR= 1.78; 95% Cl, 1.21 to 2.59).33
Although most association studies of genetic susceptibility to HCV infection have
involved the MHC, several studies have also addressed the potential role ofnon-MHC loci.
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One of the more interesting stories concerns the potential role of the chemokine receptor
(CCR5) in resistance to HCY infection." CCR5 has gained considerable attention in the
past few years because of its role as a co-receptor for the human immunodeficiency virus
(HIY). Homozygotes for a deletion variant (CCR5* .132) are conferred a relatively high
resistance to HIV infection. Although, CCR5's role as a co-receptor for HIV is clearly not
directly relevant to HCY infection, CCR5 is the principal ligand for the chemokines
macrophage inflammatory protein (MIP)-l a, MIP-l ~ and RANTES. Because chemokines
and chemokine receptors are important in lymphocyte recruitment and it is possible that the
CCR~* .132 variant may influence the outcome of other infections, such as HCY, via this
pathway. In a study by Woitas an colleagues, a higher than expected frequency of
CCR5* .132 homozygotes was observed in patients with HCY infection. It is not surprising
in many respects that this study observed a differential distribution of the frequency of
CCR5* .132 in those with HIY compared to other populations, such as those with HCY
mono-infection, as by definition, possession of CCR5* .132 makes it more difficult for one
to be infected by HIY via this chemokine co-receptor.i" 46, 47 A recent large study by
Promrat and colleagues observed a similar distribution of CCR5* ~32 homozygotes
between patients with chronic HCY and healthy controls." In a study by Mangia and
colleagues, and another study by Zhang and colleagues, it is suggested that the differential
distribution of CCR5*M2 observed by Woitas and colleagues is primarily the result of
reduced frequency of CCR5* ~32 individuals in the HIY cohorts.t" 47
Studies have addressed genetic variation in the regulatory regions of
immunomodulatory cytokine genes as well. Several studies have focused on genes such as
Interleukin-IO (lLIO) and tumour necrosis factor (TNF), and have observed no association
with respect to tumour necrosis factor alpha HCY susceptibility'" 38 but one study
observed an association with the ILIO G/G genotype and chronic infection when compared
to healthy controls (OR=2.75 (adjusted for age and sex); 95%C.I.: 1.01-7.50; p=0.048).36
Associations were observed between the Haptoglobinl-l allele and risk for HCY infection
(p < 0.001).
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Response to anti-HCV therapies
Twenty-five studies addressed the potential role of genetics in the response to
interferon therapy or variations in viral load (Table 2.3.2).9. 19.29.30.36·39.48-65 Unlike studies
of susceptibility to HCV, the majority of studies have concerned regions outside the MHe,
with an emphasis on single nucleotide polymorphisms. Three main outcomes are
commonly examined in studies of the response to anti-Hey therapies: 1) sustained
response-now commonly defined virologically as having undetectable serum HeV -RNA
levels at 6 months after the discontinuation of treatment. Older studies have defined
response biochemically as a normalisation of ALT levels; 2) initial response-this is a
disappearance in serum levels of HeV-RNA at the end of the initial phase of treatment-
commonly 12 weeks after the inception of the regimen. A portion of these individuals who
have achieved initial response may also experience a virological relapse later on, so they
are not true responders; and finally, 3) n on-responders-these are individuals who have
detectable viraemia at week 12 of therapy. They are distinct from initial responders because
they never achieved any sort of major virological decline to undetectable levels, even for a
short period oftime during the initial course (first 12 weeks) of therapy.
Relapse responders represent an intermediate phenotype between sustained
responders and non-responders. As a result, they may be classified independently as their
own phenotype in some studies, included with non-responders in some studies, or included
with sustained responders in other studies to create an "initial reponse" phenotype that
includes all individuals who a decline in HCV-RNA levels during the initial phase (first 12
weeks) of therapy. Also, some early studies define response to therapy solely based on
normalisation of ALT levels. This is not surprising as shortly after the discovery of hepatitis
e, therapy was largely based around ALT-normalisation. Additionally, it is worth noting
that some studies deal with interferon monotherapy, while others deal with interferon and
ribavirin combination therapy. Studies have not yet emerged involving the newer pegylated
interferons, both as monotherapy or in combination with ribavirin.
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Unlike the replicated associations of DQB 1*0301 and DRB 1*11 with self-limiting
infection, clear and replicated associations have not been observed with alleles of the MHC
and therapeutic outcome. In fact, there have been some contradicting observations. Kikuchi
and colleagues observed that the HLA-DR4 group was associated with non response/" In
contrast, Sim and colleagues observed the DRBI *0404 allele (a subset of the DR4
serogroup) to be correlated with response/" One major explanation for the observed
differenced between these two studies is that the populations were different with respect to
race, and gene frequencies may vary greatly from race to race. While the Kikuchi study
examined Japanese patients, the Sim paper studied Caucasians from Canada. 58. 63 Both
studies defined response based on biochemical parameters rather than virological ones.
Geographic variations in viral genotype also exist, with genotype-l predominating in North
American countries such as Canada, and genotypes 2 and 6, in addition to genotype-I, also
existing in parts of eastern Asia, and it is possible that these viral genotypic differences may
mask host genetic associations, as Kikuchi examined differences in HCV genotype, while
Sim did not. 58,63 The human MHC region is one of the most genetically diverse regions in
the human genome, and studies must be sufficiently powered to detect meaningful
differences between groups.
Contradictory associations have also been observed with respect to association
studies of cytokine gene polymorphisms and the response to interferon-based therapies for
HCV. Because of the important roles oflLlO in the immune response, several studies have
examined the role of functional polymorphisms in this gene with initial response and
sustained response. In a small-scale study, an Australian group looked at single nucleotide
polymorphisms and the resulting haplotypes that these alleles form and correlated them
with initial response to interferon monotherapy.V They observed the IL10 -592A and -819T
alleles to be correlated with initial response (OR=5.0, 95%C.I.: 1.4-19.0; p=O.OI). In
another study employing patients treated with interferon + ribavirin combination therapy,
Yee et al found that carriage of the -592A or -819T alleles, and the corresponding extended
haplotype as defined by the ILI0R allele: -591A+ -819T+ -1082A+ -2763C+ -3575T+
108bp ILIOR, conferred an advantage for sustained response to therapy (OR=2.2, p=O.016
for the individual SNPs and OR=2.65, p=O.Ol for the haplotype, respectivelyj.f
Homozygosity for the -592A or -819T alleles, or the homozygosity for the corresponding
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extended haplotype showed a very strong association with sustained response (OR=16.6,
p=O.013 for the homozygous genotypes and OR=13.7, p=O.025 for the haplotype,
respectively). A recent study failed to confirm such an association between ILI0
polymorphisms and the response to therapy." A couple of studies have examined the role
of tumour necrosis factor variants and the response to therapy. Both studies did not detect a
relationship between polymorphisms in this gene and response to therapy.62,65
One study examined the role of polymorphisms in genes involved in several genes
involved with the interferon response pathways. In particular, a Japanese group has
examined the role of polymorphisms in the MxA gene and response to interferon
monotherapy in a Japanese population and observed that the -88MxA-(G/G) genotype to be
correlated with non response and the -123MxA-(C/C) genotype to be correlated with non-
response. 56,57
Studies of HCV progression
A total of 28 studies were found to a ddress the topic of host genetics and HCV
progression, and have largely been inconsistent (Table 2.3.3).9, 11, 19,21,24,26,29,30,37,53-55,66·83
There is a trend with ORB 1*11 alleles and less severe liver disease. Asti observed
ORB1*1104 (OR=4.82) to be associated with normal ALT.ll Kuzushita reported
ORB 1*1101 to be correlated with normal ALT (OR=O.3).21 Renou reported that the
ORB1*11 allele was correlated with normal ALT (OR=2.36).78 Haruna observed the
ORB1*1101 allele to be associated with less piecemeal necrosis (OR not reported), and
Hue observed ORB 1*11 to be associated with lower Knodell scores (OR=0.35).S3, 70
Tillman also observed ORB*11 to be lower among cirrhotics (RR=O.29).81Haruna reported
an association between ORB1*1201 with less severe liver disease (OR not reported) as
well.s3 It is interesting to note that the ORBl*llOO and ORBl*1200 alleles form the OR5
serogroup. Whether these observed associations represent some sort of underlying
biological mechanisms with these alleles is not currently known. Future studies are needed
to address this question. Almost all of the studies reviewed did not adjust for potential
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environmental confounders, such as alcohol use. Future studies should examine genetic
associations in conjunction with other potential environmental as well viral factors.
Nine studies directly examined the role of HFE gene variants and the progression of
liver disease/": 69,84-89Two major polyrnorphisms are of importance in the literature:
Cys282Tyr and His63Asp (often abbreviated C282Y and H63D, respectively in single letter
amino acid notation). Of these two polyrnorphisms, heterozygotes for Cys282Tyr have been
shown to have normal to slightly elevated hepatic iron content/? Given the observation that
a number of individuals with chronic HCV infection have excess hepatic iron,91 some
investigators have examined whether heterozygosity for this variant is associated with
advanced liver disease. T he results of these studies have been discrepant, with 4 studies
suggesting an association between possession of HFE variants and increased fibrosis or
cirrhosis,": 69, 88, 92 and the other studies suggesting that there are no associations.
Methodological differences may account for these differing observations. For example,
studies employed different scoring systems for histological fibrosis. Some studies
conducted categorical analyses, while others compared averages of these semi-quantitative
categories. All of the studies were cross-sectional in design and correlations were
conducted with respect to the stage of fibrosis, irrespective of the duration of HCV
infection.
Studies of extrahepatic manifestations
Fifteen studies addressed correlations between host genetics and the occurrence of
extrahepatic manifestations in HeV (Table 2.3-4).37,69,84,86,88,93-103Two studies observed
an association between DRBl*11 and the presence of cryoglobulins (OR not reported in
Arnaroso study; OR=3.4 in Cacoub study).93,94.Both studies examined Italian populations.
Two other studies conducted in ethnically dissimilar populations found an association
between the class II DR3 allele with the presence of cryoglobulins (RR6.14 and RR=3.7,
respectivelyj.": 103Hwang and colleagues studied Chinese patients, while Lenzi and
coworkers studied Italians.98, 103.Lenzi also examined class I loci as well and found an
association with B8 and the presence of cryoglobulins. Linkage between B8 and DR3 is
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quite strong, and this haplotype has been linked with several autoimmune diseases
including autoimmune hepatitis type I, primary biliary cirrhosis and rheumatoid arthritis.l?"
108
A few studies have also addressed the potential role of the HFE gene variants
(Cys282Tyr or His63Asp polymorphisms) and iron levels. No consistent observations with
respect to this locus have been observed, with several studies reporting no association
between this variant and increased iron,8S,86,102and another study reporting an association
between this locus and higher mean ferritin levels.88 Differences in study design- for
example the definition of iron (i.e., serum ferritin levels versus iron stains of liver biopsies)
may play a major role in these differences. Some studies employed use of the S-point
METVIR scoring system for liver fibrosis while others used the 7-point Knodell
histological activity index. In addition, use of these semi-quantitative scoring systems is
accompanied by a degree of inter-observer variation. These differences preclude the use of
meta-analyses to pool data from these studies.
2.5 Concluding Remarks
A few genes have been associated with the outcomes of HCV infection. The most
replicated association is with the class II DQB1*0301 allele and self-limiting HCV
infection. With respect to the response to therapy, two studies have shown an association
between the -88M.xA-(G/G) genotype and non response to interferon monotherapy. There
appears to be a correlation between the alleles in the DRS serogroup with milder liver
disease. Two studies have shown a correlation between the DRB 1*11 allele and the
presence of cryoglobulins, while another two studies have shown correlations between the
DR3 allele and the formation of cryoglobulins.
Reproducibility is essential in this field. Unfortunately, there tends to be a bias in
the reported literature towards the publication of positive results irrespective of the quality
of the study. Another concern is that demonstration of an association with an allele, even
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after confirmation, does not necessarily imply that the allele is functionally responsible for
changes in the disease susceptibility or resistance. Allelic variants are carried on long
segments 0 f DNA which are likely to contain other polymorphisms and are inherited as
haplotypes. The patterns of linkage disequilibrium between polymorphic loci are complex
and unpredictable. Therefore comprehensive investigation is required to identify causative
variants from those which are associated through linkage disequilibrium. The resolution of
both of these issues will require much larger study populations.
There has been a tendency in recent years to dismiss the potential contribution of
genetic association studies to the scientific literature due to the lack of data on the
functional effects of many genotypic variants that have been studied. It is important to bear
in mind that the understanding of genetics in health and disease consists of several different
parts: 1) the identification of new polymorphisms, 2) the association of these
polymorphisms with disease outcomes, and 3) the understanding of the functional effects of
these variants. These three factors may not necessarily be completed at the same time, and
the importance of studies addressing only one or two of these aspects should not be
dismissed. With the human genome project it is likely that the identification of new
polymorphisms and the association of new polymorphisms with disease outcomes will far
exceed the speed at which functional studies are conducted. Similarly, the generation of
many negative studies will occur. Given the importance of replication in this field it is
important that all of the evidence be considered, regardless of whether the associations are
positive or negative.
The primary aim of investigating the genetic determinants for the outcomes of HeV
infection is to understand why some individuals develop self limiting infection, why others
are resistant to therapy, and why some individuals with chronic HeV progress more rapidly
with respect to their HeV-related liver disease than others. However, there may be, in the
future, clinical benefits arising from these studies. Host genes which influence the
resistance to persistent HeV infection may provide novel therapeutic targets and
knowledge of MHe associations may be used to identify epitopes derived from Hev
antigens to be used as vaccine candidates. For example, the identification of the importance
ofceR in HIV infection has led to the development ofCeR5 antagonists aimed at the
92
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competitive inhibition 0 f H IV a ttachment.109-112Furthermore, it could be anticipated that
genetic factors which influence the response to therapy will be used in the future as
prognostic indicators or to modify therapeutic regimens in the way that we currently use
viral genotypes. Similarly. drugs may be specifically tailored to individuals with a certain
. k 113genetic rna eup.
While there are some consistent observations (i.e., DQBl *0301 and self-limiting
infection). there are more inconsistent observations. Several factors may account for these
inconsistencies. First. there a re differences with respect to the populations studied. Gene
frequencies vary across races. and it is quite plausible that one ethnic group may have the
preferential use of different allele(s) in viral eradication than those from other ethnic
groups. Further studies of the functional aspects of HLA molecules will better elucidate the
picture of immunogenetic determinants of disease outcome in light of biological
plausibility. Confounding from other environmental as well as viral factors (such as alcohol
consumption as well as viral genotypes. respectively) as well as other as yet unidentified
factors may also contribute to differences. Variations in study design may also playa role in
the differences observed in the present review. Many of the studies were conducted on
relatively small samples. Smaller samples decrease the power of the study (likelihood of
detecting a difference between groups. assuming that a true difference exists) as well as the
precision of the measurements of association.l'" The issue of sample size is even more
critical in studies concerning the MHC. which is known to be one of the most genetically
diverse regions of the human genome. Lack of an association may not mean that
associations do not exist; rather, they may be a reflection of the lack of an under-powered
study's ability to detect meaningful relationships. Finally, differences in study design may
account for some of these differences as well. As with any case control study, the case
definition as well as control group selection will affect study outcome. For example. in the
study of self-limiting versus persistent infection, some groups compare individuals with
self-limiting infection to those with persistent infection. while others compare chronically
infected individuals to a group of healthy HCV-negative individuals."
Interestingly. most of the studies reviewed did not examine gene environment
interactions or control for behavioural confounders such as alcohol use. Future studies of
93
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HCV natural history will have to be sufficiently powered to accommodate adjustment for
not only potential confounding factors but the possibility of genetic interactions with
environmental or viral factors. Importantly, quantitative evaluation of drinking behaviours
will need to be made and will require the use of validated survey instruments.
There is an urgent need for the establishment 0 f large cohorts for the systematic
study of host genetics and the outcome of hepatitis C. These cohorts must be defined using
rigorous epidemiologic methods. In addition, these cohorts should be sufficiently large to
detect meaningful relationships between genetic markers and disease outcomes. Replication
of observed relationships is an important aspect of disease association studies. Itwould be
optimal for future studies to involve two unrelated cohorts, where hypotheses may be
generated in one cohort and replicated in another.t" The identification of genetic
polymorphisms in the human genome has been greatly facilitated by the human genome
project. However the correlation of these genetic markers with disease outcomes has just
begun. The success of this field will rely on the careful evaluation of these markers in
properly designed epidemiologic studies along with sufficient replication of putative
predictive markers in different populations.
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Chapter 3
General Methods: Cohorts and Data Collection
Management
3.1 The Cohorts
The present study employed the use of 3 cohorts: The St. Mary's Hospital Hepatitis
C Cohort (London, UK), and the Hepatitis C European Network for Cooperative Research
(HENCORE), a multi-centre European study of HCV that includes individuals from the St.
Mary's Hospital Hepatitis C Cohort, and the Alabama Hepatitis C Cohort (Alabama, USA).
As outlined below, each cohort was constructed for slightly different research questions and
accordingly, the data collected differs.
The HENCORE Cohort
The Hepatitis C European Network for Cooperative Research (HENCORE) study is
a multi-centre study of hepatitis C involving eight tertiary care referral centres in seven
countries, at eight centres: Lund, Sweden; London, United Kingdom; Hannover, Germany;
Barcelona, Spain; Athens, Greece; Torino, Italy; Padova, Italy and Lyon, France. The study
enrolled approximately 1600 Caucasian individuals with the aim of establishing guidelines
about HCV screening, control and management. Figure 3.1.1 presents a map of Europe with
the locations of each of the participating centres indicated. Enrolment was between October
1995and October 1997:
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Liver biopsies and histology
Most study participants received a liver biopsy at enrolment, which was scored by a
single pathologist using the Ishak scoring system with the modified Knodell activity
index?' 3 Pre-treatment sera were collected on these patients at the time of enrolment, as
was a sample of their DNA.
Clinical and demographic data
Standard data including baseline ALT values, along with demographic variables
such as gender, age at treatment were collected on participants and entered into a database.
Appendix I lists these demographic variables. Estimates of the year ofHCV infection were
obtained on a number of patients via interview by the attending physician.
Anti-llCV Therapy
Approximately 30% of patients in this cohort were given interferon m onotherapy
for their hepatitis C. Briefly, 3 million units of interferon mono therapy was administered by
subcutaneous injection three times weekly for 24 weeks irrespective of the patient's HCV
viral genotype, which was the standard practise at the time the study was carried-out.
Patients were given a qualitative test for presence of HeV-RNA to assess response to
therapy. Per standard definitions, those with positive tests at the end of treatment were
termed "non-responders," while those with negative tests at the end of treatment and
positive tests at 6 months after discontinuation of therapy were termed "relapsed
responders," and those who were negative at the end of treatment and negative at 6 months
after discontinuation of treatment were termed "sustained responders."
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Figure 3.1.1. Map illustrating the locations of the medical centres participating
in the H patiti C European Network for Cooperative Research (HENCORE)
tud . Centre are located in: London, UK; Lyon, France; Barcelona, Spain;
Ath n , Gre ce; Hannover, Germany; Padova, Italy; Torino, Italy; and Lund,
weden. Map source: U.S. Central Intelligence Agency)
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The St.1\lary's Hospital Cohort
The St. Mary's Hospital Cohort consists of approximately 1,800 subjects who have
been seen at the Hospital's Liver Centre for routine care of their HCY infection. The cohort
is approximately 80010Caucasian, with others from parts of Africa, the Middle East and the
Indian subcontinent. A portion of this cohort forms part of the HENCORE cohort. When
medically indicated, a liver biopsy was performed on each patient and staging of fibrosis
and necro-inflammation was conducted by a single pathologist using the Ishak score with
modified Knodell index.2•3 Approximately, 30% of individuals were treated for their Hey
using interferon monotherapy, as per the HENCORE study. Pre-treatment serum and DNA
samples have been collected and stored on almost all subjects. Clinical and demographic
data such as possible risk factors and current! past alcohol were also collected and stored.
The Alabama Hepatitis C Cohort
The Alabama Hepatitis C Cohort is a multi-centre drug therapy cohort consisting of
patients from the University of Alabama at Birmingham (UAB) in Birmingham, Alabama,
USA and the University of South Alabama in Mobile, Alabama, USA. The study aimed to
enrol a total of 400 individuals between the two centres with chronic hepatitis C for
treatment with standard interferon-a + ribavirin (Rebetron"; Schering-Plough Corporation,
USA), with approximately 100 patients recruited at the University of South Alabama and
approximately 300 from the University of Alabama at Birmingham. Both sites are major
tertiary care referral medical centres. In particular, UAB University Hospital is a major
organ transplant centre in the USA, and as a result patients are from a diverse geographic
area covering most of the state of Alabama, with a few patients coming from neighbouring
states as well. Figure 3.1.2 p resents a map of the Southern states of the U SA, with the
locations of Birmingham and Mobile highlighted. By the end of 2001, new recruitment was
ended in light of newer protocols employing the more efficacious pegylated interferons,
either alone, or in combination with ribavirin.t" The cohort is 90% Caucasian and 10%
black.
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Figure 3.1.2 Locations of study centres for the Alabama Hepatitis C Cohort. Part A.
shows the outhem states of the United States of America, with the state of Alabama
circled. Part B. The state of Alabama, with the cities of Birmingham and Mobile
depicted. Outlines within the map indicate counties. (Map source: Cartographic Research
Lab, Department of Geography, University of Alabama at Tuscaloosa).
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The treatment protocol
Treatment using interferon-a and ribavirin (IFN+R) is based on viral genotype.
Because early virologic response is highly predictive of therapeutic outcome, treatment was
initially for 12 weeks. If patients responded to therapy at the end of these 12 weeks (defmed
as non-detectable viral levels by PCR), treatment was continued. For those with the more
resilient genotype-I virus, treatment was continued for an additional 48 weeks (1 year of
total treatment). For those with non-I genotypes, treatment was continued for an additional
12 weeks (6 months of total treatment). Figure 3.1.3 summarises the protocol. All patients
received 3 million units of interferon-a three times per week by subcutaneous injection. In
addition, patients> 75 kg received 1200 mg of orally administered ribavirin twice daily,
while those < 75 kg received 1000 mg or r ibavirin twice daily. A sample of DNA was
collected on patients enrolled in this protocol.
Patient inclusion/exclusion criteria
This cohort aimed to enrol individuals with compensated chronic HCV infection
who were otherwise "healthy,"? 8 All patients with other forms of chronic liver disease such
as chronic HBV co-infection and concomitant forms of autoimmune liver disease were
excluded. Alcohol consumption was a contraindication for inclusion in this study and all
patients must have been off alcohol for at least 6 months prior to the start of enrolment
screening to be eligible. In addition, individuals co-infected with the human
immunodeficiency virus (HIV) were excluded. All patients were adults over the age of 18
and under the age of 70. Severe cirrhosis (Child's B/C) and decompensated liver disease
were also a contraindication for enrolment in the study. Individuals who had mild cirrhosis
(Child's A) and compensated liver disease were not excluded in this protocol.
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Figure 3.1.3. The DAB HeV treatment protocol. After undergoing screening, eligible
patients are given 12 weeks of interferon and ribavirin therapy (3 million units of
interferon-a three times per week, along with 1200 mg ribavirin daily if >75 kg, or 1000
mg ribavirin daily if <75 kg). If a patient is positive for HeV -RNA at week 12, treatment is
terminated and the patient is considered a non-responder. If the patient is peR negative for
HeV-RNA at week 12 and they have genotype-l infection, they are given 48 weeks of
therapy. If they have a non-I genotype infection, they are given 24 weeks of therapy. Six
months after the cessation of therapy patients are tested for the presence of HeV-RNA
again. If they are negative they are considered "sustained responders." If they are positive,
they are considered "relapsed responders."
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Assessment of viral genotypes and quantification
HCV viral genotypes as well as quantification of HCV viral load at baseline, week
4, week 12 of treatment as well as 6 months after discontinuation of treatment were
conducted by the National Genetics Institute in Los Angeles using the proprietary
Superquantf assay system. This system gives a viral genotype as well as quantitative
measurements of HCV-RNA levels (National Genetics Institute, Los Angeles, California,
USA). The reporting of HCV genotypes is according to the nomenclature proposed by
Simmonds." A competitive PCR system for viral quantification expresses viral levels as
copies per millilitre of serum. The lower limit of detection of this assay is lOO copies/ml.,
while the upper limit is 5 million copies/mL. Thus, readings at 100 copies/mL or below are
considered "negative" for hepatitis C virus. All viral genotyping and viral quantification for
this protocol were conducted by the National Genetics Institute. The protocol was instituted
prior to the adoption of international units (IU) for the quantification of HCV-RNA levels."
As a result, all viral load measurements in the studies presented here are expressed as
copies per millilitre of serum, rather than international units. Because the HENCORE study
was conducted largely before the widespread use of viral quantitation and treatment
according to viral genotypes (with genotype-I HCV receiving a full year of treatment and
non-I genotypes receiving half a year), such data are not available in the HENCORE
cohort.
Clinical and demographic data
Standard clinical data such as ALT values, routine biochemistries (platelet and
neutrophil counts, etc), were collected on all patients and stored in a database, along with
demographic variables such as gender. The process for collection of demographic variables
has been previously described, and consists of a detailed patient interview instrument that I
developed previously. I I Estimates of the year of HCV infection were obtained on
approximately half of the individuals in this cohort by this patient interview. Standard
biochemical and laboratory data were collected on each patient at each clinic visit and were
entered by the biostatistics unit of the UAB Comprehensive Cancer Centre Data handling in
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this cohort will be discussed in greater detail below. A list of key variables in this database
is presented in Appendix 2.
Liver Biopsies and Histology
All patients in this cohort received a liver biopsy prior to enrolment in the study.
However, systematic scoring of hepatic biopsies for extent of fibrosis using either the
METAVIR or ISHAK systems was not routinely conducted on all patients.v 12 Instead,
consultant liver pathologists described the biopsy sample and whether the patient was
eligible for enrolment. Table 3 .1.1 summarises the characteristics 0 f each 0 f the cohorts
employed in the present study.
Table 3.1.1. Comparisonof cohort characteristics.TheHENCORE cohort and
the AlabamaHepatitisC Cohort.
Alabama Cohort "ENCORE cohort
Therapy
Type of regimen
Viral genotyping
Viral load
quantification
Fibrosis Progression
Systematicscoring
using Ishak
Systematicscoring
usingMETAVIR
interferon+ribavirin
all patients
all patients
none
some
interferonmonotherapy
some
none
all patients
none
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3.2 Ethical approval
Ethical approval for the conduct of the present studies were obtained from the St.
Mary's Hospital Local Research Ethics Committee and the University of Alabama at
Birmingham Institutional Review Board. Studies of autoimmunity in hepatitis C were
granted by the St. Mary's Hospital Local Research Ethics Committee and the Ethics
Committee of the London School of Hygiene and Tropical Medicine. Ethical approval for
the use of data on treatment outcomes for patients participating in the HENCORE study
was obtained from the ethics committees of each of the participating centres. I
3.3 Data Collection and management
The HENCORE and St. Mary's Hospital Database:
Clinical and demographic information, including estimates of the time of HCV
acquisition were obtained on patients by staff of each of the individual centres. Copies of
these data forms were sent to both London and Lyon in paper form. Entry of the
information on these forms into Access'" was conducted independently in both centres and
cross-validated by comparing the databases from the two centres and discrepancies were
corrected by checking the original forms.
With respect to genotyping, the data are downloaded from the genotyping computer
and cross-checked by two observers. These are then uploaded into the Access® database.
For the present study, I subset data from this database, which contains information on both
HENCORE and St. Mary's Hospital patients, along with relevant genotyping information.
Appendix 1 lists some of the key demographic variables in this database. Subset data were
then converted these data to SAS version g®for data analyses.
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Data managementfor the study of antinuclear antibodies:
Standard clinical and demographic data were obtained from the Access" database
described above. Data were subset and stored in a database I created using EpiData®
(Copenhagen, Denmark: www.epidata.dk). Data generated from the studies of anti-nuclear
antibodies (ANA) were double entered, cross-validated and entered into this EpiData®
database. Data were then converted to SAS®for analyses.
The Alabama Hepatitis C Cohort
Clinical and standard demographic data were collected as each patient presented to
the clinic at the time of their visits. These data were recorded, double-entered and cross-
validated as part of standard operating procedure for this protocol. Information on risk
factors from a detailed patient interview was also collected on standardised forms, double-
entered and cross-validated. Appendix 2 lists the key demographic and clinical variables
available in this database. In addition to standard double-entry and cross-validation of data,
frequency distributions of each of the major variables were conducted after each 50 updates
to the database to search for obvious outliers and major shift in the distribution of data. All
data were kept in a FoxPro® database at the Biostatistics Centre of the UAB Comprehensive
Cancer Centre.
For genetic data, all genotypings are double-read and the two readings are cross-
validated. Mismatches are discussed between the two observers and where irresolvable, the
genotype assays are repeated. These cross-validated data are then double entered along with
the demographic and clinical data and subjected to the same data consistency techniques as
above.
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3.4 Genotyping techniques
Genotyping of single nucleotide polymorphisms was conducted using three methods
in the present study.
HENCORE cohort:
Real-time PCR (kinetic thermal cycling)
Genotyping of single nucleotide variants in this cohort was largely by kinetic
thermal cycling using real-time polymerase chain reaction (peR).13 Real-time peR detects
specific amplification products in real time, and data on peR products are gathered during
the amplification process. This technique employs the use of a fluorescently labeled
oligonucleotide probe and thus eliminates the need for post-PCk processing, such as the
need to run amplification products out on agarose gels and stain them with ethidium
bromide. With the elimination of post-amplification processing, the process is faster, and
allows for a much higher throughput.
Allele-specific PCR
In this technique, primers are designed for specific alleles at each locus. Two
reactions are needed for each locus. In the first reaction, a primer specific for allele X is
used with a common reverse primer. In the second reaction, a primer specific for allele Y is
used along with the same common reverse primer. Amplicons are typically small, with on
average, only 50 base pairs oflength.
These reactions are carried-out on 96 well plates (Figure 3.4.1.). In the odd columns
primers specific for allele X are placed, along with the common reverse primer; in the even
columns, primers for allele Yare placed (Figure 3.4.1). So for each sample, two wells are
required. For example, Sample I will be placed in well A-I and well A-2, with A-I
containing the primer specific for allele X and well A-2 containing the primers specific for
allele Y. This is repeated throughout the tray. Each tray also contains a negative control of
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water along with the pnmers to check for contamination, along with three positive
controls-an example of an individual homozygous for allele X and another for allele Y
and a heterozygous individual. The two amplifications are compared by the computer. A
cut-off threshold is manually set by the operator to prevent the computer from reading non-
specific amplification products or gene products with poor amplification. Presence of a
homozygote for allele X or Y will result in product in only 1 of the wells. Figure 3.4.2
presents an example of this scenario. Presence of a heterozygous individual will result in
products in both wells (Figure 3.4.2).
Genotyping by restriction digest
A portion of individuals in the HENCORE cohort were genotyped by restriction
fragment length polymorphism (RFLP). In this technique, restriction enzymes are
employed. Restriction enzymes are enzymes obtained from bacteria that cut specific
pallendromic patterns of DNA. For example, the enzyme, EcoRI cuts both strands of DNA
at the same site between the G and the A:
5'-G ~AATIC-3'
3'- CTTAA t G-5'
Consequently, these enzymes may be employed for genotyping of allelic variants. A
simplified scenario based on the aforementioned EcoRI example is present below:
Initially, a segment of DNA is amplified containing the locus that is to be genotyped. This
product is then incubated with a restriction enzyme. If an individual possesses a specific
allele that will allow an enzyme to cut, the original longer segment of DNA will be cut into
two segments when the product is run out on a gel. If an individual does not have this
particular sequence of DNA, then only one longer segment will be present.
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Figure 3.4.2. Schematic diagrams illustrating allele-specific amplification using kinetic
thermal cycling. A. Example of an individual homozygous for allele X. Only product for
this allele is amplified (dotted line). B. Example of an individual homozygous for allele Y.
Only product for this allele is amplified (solid line). C. Example of an individual
heterozygous for both alleles (XY). Both products are present (dotted line and solid line).
Horizontal hashed lines represent the cut-off value set by the observer so that only products
above that line are counted by the computer. This prevents the counting of non-specific or
poorly amplified products.
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Genotyping by peR-SSP
Genotyping of single nucleotide allelic variants in the Alabama hepatitis C cohort
was by polymerase chain reaction (PCR) with sequence-specific primers (SSP). In this
method, primers are designed for specific alleles at each locus. Two reactions are needed
for each locus. In the first reaction, a primer specific for allele A is used with a common
reverse primer. In the second reaction, a primer specific for allele B is used along with the
same common reverse primer. In both reactions, a pair of primers is used to amplify a
"housekeeping gene," which is another gene that is not related to the gene under study. This
serves as a positive control in the assay. Amplicons of each of the specific alleles is around
400-500 base pairs in length in this assay. The resulting PCR products are run on
agarose gels and stained with ethidium bromide for analysis. Amplicons of the house
keeping gene is typically larger (around 600-800 base pairs in length) to allow for adequate
discrimination of allele-specific amplicons from the housekeeping gene amplicon.
This assay is carried-out in a 96-well tray, with each tray containing 48 samples (2
wells for each sample, with each well containing a reaction specific for each of the alleles).
After PCR amplification, the resulting PCR-products are run-out on a gel and stained with
ethidium bromide and then photographed. Figure 3.4.3 provides an example of this type of
genotyping method. This figure presents an ethidium bromide-stained gel of PCR-SSP
typing of variants for the Tapasin gene.
3.5 Statistical Methods
Statistical software
Power calculations were conducted using the Epilnfo'" 2000 software (Centers for
Disease Control and Prevention, Atlanta, USA). Statistical analyses were conducted using
the SAS®statistical package (Cary, North Carolina, USA). Conversions to SAS®
146
Chapter 3
lOO-bp
Marker
Genotype Genotype Genotype
111 1/2 2/2
0~0Lanes: 1
... Control band
... Allele-specific
band
Figure 3.4.3. Example of genotyping using peR-SSP (polymerase chain reaction with
sequence specific primers) for dimorphic allelic variants. Lane 1 contains the molecular
marker (100 base pair ladder). Lane 2 and 3 show an example of an individual who is
homozygous for allele 1-- presence of band in only the lane with the reaction mixture
specific for allele 1 (lane 2), while lanes 4 and 5 show an example of an individual who is
heterozygous for allele 1 and alleles 2 --presence of a band in each of the allele land allele
2-specific reaction mixes (lanes 4 and 5, respectively). Lanes 6 and 7 show an example of
an individual who is homozygous for allele 2 -- presence of band in only the lane with the
reaction mixture specific for allele 2 (Jane 7). All reaction mixtures contain primers specific
for a "hous keeping gene" that serves as a positive control band.
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from the Access® (Microsoft Corporation; Seattle, Washington, USA) and EpiData®
(Copenhagen, Denmark) databases was achieved using the StatTransfer® programme
(Circle Systems, Inc., Seattle, Washington, USA). Additional analyses and graphics were
conducted using the EXCEL® programme (Microsoft Corporation, Seattle, Washington,
USA).
Exploration of continuous and categorical variables
For examination of the distribution of continuous variables, the SAS® PROC
UNIVARIATE (procedure used to obtain basic descriptive statistics such as median, mode
and range) and PROC MEANS (procedure used to obtain the mean), while the PROC
FREQ (procedure to give frequency distributions) command was used to examine the
frequency distributions of categorical data.
Data cleaning and missing data
All datasets were cleaned by initially examining frequency distributions of variables
(both categorical and continuous) to detect obvious outliers. The dataset was then visually
scanned to pick up any unusual observations. Such observations were cross-checked against
original data entry forms to identify and rectify errors.
Information was missing on gender and ethnicity was missing on approximately
29% and 30% of individuals, respectively, in the HENCORE database. Individuals with
missing data were dropped from any analyses involving those variables.
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Univariable associations of categorical data
For univariable associations of categorical data, standard Chi-square (t) statistics
for contingency tables were used. For calculations involving a cell with a count ~5, Fisher's
exact p-values and confidence limits were calculated using the SAS® software. Otherwise,
standard maximum likelihood p-values and confidence limits were obtained. The PROC
FREQ command (to obtain frequency distributions for categorical data) was used in this
procedure along with the CHISQ CMH (chi-square and Cochrane Mantel-Hanzel statistics).
Univariable comparisons of non-parametric data
For comparisons of non-parametric data, the SAS®P ROC NPARI WAY (for non
parametric l-way tests) command with the WILCOXON stipulation (to specify the use of
the Wilcoxon tests) was used to employ the Wilcoxon-rank sum test. This test was
employed in Chapter 6 for the study of CTLA4 gene variants viral dynamics to examine
differences in viral load at each time point.
Multivariable analyses
For multivariable analyses of categorical data, logistic regression was employed
using the PROC LOGISTIC procedure in SAS®. For the analyses of matched-pairs,
conditional logistic regression was used using the PROC PHREG procedure in SAS®.
Longitudinal Analyses
For evaluation of viral dynamics over the course of anti-HCV treatment,
longitudinal analyses by mixed modelling was used." The PROC MIXED procedure in
SAS®was employed. IS Briefly, this procedure is a mixed model procedure that incorporates
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both fixed and random effects. It is more robust than standard repeated measures by
analysis of variance and allows for unequal spacing of measurement points.
Spatial analyses
For analysis of geographic distributions of anti-nuclear antibodies (ANA) in patients
chronically-infected with HeV two methods were employed. First, multi-level modelling
was employed with the PROC MIXED procedure (procedure for random and fixed effects
mixed modelling) using SAS® software. IS. 16 Second, logistic regression was employed with
study centres listed in hierarchical order by geographic latitude.
Genetic Studies: associations of allele frequencies with clinical outcomes
In genetic association studies, the frequency of individual alleles was assessed by
direct counting. Variants on both chromosomes in each individual are assessed in the
calculation of allele frequencies. Thus, there are twice as many alleles as individuals (2N)
in a study.
Genetic Studies: associations of genotype frequencies with clinical outcomes
Frequencies of genotypes were assessed by direct counting. Briefly, the combination
of alleles on both chromosomes at a particular genetic locus are assessed as a single unit in
each individual. Thus, for a dimorphic single nucleotide polymorphism, three possible
variants may exist for each individual:
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Table 3 .5.1. Possible combinations of genotypes at each dimorphic locus for single
nucleotide polymorphisms.
Combination Chromosome 1 Chromosome 2
Possibility 1
Possibility 2
Possibility 3
Variant 1 Variant 1
Variant 1 Variant 2
Variant 2 Variant 2
Unlike allele frequencies, the proportion of individuals with each genotype should
add up to 100%. For univariable calculations of genotypes with clinical outcomes, the
standard Chi-square test. Maximum likelihood or Fisher's exact confidence-limits and
p-values were calculated as appropriate (see aforementioned section on univariable
associations of categorical data).
Genetic Studies: associations of allele carrier frequencies with clinical outcomes
Allele carrier frequencies, also sometimes referred to as "phenotype" frequencies,
assess whether an individual carries a particular allele. Allele carrier frequencies were
also assessed in the present study by direct counting. Univariable associations of allele
carriage with clinical outcomes, the standard Chi-square test were calculated. Maximum
likelihood or Fisher's exact confidence-limits and p-values were calculated as
appropriate (see aforementioned section on univariable associations of categorical data).
Possible interactions between genetic variants and other factors as gender and alcohol
use were also explored.
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Correction for multiple comparisons
To control for the possibility of chance associations, many investigators employ the
use of the Bonferroni correction for multiple comparisons. This technique multiplies the
p-value by the number of comparisons made. This correction reduces type I error at the
expense of type II error.l" Due to the hypothesis-generating nature of this study, I have
deliberately opted not to employ the use of the Bonferroni correction. Rather than risk
the possibility of dismissing an association solely based on the p-value, which varies
according to both study size and the strength of association,'! I have not employed this
correction. However, the number of comparisons made will be clearly presented to
allow the reader to judge the quality of data for hislherself.
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Chapter 4
Studies of Data Consistency and
Reproducibility
4.1 Study aims and m ethods: agreement a nd reproducibility in genetic
and autoantibody data collection
To sy stematically examine the consistency and reproducibility 0 f t he genetic and
autoantibody data generated in the present study, I conducted a series of evaluations to
statistically ascertain these factors.
4.2 Evaluation of automated genotyping results
As mentioned previously, every automated genotyping run is validated by a human
reader. By checking the amplification curves themselves, the reader is able to validate the
automated scoring system and look for samples that may have had poor amplification not
picked-up by the automated system; for example, those samples that do actually amplify,
but amplify only moderately late, or those with poor amplification curves in general. To
evaluate this process, assessment was made of the consistency and reproducibility of this
process by conducting a series of tests to evaluate the level of observer with machine
agreement, observer with observer agreement, and intra-observer agreement using the
kappa (K) correlation coefficient.' Calculations were made using the SAS® software (Cary,
North Carolina, USA). Briefly, the kappa correlation coefficient is used to assess the degree
of intra-observer agreement. The kappa score ranges between 0 and 1. Data collected as
part 0 f an observer agreement study are arranged in a contingency table, where column
levels represent the ratings of one observer and the row levels, the rating of the other
observer. Each cell represents one possible observation of each observer, with the diagonals
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of the table represent the agreements between the two observers. 2 Kappas less than 0.4
represent "slight agreement." Those greater than or equal to 0.4 and less than 0.8 are
represent "moderate agreement." Kappas greater than or equal to 0.8 are represent
"excellent agreement/"
For this evaluation we selected, at random, one of the loci we genotyped for this
project: an A to G single nucleotide polymorphism for 48 individuals at the -277 position
of the NOS2A gene, which encodes the protein inducible nitric oxide synthase. Genotyping
at this locus was conducted using kinetic thermal cycling as described earlier. These results
were first validated by the first observer (LJY) and then independently by the second
observer (Dr. Susanne Knapp, Research Associate, Imperial College Faculty of Medicine at
St. Mary's Hospital, London, UK). Next, both observers independently repeated their
evaluations of the automated genotyping results approximately 4 months after the initial
scoring to limit memory of the first reading. Discrepancies in genotyping were reviewed
jointly and a consensus was reached between the two observers after reviewing the raw data
(amplification curves). If discrepancies could not be resolved, or one of the two observers
felt that the curves were spurious (i.e., insufficient amplification of one of the alleles) the
discrepant sample was re-genotyped.
Several comparisons were made to assess the genotyping process:
1) The first study evaluated the agreement between the first observer (LJY)
and the automated genotyping system.
2) The second evaluation compared the level of agreement between the
second observer (Dr. Knapp) and the automated system.
3) The third comparison examined the consistency within the first observer
(UY)
156
Chapter4
4) The fourth comparison examined the consistency within the second
observer (Dr. Knapp).
5) The fifth assessment evaluated t he level 0 f agreement between t he first
observer (LJY) (Second reading from analysis 3 above) and a second
reader (Dr. Knapp) (First reading from analysis 4 above). The use of the
first or second readings of LN and Dr. Knapp for the genotype results
used in this comparison were selected at random.
4.3 Anti-nuclear antibodies in hepatitis C -positive patients
To evaluate the determination of antinuclear antibody (ANA) positivity and
negativity, we compared scorings by a first reader (LN) and a second reader (Dr. Peter
Kelleher, consultant clinical immunologist, St. Mary's Hospital, London, UK) of all
samples we evaluated for ANA from the St. Mary's Hospital cohort (N=207). To evaluate
agreement regarding reading of ANA autoantibody patterns and titres, all positive samples
from the St. Mary's Hospital cohort (N=18) and the Padova, Italy cohort (N=22) (Total:
N=40) were double read by the first reader (LN) and the second reader (Dr. Peter Kelleher)
for both ANA pattern and titre. Agreement between the two observers was assessed by the
kappa (K) correlation coefficient.! Additionally, inter-observer agreement was assessed for
the first reader. For this study, all samples positive on the initial screen at a 1:40 dilution
were titred. Titre readings were assessed at: 1:40, 1:80, 1:160, 1:320 and 1:640 dilutions.
The 1:40 dilution from this titre process was used as a second independent reading to assess
the consistency 0 f pattern scoring by t he first 0 bserver (LN). Due to 1imited resources,
titres are assessed for positive individuals only once. For this reason a study assessing
consistency of titre readings within the first observer (LN) was not conducted.
In summary, four compansons were made to assess the consistency and
reproducibility of ANA data:
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1) The level of agreement between the first observer (LJY) and the second
observer (Dr. Kelleher) with respect to ANA positivity and negativity
2) The level of agreement between the first observer (LJY) and the second observer
(Dr. Kelleher) with respect to the pattern of autoantibody staining.
3) The level of agreement between the first observer (LN) and the second observer
(Dr. Kelleher) with respect to the patient's ANA titre.
4) The level of consistency within the first observer (LJY) between a first and
second scoring of ANA patterns on the same samples on two separate occasions.
4.4 Results: agreement and reproducibility in genetic and autoantibody
data collection
Evaluation of automated genotyping results
Table 4.4.1 summarises the agreement between the first observer (LN) and the
automated genotyping system on genotyping of 48 samples. There was a high level of
agreement between the observer and the automated genotyping system (1(=0.93; 95%C.I.:
0.84-1.0). Disagreements generally concerned heterozygous samples, with the automated
system calling one sample a heterozygote and the first reader calling it an AA homozygote.
In another sample, the automated system called this person a heterozygote, while the first
observer called this individual a GG homozygote.
Table 4.4.2. presents the agreement between the second observer (Dr. Knapp) and
the automated genotyping system of 48 samples (1(=0.93; 95%C.I.: 0.81-1.0).
Disagreements concerned heterozygote samples. In one sample, the automated system
caIled one individual an AA homozygote, while the second observer called it an AG
heterozygote. In another sample, the automated genotyping system called an individual an
AG heterozygote, while the second observer called that person an AA homozygote.
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Table 4.4.1. Summary of observer agreement. Agreement between the first observer (LJY)
and automated genotyping.
Automated genotyping
Reader
AA ~G GG Failed Total
~ 18 1 0 0 19
AG 0 ~1 0 0 ~1
GG 0 1 7 0 8
Failed 0 0 0 0 0
Total 18 23 7 0 48
First
(UY)
K =0.93 95%C.I.: 0.84 - 1.0
Table 4.4.3 and 4 .4.4 present the results 0 fintra-observer agreement for the first
reader and second reader, respectively (1(=0.90; 95%C.I.: 0.79-1.0 and 1(=0.93; 95%C.L:
0.90- 1.0, respectively). Discrepancies between the first and second readings for the first
reader generally concerned the classification of heterozygotes. In the first reading, one
individual was classified as an AO heterozygote and as an AA homozygote in the second
reading, while another individual was classified as an AO heterozygote in the first reading
and a GO homozygote in the second reading. A third individual was classified as an AA
homozygote in the first reading, and as an AO heterozygote in the second reading.
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Table 4.4.2. Summary of observer agreement. Agreement between the second observer
(Dr. Knapp) and automated genotyping.
Automated genotyping
Reader
AA AG GG Failed Total
~ 17 1 0 0 18
AG 1 22 0 0 23
GG 0 0 7 0 7
Failed 0 0 0 0 0
Total 18 23 7 0 48
Second
(Dr. Knapp)
K =0.93 95%C.I.: 0.84 - 1.0
The only disagreement between the first and second reading by the second
observer concerned the classification of an individual as an AG heterozygote in the first
reading and as an AA homozygote in the second.
Table 4.4.5. evaluates the agreement between the first and second observers,
Discrepancies generally concerned the classification of heterozygotes. Three individuals
were classified by the second reader as heterozygotes and as AA homozygotes by the first
reader. Another individual was classified as an AA homozygote by the second reader and as
an AG heterozygote by the first. A fifth individual was classified as an AG heterozygote by
the second reader and as a GG homozygote by the first reader.
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Table 4.4.3. Summary of intra-observer agreement. Agreement between a first and second
reading on two separate occasions of the same automated genotyping results by the
first reader (LJY).
Second
Read
First Read
[AA AG GG Failed Total
AA 18 1 0 0 19
~G 1 20 0 0 21
GG 0 1 7 0 8
Failed 0 0 0 0 0
Total 19 22 7 0 [48
K=0.90 95%C.I.: 0.79 -1.0
Table 4.4.4. Summary of intra-observer agreement. Agreement between a first and
second reading on two separate occasions of the same automated genotyping results
by the second reader (Dr. Knapp).
Second
Read
First Read
AA AG GG Failed Total
'AA 16 1 0 0 17
AG 0 24 0 0 24
GG 0 0 7 0 7
Failed 0 0 0 0 0
Total 16 25 7 0 48
K=0.97 95%C.I.: 0.90 - 1.0
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Table 4.4.5. Summary of observer agreement. Agreement between the first observer (LJY)
and second reader (Dr. Knapp) of automated genotyping results.
Second reader (Dr. Knapp)
First
AA AG GG Failed Total
AA 16 3 0 0 19
AG 1 20 0 0 21
GG 0 1 7 0 8
Failed 0 0 0 0 0
Total 17 24 7 0 48
Reader
(LJY)
1C=0.83 95%C.I.: 0.69 - 0.98
4.5 Results: Anti-nuclear antibodies in hepatitis C -positive patients
Table 4.5.1 highlights the agreement between the first observer (LJY) and the
second reader (Dr. Peter Kelleher) with respect to the determination of ANA positivity or
negativity on Hep-2 cells as detected by indirect immunofluorscence (IIF) of 40 samples.
The main discrepancies concerned LJY calling a sample positive, while Dr. Kelleher calling
it a negative. Although one sample was called negative by LJY and positive by Dr.
Kelleher. For all discrepancies, Dr. Kelleher's determinations of patterns were used in the
final dataset.
Table 4.5.2 presents the agreement between the first and second observers with
respect to the classification on ANA patterns. There were only two discrepancies. The
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Table 4.5.1. Summary of intra-observer agreement. Agreement for scoring of ANA positivity
Between the first observer (LJY) and the second observer (Dr. Kelleher).
Dr. Peter Kelleher
UY
Positive Negative Total
Positive 18 8 26
Negative 1 180 181
~otal 19 188 207
K=0.78 95%C.I.: 0.64 - 0.92
Table 4.5.2. Summary of intra-observer agreement. Agreement for scoring of ANA pattern
for a first observer (LJY) compared to a second observer, Dr. Peter Kelleher, consultant
clinical immunologist, St. Mary's Hospital, London UK).
Second Observer
(Dr. Kelleher)
First
Homogenous Speckled Nucleolar Other Total
Homogenous 3 0 0 1 4
Speckled 0 30 0 0 30
Nucleolar 0 0 3 0 3
Other 1 0 0 2 3
Total ~ 30 3 3 ~O
Observer
(UY)
K =0.88 95%C.I.: 0.73 -1.03
163
Chapter4
primary discrepancy was with the classification of homogenous and "other" patterns. One
sample was labelled "other" by the first reader and homogenous by the second, while the
other was labelled homogenous pattern by the first reader and "other" by the second.
Table 4.5.3 presents the agreement between the first and second observers with
respect to scoring of ANA titre. All four discrepancies concerned a tendency for observer
one to score at a lower titre than observer two. One individual was scored as having a
Table 4.5.3. Summary of intra-observer agreement. Agreement for scoring of ANA titre for
a first observer (LJY) compared to a second observer, Dr. Peter Kelleher, consultant clinical
immunologist, St. Mary's Hospital, London UK}.
Second Observer
(Dr. Kelleher)
First
1:40 1:80 1:160 1:320 Total
1:40 17 1 0 0 18
1:80 ~ 14 2 0 16
1:160 ~ 0 5 0 5
1:320 ~ 0 1 0 1
Total 17 15 8 0 [10
Observer
(LJY)
K =0.84 95%C.I.: 0.69 - 0.99
titre of 1:40 by the first observer, while the second observer scored this individual at 1:80.
Two individuals were scored by observer one at the 1:80 level, while observer two scored
them at the 1:160 level. The final discrepancy occurred when the first observer scored a
sample at 1:320 while the second scored that sample at 1:160.
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Table 4.5.4 swnmarises the agreement within observer one with respect to the
scoring of ANA pattern. The only discrepancy between the two readings was the scoring of
one individual as a homogenous in the first reading session and as an "other" in the second.
Table 4.5.4. Summary of intra-observer agreement. Agreement for scoring of ANA pattern
within the first observer (LJY) of two separate scorings of the same patient samples.
First Session
Session
Homogenous Speckled Nucleolar Other 1T0tai
Homogenous ~ 0 0 0 ~
Speckled 0 30 0 0 30
Nucleolar 0 0 3 0 3
Other 1 0 0 2 3
11'0tal 5 30 3 2 ~O
Second
K =0.94 95%C.I.: 0.83 -1.05
4.6 Discussion: automated genotyping
These studies suggest that there is a high level of both intra- and inter-observer
agreement with respect to data generated in genotyping assessment. In the method of the
kappa statistic, as developed by Cohen, kappa values greater than 0.80 are considered to
have "excellent levels of agreement," kappa values greater than or equal to 0.4 and less than
0.80 are considered to have "moderate" agreement. Kappa values less than 0.4 have "slight"
agreement.v i
Both the first and second observers had a very high level of agreement with the
automated genotyping system (1(=0.93 for both). Moreover, both observers showed a high
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level of internal consistency when comparisons were made of scorings conducted on two
separate occasions, with the second observer showing a slightly higher level of agreement
between her first and second readings than the first (K=0.97 for the second and K=0.90 for
the first). Both individuals also had a moderately strong level of agreement with respect to
each other (K=0.83).
Discrepancies between either observer and the automated system generally
concerned the classification of heterozygous individuals. As mentioned previously in
Chapter 3, a common problem with heterozygous individuals is the preferential
amplification of one of the alleles over the other. It is possible that poor amplification of
template DNA that may have produced sufficient amplicons to be detected by the
automated system, but the over numbers of amplicons and quality of the resulting aggregate
product may not have been adequate for the individual who is checking the data to label as
a heterozygote. Such an example can be seen in Table 4.4.1 where the two disagreements
concerned individuals labeled as an AG heterozygote by the automated system and AA and
GG homozygotes by the first reader. In fact, the second reader scored one of the AG
heterozygotes from the automated genotyping system as an AA homozygote. The other
disagreement between the second and the automated system also concerned a heterozygote
individual, where a sample was labeled AG by Dr. Knapp and AA homozygote by the
automated system.
The results of this study suggest that the automated genotyping system employed in
the present study is consistent and reproducible, with a high level of both intra- and inter-
observer consistency. The relatively small sample sizes precluded the achievement of
nominal statistical significance for some of the comparisons made in the present study,
although all comparisons had a strong degree of correlation (K ~ 0.83).
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4.7 Discussion: anti-nuclear autoantibody screening
This study suggests that there is moderate to strong agreement between LN and Dr.
Kelleher regarding the scoring of ANA positivity (1(= 0.78), ANA pattern (1(= 0.81), as well
as ANA titre (1<:= 0.84)
Discrepancies between LN and Dr. Kelleher regarding autoantibody pattern
generally concerned the more uncommon patterns placed in the "other" category in the
present study (Table 4.5.2). In addition, LN had a tendency to score lower than Dr. Keller
with respect to autoantibody titre (Table 4.5.3). Furthermore, LN exhibits a high degree of
intra-observer consistency with respect to his scoring of ANA patterns (1<:= 0.94) (Table
4.5.4).
In summary, moderate to strong correlations were demonstrated with respect to both
inter- and intra-personal consistency and reproducibility for scoring of ANA positivity,
ANA pattern and ANA titre. The results of this study suggest that the ANA data generated
in the present study by LJY are consistent and reproducible.
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Chapter 5
Autoimmunity in Hepatitis C:
Correlates of Antinuclear Antibody (ANA) Positivity and
Its Clinical Relevance
5.1 Background: Autoimmunity in hepatitis C virus infection
Antinuclear antibodies (ANA) are a variety of antibodies directed against
constituents of cell nuclei including DNA, RNA and various nuclear proteins.' Patients
with various autoimmune abnormalities including connective tissue or rheumatic diseases
such as systemic lupus erythmatosus (SLE) frequently present with high levels of ANA.l
For the diagnosis of some diseases such as SLE, positive titres of ANA form an integral
part of the diagnosis, and a negative ANA rules out the disease. I. 2 ANA positivity is seen
with several other disorders such as rheumatoid arthritis and scleroderma. Positive ANA
results have also been reported in healthy, older people.' These individuals, unlike those
with autoimmune diseases such as SLE, tend to have very low titres.'
The prevalence of extrahepatic manifestations including autoimmune conditions in
chronic hepatitis C virus (HCY) infection have been reported to be high." S Autoimmune
manifestations range from the presence of non-organ specific autoantibodies to the Sicca
syndrome or cryoglobulinaemia. A myriad of autoantibodies have been described in chronic
HCY including rheumatoid factor (RF), smooth muscle antibodies (SMA), and antinuclear
antibodies (ANA).4-6 The prevalence of some antibodies such as antinuclear antibody
(ANA) has been reported to be as high as 41% in individuals with chronic HCY infection."
7 Interestingly, serological surveys also suggest that there is a gradient in the prevalence of
autoimmune manifestations, with a higher prevalence in southern Europe than Northern
Europe,"
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In addition to autoimmune manifestations, chronic HeV infection has also recently
also been associated with cognitive dysfunction. In a recent study, Forton and colleagues
examined mono-infected HeV and HBV patients with mild histology to rule out any
encephalopathy from advanced liver disease, and found individuals with HeV viraemia to
have significantly lower cognitive scores than individuals who had cleared HeV viraemia,"
They also observed a number of these individuals with cognitive impairment to have
elevated levels of choline/creatine ratios by magnetic resonance spectroscopy compared to
healthy volunteers and individuals with chronic hepatitis B virus infection." 10
The systemic autoimmune disease systemic lupus erythematosus (SLE) is
characterised by diverse and varied manifestations, ranging from skin rash to cerebral
infestations that may be as mild as subtle cognitive dysfunction or as severe as life-
threatening coma. The mechanisms accounting for such cognitive and psychological
impairments is unknown. Some studies suggest that anti-DNA antibodies may be
involved. I I Recently, DiGiorgio and colleagues identified that a subset of anti-DNA
antibodies cross-reacts with the N-methyl-D-aspartate (NMDA) receptors, NR2a and
NR2b, in neuropsychiatric IUpUS.12 The NR2 receptors are the ligand for the
neurotransmitter glutamate and are expressed on neurons throughout the forebrain.13-16
Studies suggest that the NR receptor is involved with learning and memory." In major
psychosis, glutamate receptors can display altered expression, while over-stimulation of
NR2 can cause neuron death from over excitation through an excessive influx of calcium
into cells.18-21 Stimulation of NR2 by phenylcyclohexylpiperidine, a glutamate receptor
antagonist, cases hallucinations and paranoia.22-24
In the present study I identified correlates of ANA positivity in a large multi-centre
cohort of individuals with chronic hepatitis e. I also examined the effect of ANA positivity
on Hev clinical outcome and looked for possible geographic variations in ANA
prevalence. Given the relatively high reported prevalence of ANA in individuals with
chronic hepatitis e, and reports of cognitive dysfunction in individuals with hepatitis e,we
also hypothesised that the presence of ANA is correlated with cognitive dysfunction in
HeV.
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5.2 Methods
Indirect Immunofluorescence: the principle
ANA pattern and titre was assessed by indirect immunofluorescence on Hep-2 cells
using standard techniques.v 25. 26 Hep-2 ANA substrate slides were purchased from The
Binding Site Limited (Birmingham, UK). A single slide contains 10 wells coated with Hep-
2 cell ANA substrate.27 Hep-2 cells are an epithelial cell line derived from a human
carcinoma of the larynx, and have replaced frozen rat liver sections as the main substrate
for demonstration of ANA.2• 25. 27 Hep-2 cells are characterised by several advantages over
frozen rat livers. First, Hep-2 cells have extremely large nuclei compared to rat liver cells,
allowing for better visualization of nuclear patterns and consequently allow for an increase
in assay sensitivity. Cells derived from the same Hep-2 line are characterised by less batch
to batch variability when compared to frozen rodent tissue. Hep-2 cells are an actively
dividing c ell line which also allows for the exposure of greater numbers of antigens not
normally expressed in resting cells of rat liver sectionsr"
The principle of this process relies on the indirect visualisation of ANA bound to
substrate fixed on slides (ANA substrate slides from The Binding Site Limited,
Birmingham, UK), that is then viewed indirectly via immunofluorescence from a secondary
antibody that is bound to antinuclear a ntibodies. Figure 5.2.1 presents a diagram 0 f this
process. As illustrated in part A of Figure 5.2.1, patient sera is placed in
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A.
Patient
/sera
ANA antigen
/ substrate
Well of __.. \ )
slide \'---_----'
B. FITC-conj ugate •*) Secondary antibody, I Specific for human
Immuneglobulins
::A ill patien~
Well of __.. \ • I
sli~ \ }
ANA antigen
substrate
Figure 5.2.1. Schematic diagram of the indirect immunofluorescence (IIF)
process. Part A. Patient sera is placed in the well of the slide containing the
ANA antigen substrate. Unbound ANA are then washed off. Part B. A
secondary antibody specific for human immunoglobulins that is conjugated with
FITC is then laid on top of the ANA-substrate complex from part A. Unbound
antibodies are washed off. The slides are then visualised using an ultraviolet
light microscope.
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the wells of the slide containing the ANA substrate. This mixture is incubated for a short
period of time to allow any ANA present to bind. Excess sera containing unbound ANA are
then washed off. Next, a secondary antibody from sheep, specific for human
immunoglobulins that is conjugated with fluorescein isothiocyanate (FITC) (sheep anti-
human heavy and light chain immunoglobulin antibodies; The Binding Site Limited,
Birmingham, UK) is layered on the ANA-substrate complex from above (Part B of Figure
5.2.1) and incubated. Excess unbound secondary antibody is then washed off. An ultraviolet
microscope is then used to visualise the resulting product. The FITC conjugate fluoresces in
the presence of ultraviolet light, allowing for the reading of ANA positivity as well as
patterns.
Indirect Immunofluorescence: the procedure
The laboratory protocol for this procedure is provided in Appendix 3. Patient sera
were screened at a dilution of 1:40. Samples positive at this dilution were then evaluated for
titre by doubling dilutions to the endpoint. Samples were prepared in batches of 4-5 slides.
The first slide of each batch always contained 6 control samples. The first well was a
negative control containing sera from an individual known to not have ANA. The next 6
wells contained positive controls at doubling dilutions: 1:40, 1:80, 1:160, 1:320, 1:640. The
positive control was s era from a patient previously known to be positive for A NA. The
remaining 4 wells contained additional patient samples for screening at 1:40 dilutions.
Figure 5.2.2 illustrates the sample arrangement of this first slide.
The remaining 3-4 slides contained a combination of patient samples for initial
screening at 1:40 dilution as well as samples that previously screened positive at 1:40 and
subsequently needed tittering. To assess ANA titre, these samples were run at doubling
dilutions to the endpoint. Figure 5.2.3 gives an example of a possible arrangement for these
slides.
To facilitate categorical analysis, positive samples were grouped into 3 possible
categories for ANA pattern: speckled, homogenous or nucleolar. Figure 5.2.4 presents
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examples of these patterns. A fourth category of "other" was created for other less frequent
patterns that do not fit into the above categories. Figure 5.2.5 presents examples of other
possible patterns that would be included in this category.
645 patients from three European liver centres were screened for ANA using this
method. Participating centres included Lund, Sweden (225 patients); London, United
Kingdom (207 patients); and Padova, Italy (213 patients). Patients from Lund and Padova
were individuals from the HENCORE study and were subject to the enrollment criteria of
that study (discussed in Chapter 2). For the patients from London, the 207 patients were
selected at random from the entire pool of individuals in the St. Mary's Hepatitis C Cohort.
Caucasians in this study are defined as Northern European, Southern European, or
Eastern European. Because of the frequencies of all of the other categories of non-
Caucasian races are too small to provide meaningful categorical analyses individually,
analyses was conducted in the cohort as a whole (all races) and then with Caucasians only.
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Label
175
~-+-- Positive control 1:40
++--+-- Positive control 1:80
~-+-- Positive control 1:160
Positive control 1:320
Figure 5.2.2. Example of control slide set up. The first slide in every batch of ANA
slides is set up in this manner. The slide contains one negative control as well as a
series of positive controls at different dilutions. The remaining wells on the slide are
used to screen samples.
Sample 6 1:40
Sample 6 1:80
Sample 6 1:160
Sample 6 1:320
Sample 6 1:640
Label
Sample 1
Sample 2
Sample 3
Sample4
Sample 5
Figure 5.2.3. Example of sample slide set up. Sample slides contain
patient samples for preliminary ANA screening as well as dilutions of
previously positive ones for auto-antibody titre determination. Here,
samples 1-5 and 7 are samples for screening at 1:40 dilution, while
sample 6 (wells 6-9) is a sample that screened positive on a previous run
and is currently being assayed for titre.
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A.
B.
c.
Figure 5.2.4. The major ANA patterns considered in the present study. Patterns are
detected by indirect immunofluorescence (IIF) on Hep-G2 cells. The patterns shown
are: A. Speckled. B. Homogenous C. Nucleolar.
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A.
B.
c.
Figure 5.2.5. Example of other possible less frequent ANA patterns. A. Centromere
pattern.B. Cytoplasmic speckling. C.Nuclear dots.
(Photograph: The Binding Site Limited, Birmingham, UK)
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ANA and HeV-related cognitive impairment
23 patients were obtained at random from a group with chronic HeV infection who
were previously evaluated by Forton et al. for levels of choline and creatine in the basal
ganglia and white matter by magnetic resonance spectroscopy," They were screened for the
presence of ANA. Individuals in this group were a collection of HeV patients with biopsy-
proven mild liver histology due to HeV mono-infection," Individuals were subjected to a
computer-based cognitive assessment test and also completed depression, fatigue and
quality oflife tests.s Individuals with Hev viraemia exhibited significantly more cognitive
dysfunction than a group of individuals who had cleared HeV viraemia.' Further analysis
of a subgroup of 17 of the 23 individuals with magnetic resonance spectroscopy
demonstrated elevated choline/creatine ratios in the basal ganglia and white matter,
suggesting a biological cause to this abnormality.v"
All ANA assays were conducted without knowledge of the patient's cognitive
scores. We intended to analyse this study by comparing the mean choline/creatine scores of
the ANA positives to the mean choline/creatine scores of the ANA negatives, the HeV
positive individuals as a whole, and to a group of healthy volunteers using Student's t-test
and one-way analysis of variance (ANOVA) for normally distributed data. If the data are
not normally distributed, log-transformed data were to be used in the calculations. All
choline and creatine data were kindly provided courtesy of Dr. Daniel M. Forton.
Liver biopsies
Liver biopsies stained with haematoxilin and eosin for individuals from United
Kingdom who were positive for ANA were matched 1 to 1 to an individual from the United
Kingdom who were negative for ANA by gender and age at treatment (± 2 years). Biopsies
were evaluated by a single pathologist (Dr. Robert D. Goldin, consultant histopathologist,
St. Mary's Hospital, London, UK), who was blinded to the ANA status of the individual
biopsies and all other clinical information. In addition to scoring of inflammation (grade)
and fibrosis (stage) using the modified Histological Activity Index (Ishak) semiquantitative
scoring system, the biopsies were scored for the amount of fat (less than 10% or more),
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portal lymphoid aggregates (presence or absence) , bile duct damage (presence or absence),
esosinophils (conspicuous or not) and plasma cells (conspicuous or not) Analyses were as
matched pairs using conditional logistic regression.
Data collection, management and statistical analyses
As already described in Chapter 2, all ANA data, along with clinical information,
were kept in a database I created using the EpiData® programme.(Copenhagen, Denmark)
Relevant demographic and clinical data were directly downloaded from the HENCORE
database, while results of ANA tests were recorded on data entry sheets (Appendix 4),
double-entered and cross-validated. The dataset was converted to SAS® (Cary, North
Carolina, UK) by the StatTransfer ®programme (Seattle, Washington, USA) for statistical
analyses. Appendix 5 provides the data dictionary for this database.
Standard statistical techniques including Chi-square tests for contingency tables for
univariable data and logistic regression for multivariable analyses were used to assess
correlates of ANA positivity. Both maximum likelihood and Fisher's exact p-values and
confidence limits were calculated as appropriate. To facilitate categorical analyses,
continuous variables including duration of HCV infection, current age, and age at HCV
acquisition were dichotomised at the median (20, 48 and 27, respectively). HCV viral
genotypes were dichotomised into type 1 and non-I. Amount of alcohol consumption was
divided into those who were "high drinkers" (> 40 units per week) and "low drinkers" (~ 40
units per week). To increase the likelihood of detecting an effect with fibrosis score and
necro-inflammatory score with ANA positivity, the extremes were analysed. Individuals
with a fibrosis s core ~5 were compared to those with scores g. For analyses 0 f n ecro-
inflammatory score those with a score of ~7 were compared to those g. Because 98% of
the patients with a reportable HCV risk factor had a history of either injection drug use or
the receipt of blood or blood products, we restricted our analyses of source of HCV to these
two factors. For analyses of the effect of geographic location, centres were compared in a
hierarchical order by geographic latitude. Factors with a p-value ~ 0.20 in univariable
analysis were entered into a multivariable logistic regression model." For analyses of
geographic distribution of ANA, data were analysed by both logistic regression and by
multi-level modeling using the SAS® system.29•30
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For analyses 0 f the effects 0 fA NA positivity 0 n progression of fibrosis, 0 rdered
logistic regression was used with the stages of fibrosis as the outcome variable. ANA
positivity and estimated duration of Hev infection were included as the explanatory
variables. The patient was assumed to have a fibrosis score of 0 at the time of infection, and
a rate calculated by taking the difference between the patient's current biopsy score and the
assumed zero fibrosis at the time of infection and adjusting for the patient's estimated
duration of infection in a multiple logistic regression model.
5.3 Results
ANA cohort demographics
Table 5.3.1 present the distribution of demographic characteristics of the ANA
study cohort. Data are presented for the cohort as a whole as well as by individual centre.
Patients from Italy tended to be older, while the estimated durations of Hev infection did .
not vary significantly between each study centre. The similar durations of HeV infection
and older patient age in Italy suggest that HeV patients in Italy were infected at an older
age. This is confirmed in the distributions of age at infection, where individuals in Italy
tended to be infected in their mid-thirties, while individuals in the other centres were
infected in their mid to later twenties. Males predominated in the cohort as a whole and
in each study centre. The male to female ratio was similar between the three centres. Viral
genotype-l predominated in all of the study centres. Most patients had mild to moderate
fibrosis (~ fibrosis score of 3) in all of the centres.
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Table 5.3.1. Demographics of the ANA cohort as a whole and by individual centre.
CENTRES COMBINED LUND LONDON PADOVA
FACTOR (N=645) (N=225) (N=207) (N=213)
Patient age 50.9 ± 12.6 48.0 ± 10.2 48.4 ± 11.1 56.1 ± 14.5
(mean ± SO)
Duration of HCV infection 21.1 ±9.3 21.0 ± 7.0 23.1 ± 9.8 19.9 ± 9.9
Age at infection 30.6 ± 14.2 27.3 ± 12.2 25.0 ± 11.3 36.1 ± 15.0
(mean ± SO)
Males: Females 58.7%: 41.3% 58.2% : 41.8% 61.1%:38.9% 56.8% : 43.2%
Viral genotype 55.2% : 44.8% 53.9% : 46.1% 64.3%: 35.7% 52.3%: 47.7%
(genotype 1: non-1)*
Fibrosis score distribution
0 5.0% 0% 11.8% 0%
1 17.8% 16.5% 22.5% 12.5%
2 26.7% 27.8% 21.9% 32.5%
3 18.1% 19.1% 17.8% 17.5%
4 12.9% 18.3% 3.6% 20.8%
5 8.4% 9.6% 8.3% 7.5%
6 11.1% 8.7% 14.1% 9.2%
Race
Northern European 51.0% 90.2% 60.7% 0.9%
Southern European 37.2% 1.8% 11.0% 98.2%
Indian/Indian Subcontinent 1.9% 0.5% 5.8% 0%
Black African 1.6% 0.9% 4.2% 0%
North African 3.4% 0.4% 10.5% 0%
Eastem European 2.1% 4.0% 2.1% 0%
Afro-Caribbean 1.0% 0% 3.1% 0%
Oriental 0.6% 0% 2.1% 0%
South American 0.6% 0.4% 0.5% 0.9%
Middle Eastern 0.6% 1.8% 0% 0%
*These samples were collected during the era of interferon monotherapy. prior to the treatment of
HCV according to viral genotype. As a result not every individual was genotypes for virus. These
frequencies are based on retrospective genotyping of collected patient serum samples.
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ANA positivity: prevalence and geographic differences
Among the 645 patients studied, 50 (7.75%) were positive for ANA at 1:40 or
greater, with 4.4% positive in Lund, 8.7% in London, and 10.33% in Padova. Table 5.3.2
summarises the observed prevalence data from each of the individual centres as well as the
cohort as a whole. Amongst the cohort as a whole, there was an increase in ANA
prevalence in a southerly direction (OR=0.66; 95%C.I.: 0.46-0.94; p=0.023). Similar
observations were observed by multi-level modelling, comparing Northern and Southern
Europeans (F=2.96; p=0.0860).
Table 5.3.2. Summary of ANA positivity by study centre.
LOCATION NO. POSITIVES PREVALENCE
Lund, Sweden (N=225) 10 4.4%
London, UK (N=207) 18 8.7%
Padova, Italy (N=213) 22 10.3%
Centres combined {N=645} 50 7.8%
Figure 5.3.1 summarises the distributions of ANA pattern as well as titre among the
total cohort as well as the individual centres. 84% of positive individuals had low titres of
ANA (1:80 or lower) in the entire cohort and 100% had titre of 1 :160 or lower (Figure
5.3.1). Speckled pattern was the most commonly observed ANA pattern. Of the 50 ANA
positive samples in the combined cohort, 34 (68%) were speckled, 4 (8%) homogenous, and
3 (6%) were nucleolar. Nine (18%) had other patterns, which included 3 with cytoplasmic
speckling and 6 with nuclear dots. No significant differences with respect to the
distribution of ANA pattern were observed between the distribution of these patterns among
the three centres (Figure 5.3.1).
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Correlates of ANA positivity
Table 5.3.3 Part A presents univariable correlates of ANA positivity at ~ 1:40.
Duration of HCY infection, age at HCY infection, current age, self-reported alcohol
consumption, fibrosis stage, source of infection, and necro-inflammatory score were not
correlated with ANA positivity. Female gender (OR=3.2; 95%C.I.: 1.72 - 5.95; p=O.OOOI)
and geographic location (OR=0.66; 95%C.I.: 0.46 - 0.94; p=0.023) were associated with
ANA positivity. The association with female gender persisted when the analyses were
restricted to Caucasians only (OR=2.7; 95%C.I.: 1.3 - 5.57; p=0.0078). In a multivariable
model of the effect of gender on ANA positivity, controlling for geographic location, the
current age of the patient and fibrosis, only gender retained its significance (Table 5.3.3
Part 8.). The association of female gender with ANA positivity (OR=3.3; 95%C.I.: 1.46-
7.37; p=0.0025) was observed when positivity was defmed as having a titre ~1:80 (Table
5.3.4). Geographic location was no longer statistically significant (OR=0.76; 95%C.I.: 0.48
- 1.21; p=0.25I 0) at this titre. Gender retained its significance in a multi variable model at a
titre of~ 1:80 (OR=3.4; 95%C.I.: 1.36 - 8.54; p=0.0087).
Similar results for the effect of geographic location were observed when analysed
by multilevel modelling at a titre of ~ 1:40 (F=2.9; p=0.0585) and ~ 1:80 (F=2.6;
p=0.0722). The small numbers of ANA-positive individuals precluded achievement of
statistical significance when this statistical method was applied.
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Table 5.3.3. Correlates of ANA positivity at ~ 1:40 titre.
A. Univariable correlates of ANA positivity. B. Multivariable analysis.
A. UNIVARIABLE CORRELATES
FACTOR OR 95%C.I. p-value
Duration of HCV Infection 0.72 0.38 -1.44 0.3219
Age at HCV Infection 0.92 0.29 -1.70 0.7796
Gender 3.2 1.72 - 5.95 0.0001
Alcohol consumption 0.63 0.19 - 2.08 0.4416
Fibrosis stage- 0.59 0.29 -1.17 0.1277
Source of infectionb 0.88 0.38 - 2.03 0.7569
HCV viral genotype 0.84 0.45-1.55 0.5742
Current age 1.51 0.84 - 2.71 0.1632
Geographic location 0.66 0.46 - 0.94 0.0225
Necroinflammatory score? 1.17 0.46 - 2.94 0.7457
B. MULTIVARIABLE ANALYSES
FACTORS IN MODEL OR 95%C.I. p-value
Gender 3.0 1.54 - 5.93 0.0013
Geographic location 0.74 0.49-1.10 0.1299
Current Age 1.42 0.72 -2.79 0.3150
Fibrosis stage- 0.77 0.28 - 2.09 0.6070
·Comparison of severe fibrosis score (~ 5) versus lower fibrosis score (~ 2).
blnjection drug use or exposure to blood/blood products
"corrpartson of high necroinflammatory score (~ 7) to lower score (~ 2)
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Table 5.3.4. Correlates of ANA positivity at ~ 1:80 titre.
A. Univariable correlates of ANA positivity. B. Multivariable analysis.
A. UNIVARIABLE CORRELATES
FACTOR OR 95%C.I. p-value
Duration of HCV Infection 0.62 0.26 -1.48 0.2791
Age at HCV Infection 0.53 0.21 - 1.33 0.1701
Gender 3.3 1.46 - 7.37 0.0025
Alcohol consumption 0.36 0.05 - 2.73 0.3055
Fibrosis stage- 0.81 0.24 - 2.81 0.7458
Source of infection" 1.72 0.54 - 5.51 0.3564
HCV viral genotype 0.99 0.45 - 2.18 0.9783
Current age 1.46 0.68 - 3.14 0.3304
Geographic location 1.0 0.44 - 2.45 0.9963
Necroinflammatory score" 1.25 0.35 - 4.50 0.734
B. MULTIVARIABLE ANALYSES
FACTORS IN MODEL OR 95%C.1. p-value
Gender 3.4 1.36 - 8.54 0.0087
Geographic location 0.89 0.53 -1.50 0.6628
Current age 1.52 0.62 - 3.76 0.3643
Fibrosis stage- 0.88 0.25 - 3.18 0.8489
-Comparison of severe fibrosis score (~ 5) versus lower fibrosis score (~2).
blnjection drug use or exposure to blood/blood products
cComparison of high necroinflammatory score (~ 7) to lower score (~2)
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Impact of ANA positivity on HCV clinical outcome
ANA positivity had no significant effect on HCV clinical outcome. There was a
trend with ANA positivity and faster progression of HCV fibrosis (OR=1.8; 95%e.l.: 0.81
- 4.2; p=0.1452), but this did not achieve statistical significance. Alterations in response
rates were not observed when stratified by ANA positivity. Among all of those who were
treated, 26.7% achieved sustained response; among ANA negative individuals who were
treated, 26.3% achieved sustained response, while among ANA positive individuals 33.3%
achieved sustained response; 95%C.I.: 0.51 - 3.9; p=0.5126). ANA titre did not playa
significant difference on these results, as similar observations were obtained for the effects
of ANA positivity on fibrosis progression and response to therapy if ANA positivity is
defined at ~ 1:80. Among ANA negative individuals who were treated, 26.3% achieved
sustained response, while among ANA positive individuals 20% achieved sustained
response; 95%e.l.: 0.14 - 3.4; p=0.6595) when positivity was defined at this titre.
ANA and cognitive dysfunction
Only 3 of the 23 individuals studied in this group were positive for ANA. The
extremely low frequencies of ANA positivity prohibited any further meaningful statistical
analyses. I, nevertheless, wanted to see where these three individuals stand on the spectrum
of cognitive scores. If they all had scores indicative of severe cognitive impairment, then it
is possible t hat further studies might be warranted. Analyses 0 f these three patients a lso
showed that there were no consistent trends with respect to choline/creatine ratios in both
the basal ganglia and white matter when compared to the mean score of HeV infected
individuals as well as a healthy control population (Table 5.3.4). The scores of patient two
are relatively similar to the HeV population as a whole and the healthy controls. The other
two patients exhibit only slightly higher scores.
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Table 5.3.5. Summary of ANA positive patients' choline/creatine scores as assessed
by magnetic resonance spectroscopy (MRS). *
Basal ganglia White matter
Patients Choline/creatine ratio Choline/creatine ratio
Patient 1 1.16 1.44
Patient 2 1.08 1.14
Patient 3 1.14 1.22
All HCV Patients (N=36) 1.16±0.19 1.31 ± 0.22
Mean±SD
Healthy controls (N=29) 1.06 ± 0.12 1.16±0.12
Mean±SD
*AII MRS data were provided courtesy of Dr. Daniel M. Forton.
Liver biopsies
Among the 18 individuals from the United Kingdom who were positive for ANA,
17 had biopsies available for examination. Among the 17 pairs of biopsies examined
(N=34 samples total), there were no differences observed with respect to the distribution of
fat, eosinophils, and bile duct damage between ANA positive liver biopsies and ANA
negative biopsies (p> 0.320 for all). In contrast, plasma cells were more frequent in those
who were ANA positives (Hazard Ratio=9.0; p=0.037) (Figure 5.3.2). There were fewer
lymphoid aggregates among ANA positive samples, although the difference was not
statistically significant (Hazard Ratio=0.291 p=0.118) (Figure 5.3.2)
189
A.
B.
Figure 5.3.2. Haematoxylin and eosin stained liver biopsies (Original
magnification x 400). Part A. presents a biopsy from an ANA positive individual.
Part B. presents the biopsy from an ANA negative individual. Conspicuous
plasma cells are present in the ANA positive individual. In the ANA negative
individual, there is a lymphoid aggregate but only scanty of plasma cells.
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5.4 Conclusions
This study observed a prevalence of low levels of ANA among 7.8% of individuals
in three centres across Europe. This study confirms previous studies showing an increased
prevalence of ANA in individuals with chronic hepatitis C.6, 7, 31 We observed an 8.7%
ANA prevalence in London. This is over two-fold higher than the normal background
prevalence of ANA in west London, which is approximately 2%-3% (Dr. Peter Charles,
Charing Cross Hospital, London, UK: personal communication). An ANA prevalence of
10.3% was also observed in chronic HCV patients in Italy. This is comparable to a previous
large, random, population-based study of ANA prevalence in Italy, which reported
prevalence to be about 10%_14%.31,32
The p resent study observed ANA prevalences t hat are smaller than some figures
reported by other groups. Several factors may account for this difference. First, there may
be a different mixture in the cases seen by the other study centres, where individuals with
autoimmune co-morbidities or a predisposition for autoimmunity could be preferentially
selected in some way. Second, there may be differences in viral strains causing these
differences, although viral genotype is not associated with A NA positivity either in this
study or in others.": 32Third, there may be technical differences. Differences may exist in
the techniques employed to assay ANA. Our study employed the use of Hep-2 cells, while
some older studies employed the use of rat liver ANA substrate. Fourth, there may be true
differences in the populations where host-related factors such as genetics may play a
pathogenic role.
This study observed a significant geographic gradient in ANA prevalence, where the
prevalence of ANA increases in a southerly direction. This observation supports other
studies of autoimmunity in hepatitis C where the prevalence of autoimmune manifestations
appears to be greater in Southern Europe compared to Northern Europe," For example,
HCV-related cryoglobulinaemia has been reported extensively in southern Europe, but not
in northern Europe,"
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The present study observed that women are more likely than men to develop ANA.
This is consistent with the association of female gender with autoimmunity and a previous
study of patients with Hev that showed women tended to develop autoantibodies.i" 34
While the mechanism behind the association of gender with autoimmunity has not yet been
elucidated, it is believed that hormones such as oestrogen may play an important role."
Furthermore, it is possible that certain individuals with a genetic predisposition are more
likely to develop autoantibodiesr" This study also supports previous observations that HCV
genotype and route of HeV acquisition are not correlated with autoantibody formation. 31,32
The observation that ANA positive patients have more plasma c ells in their liver
biopsies raises the possibility that increased plasma cells may be a marker for B cell
polyc1onal activity with a secondary clinical manifestation of increased serum
immunoglobulins with 0 r without autoantibody production. A study b y Watanabe eta 1.
examined liver biopsies from patients with primary biliary cirrhosis who were anti-
mitrochondrial antibody (AMA) positive and patients who were AMA-negative and ANA-
positive and found patients with ANA to have significantly greater numbers of plasma
cells.36 Future studies may examine the pathological bases for this correlation more
extensively.
Importantly, our study suggests that positivity for ANA at low titres does not alter
response to interferon therapy and positivity for ANA at low levels should not be a
contraindication for treatment. There was an association of ANA positivity with an almost
two-fold higher chance of having faster fibrosis, although this did not reach statistical
significance. Our observation with respect to the response to interferon therapy confirms
observations from a previous study showing that the presence of serum autoantibodies does
not alter response rates to interferon therapy in Hev.34 Studies have suggested that levels
of alanine amino transferase (ALT) and gamma-glutamyl transferase (GGT) are associated
with the formation on non-organ-specific autoantibodies in HeV.3l, 34 These factors were
not assessed in the present study. It would be interesting for future studies to explore in
greater detail whether these and other biochemical markers of liver function such as
albumin levels or prothrombin time are correlated with ANA positivity. Future studies are
also needed to address the possible role of host and environmental factors in autoantibody
formation in HeV.
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Studies of healthy individuals suggest that a number have low levels of ANA.3. 26
Tan and colleagues reported the prevalence of ANA in healthy individuals to be 31.7% at a
dilution of 1:40, 13.3% at 1:80, 5.0% at 1:160, and 3.3% at 1:320.3.26 They also did not
observe any significant differences in the occurrence of ANA positivity across different age
groups (20-60 years)." 26The extraordinarily high prevalence reported in this study is likely
to reflect the increased sensitivity of the Hep-2 cell substrate over the rat liver substrate, and
illustrates how assay methodology and reader subjectivity are present in this widely-
employed standard clinical technique.
The mechanisms for autoantibody positivity in individuals with are not known. A
couple of hypotheses have received much attention in recent years. One hypothesis is that
viral infection may induce the release of cytokines that activate auto-reactive T-cells and
induce autoimmune pathogenesis.f Another hypothesis is that molecular mimicry is
involved.38 Infection with HeV or hepatitis delta can induce antibodies to the same antigens
recognised ina utoimmune hepatitis.37. 39Antibodies to liver, kidney microsome antigens
(LKM) found in some individuals with chronic Hev have been found to react to linear and
conformational epitopes of the cytochrome mono-oxygenase, P450 2D6 (eyp 2D6).39-42
Such studies of the epitopes of ANA found in individuals with chronic HeV infection have
not been conducted. Future studies into the aetiology of ANA formation in HeV may focus
on characterisation of ANA epitopes.
It would be interesting for future studies to explore whether the mechanisms
affecting ANA positivity in patients with HeV infection are the same as those in other
autoimmune conditions. It is possible that the presence of HeV in some individuals induces
low titres of natural IgG antibodies directed to nuclear epitopes, and future work on epitope
mapping may increase the understanding of ANA formation in chronic HeV. Future studies
may also address possible host genetic as well as environmental pathogenic mechanisms of
ANA formation in HeV. This will, however, necessitate large study populations to provide
enough cases to enable studies with sufficient power to detect meaningful associations.
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Chapter 6
Host genetics and Hepatitis C Outcome
6.1 Introduction
A number of studies have suggested an important role for host genetic diversity
in influencing the outcome of hepatitis C virus (HCV) infection (see Chapter 2 for
systematic review). In this study I examined the possible correlations between genetic
variants in several genes and the outcome of HCV infection. Iused the candidate gene
approach to see whether specific genes in key pathways of the host immune response to
the hepatitis C virus affect the susceptibility to persistent HCV infection or the response
to interferon therapy.
Interferon-Stimulated Genes
The interferon system is a crucial component of the immune response to
infectious agents. Type I interferons induce different proteins with anti-viral action
including 2'-5'0Iigo-adenylate synthetase (OAS), double stranded RNA-dependent
protein kinase (PKR) and myxovirus resistance I (MxA).l Upon binding to double
stranded RNA (dsRNA), OAS catalyses the formation of 2'-5'-linked oligoadenylate
and activates RNAseL, which breaks down viral and cellular RNA.2• 3 PKR is also
activated by d sRNA which leads tot he phosphorylation 0 fits substrate, e IF2, which
inhibits the guanosine nucleotide exchange factor, eIF2B, and halts viral replication." 5
PKR may function to shut-down protein synthesis following infection of a cell and limit
the proliferation of uninfected cells." Interactions between the Hepatitis C virus (HCV)
and PKR are believed to be an important mechanism behind the resistance of HCV to
interferon therapies.' MxA protein has selective activity against several viruses.i'"
However, the precise mechanism of action has not been elucidated. Studies of in vivo
MxA levels in responders to interferon treatment of HCV have shown greater levels in
virological responders than non-responders." Similarly, MxA mRNA levels have been
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reported to significantly increase after initiation of interferon therapy only in those who
respond.V Given the importance of the PKR. OAS and MxA in the immune response.
polymorphisms in the genes encoding these three proteins were selected as candidate
genes in this project.
Inducible Nitric Oxide Synthase (NOS2A) Haplotypes and the Outcome of Hepatitis C
Nitric oxide (NO) is an important signaling molecule involved with combating
microbial infections. It is formed by the oxidative deamination of the amino acid L-
arginine to L-citrilline by nitric oxide synthases (NOS).13NO possesses potent anti-
microbial effects. including the ability to inhibit the growth of many infectious
organisms in vitro.14 Three isoforms of NOS enzymes are currently known to exist:
neuronal nitric oxide synthase (nNOS), endothelial nitric oxide synthase (eNOS), and
inducible nitric oxide synthase «iNOS) also referred to as NOS2). Of these three
isoforms, iNOS is absent in resting cells, but is capable of being rapidly expressed in
response to pro-inflammatory stimulti such as cytokines, including interferon. When
present. iNOS is capable of synthesising 100-1000 times more NO than the other forms
over a prolonged period of time.l'' These properties make iNOS an important part of the
host response to infectious agents. Experiments employing iNOS inhibitors and iNOS
knockouts have demonstrated, in vivo, the important role of iNOS in the host defense to
infectious agents.IS•IS
iNOS is encoded by the NOS2A gene, and several polymorphisms have been
described in the NOS2A gene at positions -277, -1026, and -1659, numbered relative to
the transcription initiation site. Strong linkage disequilibrium exists between these loci
and several conserved, well-defined haplotypes have been observed in Caucasian
populations.V With the importance of iNOS in the host defense against infectious
agents, I selected the NOS2A gene as another candidate gene. Given the strong linkage
disequilibrum between variants in the NOS2A gene and the well-defined and conserved
haplotypes that these variants form,'" I will examine in this study, the correlations of
NOS2A gene haplotypes with self-limiting versus persistent HCV infection as well as
the response to interferon therapy. The use ofhaplotypes have also proven useful for the
identification of susceptibility regions in previous studies aswell."
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T-Lymphocyte Response and Response to Therapy
As summarised in chapter 1, interferon a- (the standard short-acting forms and
the increasingly used newer long-acting pegylated interferons) alone or in combination
with ribavirin (IFN+R) are currently the standard regimen for the treatment of chronic
hepatitis C virus (HCV) infection,21-23but is frequently accompanied by significant side
effects that may often be debilitating." Moreover, only 40-80% of suitable candidates
treated with this regimen achieve sustained response (SRs}-defined as having achieved
an undetectable HCV -RNA level at 6 months after discontinuation of therapy_25,26The
shortcomings of this regimen have prompted a search for factors that could predict those
most likely to benefit from it.
Clearance of HCV viraemia naturally and in the context of IFN+R therapy has
been correlated with a strong immune response. Both CD4+ T-helper and CD8+
cytotoxic T-Iymphocyte (CTL) responses are important in the response to HCV
infection.27-34,35-37Host genetic factors that govern these responses may also modify the
course of HCV infection. Polymorphisms in HLA molecules as well as cytokine genes
appear a ssociated with natural clearance and histologic progression of HCV infection
(Chapter 2)
The cytotoxic T-Iymphocyte antigen-4 (CTLA4), encoded by a gene on
chromosome 2q33, is expressed on activated CD4+ and CD8+ r-eeus." It binds to the
ligands B7-I (CD80) and B7-2 (CD86),39-41 and down-regulates T-cell function.t" 42-45
CTLA4 is expressed 24- 48 hours after T-cell activation and the expression is inversely
correlated with CD28 expression, at alternative B7-I ligand which induces T cell
activation. Mice deficient in CTLA4 exhibit polyclonal T-cell activation and
proliferation.46-49 A single nucleotide polymorphism (SNP) resulting in a C-to- T
transition at position -318 of the CTLA4 promoter has been described.i" In addition, a
G-to-A transition at position 49 in exon 1 of the CTLA4 gene encodes an alanine (Ala)-
to-threonine (Thr) substitution in codon 17 of the leader peptide.i': 52
Recent functional studies have produced evidence that polymorphisms at
position -318 of the promoter, position 49 in exon 1, and the resulting haplotypes
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formed by the variants of these two loci exert a differential functional effect on CTLA4-
driven down-regulation ofT-cell activation.53-57
Considering the possible importance of CTL responses in HCV clearance, the
involvement of CTLA4 regulating those responses, I selected CTLA4 as another
candidate gene. I specifically tested the hypothesis that CTLA4 variants are associated
with sustained response to IFN+R therapy.
Table 6.1.1. summarises the genes included the in the present study. Information
on the chromosomal location of the gene along with the aforementioned biological
functions are also listed.
Table 6.1.1. Summary of genes studied, their chromosomal location,
and the biological function of the proteins encoded by the genes.
Gene Chromosomal
Location
Biological Function
MxA
OAS-1
PKR
NOS2A
CTLA4
21q22.3
12q24.2
2p22.3
17q11.2
2q33
MxA protein has anti-viral properties
Breaks down viral and cellular RNA
Inhibits viral replication
iNOS protein has anti-viral effects
Downregulator of T-Iymphocyte response
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6.2 Methods
Patients
I nterferon-stlm ulated genes
For this study, I examined 638 Caucasian subjects enrolled in the HENeORE
(Hepatitis C European Network for Collaborative Research) study; the details of this
study have been published before and are described in chapter 3.58 Briefly, this is a
multicentre European study of Hey that enrolled individuals from nine centres between
October 1995 and June 2001 and the cohort includes individuals with both self-limiting
and persistent Hey infections. A portion of these individuals have also been treated
with interferon monotherapy. Patients were recruited randomly or sequentially in each
centre in order to minimise selection bias. Each patient gave informed consent and
ethical approval was obtained from the local research ethics committee at each centre.
Patients were classified into the following groups as follows: 1) self limiting
Hey infection: individuals with antibodies to HCY who have no evidence of viraemia
on at least two occasions and who have persistently normal liver transaminase levels; 2)
persistent Hey infection: individuals who have evidence of viraemia for at least six
months; 3) sustained treatment response: patients with persistent HCY infection treated
with interferon a. alone who had normal liver transaminases and no evidence of
viraemia six months after the end of treatment; 4) response-relapse: patients with
persistent HCY infection treated with interferon a. who had normal liver transaminases
and no evidence 0 f v iraemia at the end 0 f treatment, b ut i n whom viraemia returned
during the follow-up period 0 f 6 months; 5) non-response tot reatment: patients with
persistent Hey infection treated with interferon a. who never lost viraemia during
treatment. Individuals considered "initial responders" to interferon were those who
experienced a loss ofHCY viraemia during the first 12weeks of treatment, regardless of
whether they ultimately achieved sustained response (sustained responders + relapse
responders).
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NOS2A promoter haplotypes and hepatitis C outcome
For this study, we studied 619 Caucasian patients enrolled in the HENCORE
(Hepatitis C European Network for Collaborative Research) study. The characteristics
of this cohort as well as the definition of patient groups are the same as those stated
above for the study of interferon-stimulated genes.
Rev antibodies and viraemia
For patients in the aforementioned studies, antibodies to HCV antigens were
detected with either an enzyme linked immunoassay (EIA) or a recombinant
irnrnunoblot assay (RIBA) containing 4 HCV antigens on a cellulose acetate strip used
according to the manufacturer's instructions (Abbott Laboratories, North Chicago, IL).
The presence or absence of viral particles in serum was determined by reverse
transcription polymerase chain reaction using a commercially available assay
(Amplicor, Roche) with a sensitivity of approximately 200 genomes/ml.
CTLA4
Among individuals with chronic hepatitis C referred to the UAB Liver Center,
312 received INF+R therapy under a clinical trial protocol. Suitability for therapy was
determined by inclusion/exclusion criteria and guidelines established internationally.P:
26 Briefly, all had compensated liver disease due to HCV, and none had other forms of
chronic liver disease or other major co-morbid conditions. All were seronegative for the
human immunodeficiency virus type 1 (HIV-l) and hepatitis B virus (HBV).25,26
By December of 2000, approximately 170 individuals had completed therapy. In
a nested case-control study, the first 79 consecutive Caucasian responders and the first
79 consecutive Caucasian non-responders who had completed therapy and consented to
DNA genotyping were included in the present study. Individuals with non-l genotype
infections who responded (reached undetectable viral RNA levels) by week 12 received
treatment for a total of 6 months, while those with genotype-l infections who responded
by week 12 continued to receive therapy for 1 year.
HCV genotypes and HCV-RNA levels were assessed before, at weeks 4 and 12
during, and at 6 months after discontinuing treatment (National Genetics Institute, Los
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Angeles, CA). A sustained responder (SR) was defined as having had an undetectable
plasma HCV RNA level at 6 months after discontinuation of therapy. This included
individuals who were weakly positive for HCV-RNA at week 12 (under 1,000
copies/mL) but had no detectable HCV-RNA at 6 months after discontinuation of
therapy (delayed responder). A non-responder (NR) was defined as having either
detectable virus at week 12 of therapy, at which time treatment was discontinued, or
detectable virus at 6 months after discontinuation of therapy despite a virologic response
during the initial course (flare-up). From trial patients who met these criteria, 79 SRs
and 79 NRs were included.
ALT was assessed by standard clinical laboratory techniques (Kirklin Clinic
Laboratory, Birmingham, AL). For categorical analyses, a threshold value of 1.5 times
above the upper limit of normal (~ 72 or < 72) was used, a commonly accepted
definition of "high" ALT level. HCV isolates were dichotomised as either 1 or non-I
genotype because infections with genotype 1 viruses are less responsive and require a
longer course of treatment.25, 26 Baseline viral load was divided into "high" for
individuals with ~ 2,000,000 copies/mL and "low" for individuals < 2,000,000
copies/mL, the value adopted by most treatment algorithms for assessing probable
response.i': 25, 26 The threshold value for "older" and "younger" age was 4 0 years as
used by previous studies.25,59
Laboratory procedures
Screening for novel polymorph isms
This study also involved the identification of several novel polymorphisms in the
promoter region and the functional domains of the PKR and OAS-J genes, along with
the promoter region of MxA by direct sequencing of these regions, Sequencing was
performed using Big-Dye Terminator Chemistry (Applied Biosystems, Warrington, UK)
and an ABI377 automated DNA sequencer. Sequences were aligned and analysed using
Sequence Navigator Software (Applied Biosystems, Warrington, UK). Screening for
these polymophisms was conducted by Dr. Susanne Knapp (Imperial College, UK). I
later used these polymorphisms to examine possible correlations with HCV outcome.
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Genotyping of allelic variants
OAS-}
An A to G SNP at position 84 bp in the untranslated 3' end of exon 8 of OAS-l
(position 347 of HUMOAS081M18101)was genotyped using allele specific real time
PCR. Each reaction comprised 0.2 J.lMof each of the primers specific for exon 8 (Table
6.2.1); 2.5 units of Stoffel Gold Polymerase (David Birch, RMS); Ix Stoffel Gold buffer
(10 mM Tris-HCI, 10 mM KCL at pH 8.0); an additional 30 mM KCI for a final
concentration of 40 mM ; 2 mM MgCh; 50 J.lMeach dATP, dCTP, and dGTP; 25 mM
TTP; 75 mM dUTP: 2 units of UNG (PE), 0.2 x SybrGreen I (Roche Molecular
Probes); 2 J.lMROX (Roche Molecular Probes); 5 % DMSO; and 2.5 % Glycerol.
Kinetic PCR reactions were performed on a GeneAmp 5700 Sequence detection System
(PE Applied Biosystems). An initial incubation step of 2 min at 50°C (to allow UNG
mediated elimination of carry-over PCR product contamination),
Table 6.2.1. Sequences of primers used to genotype polymorphisms in the OAS gene.
Gene Site Oligo Name Oligo sequence (5' to 3') Annealing positions
and reference
sequence·
OAS exon 8 reverse A-allele CTCACTGAGGAGCITTGTCt
exon 8 reverse G-allele CTCACTGAGGAGCITTGTCc
323-3430fM11810
323-343 of M11810
exon 8 forward common CAGGTGGGACTCTTGATCCAG 366-348 of M11810
rimer
·Sequence Identification numbers are Genbank Accession Numbers.
and an enzyme heat activation step of 12 min at 95 DCwere followed by 40 two-step
amplification cycles of 20 sec at 95 DCfor denaturation and 20 sec for 58°C for
annealing and extension, and a final 5 minutes extension at 72°C. All PCR reactions
were performed on 5-50 ng genomic DNA in a total volume of 20 ul.
MxA
The biallelic Gff polymorphism in the promoter region of MxA at position -88
from the transcription start site,60 was genotyped by restriction fragment length
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polymorphism (RFLP) using the enzyme HhaI (New England Biolabs). The primer
sequences for the MxA-88 position can be found in Table 6.2.2 and were used to
amplify a fragment of 351 bp. Amplification was carried out in a volume of 20 ul,
containing 10-100 ng DNA, 2.5 mM MgCh, 500 oM of each primer, 500 J1M dNTP's,
lx PCR buffer (Qiagen), 1 unit Taq DNA polymerase (Qiagen), 0.16 ul TaqStart
Antibody (BD Clontech). The cycling conditions in an Applied Biosystems 2400 or
9700 machine were: denaturation at 94 QC for 5 minutes, subsequently 35 cycles of
denaturation at 94 QCfor 30 seconds; annealing at 58 QCfor 30 seconds; and extension
at 72 QC for 1 minute. This was followed by a final extension step at 72 QC for 7
minutes. For the HhaI restriction digest 8 ul of the PCR product were digested for at
least 4 hours or over night in a volume of 20 J,ll and 5 units of HhaI according to
manufacturers specifications. 10 J,llof the digested PCR product were run out on 2%
agarose gels and analyzed. In the presence of the G allele the 351 bp long product is
Table 6.2.2. Sequences of primers used to genotype polymorphisms in the MxA gene.
promoter -545
promoter -545
Oligo Oligo sequence (5' to 3') Annealing positions and
Name reference sequence=
forward TGAAGACCCCCAATTACCAA 269-287 of X55639
reverse CTCTCGTTCGCCTCTTTCAC 619-600 of X55639
forward GGCCTGGCCTGACAACTAT 29666-29684 of AL773577
reverse CATCCAAGCCTGCACGTAT 30068-30050 of AL773577
Gene Site
MxA promoter -88
promoter -88
·Sequence Identification numbers are Genbank Accession Numbers.
cut into 260, 51, 23 and 16 bp. A SNP (GtA) at position -545 from the transcription
start site was genotyped using BsaI (New England Biolabs) to differentiate between the
alleles. A 402 bp fragment was amplified at the conditions previously described, using
primers of Table 6.2.2. Restriction digestion was carried out using 8 JlI of the PCR
product in 20ul volume in the presence of 2 units BsaI. Presence of the A-allele was
indicated by the absence of the BsaI cutting site, whereas the G allele results in the
creation of a 287 bp and a 115 bp fragment.
PKR
Point mutations in the promoter region of PKR were genotyped by sequence
analysis. In addition restriction fragment length polymorphism (RFLP) with the enzyme
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SgrAI was used to genotype the SNP at position -168 (168 bp from the transcription
start) of the PKR gene. A 282 bp fragment was amplified using the forward primer
PPKR-168F and the reverse primer PPKR-168R (see Table 6.2.3). In the presence of the
T allele a second SgrAI site was introduced which leads to the separation of 19, 97 and
166 bp fragments after digestion and gel separation, whereas in presence of the T allele
the SgrAI digest only gives rise to a 116 and 166bp fragment.
A short tandem repeat (eGG) in exon 1 of the 5' untranslated region ofPKR was
genotyped on the automated ABI377 sequencer (perkin Elmer Applied Biosystems).
peR products were obtained using a FAM labelled sense primer (primer PPKR3S, see
Table 6.2.1) and allowed size discrimination of the fluorescently labelled products. The
products were diluted between 1:5 and 1:20 in water and 1 J.tlof the diluted product was
added to 4 J.tlof formarnide, TAMRA 350 size marker and BluedextranlEDTA buffer
(ratio 3:1:1). The samples were heated to 94°e for 5 minutes and then cooled on ice
immediately. 2 J.tlof this solution was loaded onto a denaturing 4.25% polyacrylamide
gel and run on an ABI 377 genotyping system. Allele discrimination was performed
using Genescan and Genotyper software.
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Table 6.2.3. Primers used to genotype polymorphisms in the PKR gene.
Annealing positions
Site Oligo Name Oligo sequence (5' to 3') and reference
sequence*
Promoter region PPKR3S AGGGTTCCTGGCCGTGCAGG 442-461 of HSU51 035;
including exon-1 441-460 from Kuhen
et al" 1997
Promoter region PPKR4A CCGCGCTCCCTCGGCTGC 751-734 from Kuhen
including exon-1 et al" 1997.
Promoter region PPKR-168F GACTAGGCCAGCGGAGAAC
Promoter region PPKR-168R GCTTCGGGAGAGCTGGTT
exon-4 PKR4S ATATTCTCTTTGTAATCAGG 2-21 U5635
exon-4 PKR4A AAAAATGGCAATCACTCACC 160-141 U5635
exon-6 PKR6S CCTTCTATGATTTCTCCTAG 1-21 U5637
exon-6 PKR6A ATCCAAAGGCAATACGTACC 167-147 U5637
exon-11 PKR11S ACAGTGTTTTATCTTTAAGG 2-21 of U50642
exon-11 PKR11A GTAAACATTTACTACTTACTCG 162-141 of U50642
exon-12 PKR12S CCCTGTTCCTTTTAACTAGG 2-21 of U50643
exon-12 PKR12A CTCAGGATCATAATCACTGC 159-140 of U50643
exon-13 PKR13S CTGTGAATTTTATACCCAGG 1-21 of U50644
exon-13 PKR13A GTATTACTTTTTCCACTTACC 221-201 of U50644
exon-17 PKR17S GACTCTCACTGTCATTGCAG 1-20 of U50648
exon-17 PKR17A GTGTCATTGCACTCCAGCCT 401-420 of U50648
-Reference sequences are Genbank accession numbers.
NOS2A promoter
Three single nucleotide polymorphisms were targeted in the present study: An A
to G substitution at position -277, a G to T substitution at position -1026, and a C to G
substitution at position -1659 of the NOS2A gene were genotyped by allele specific real
time PCR.61 The primers used for this procedure are provided in Table 4. Each reaction
was comprised of 0.2 IlM of each of the primers specific for exon 8 (Table 6.2.4.); 2.5
units of Stoffel Gold Polymerase (David Birch, RMS); Ix Stoffel Gold buffer (10 mM
Tris-HCI, 10mM KCL at pH 8.0); an additional 30 mM KCI for a final concentration of
40 mM ; 2 mM MgCh; 50 J-lMeach dATP, dCTP, and dGTP; 25 mM TIP; 75 mM
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dUTP: 2 units ofUNG (PE), 0.2 x SybrGreen I (Roche Molecular Probes); 2 J.lMROX
(Roche Molecular Probes); 5 % DMSO; and 2.5 % Glycerol. Kinetic PCR reactions
were performed on a GeneAmp 5700 Sequence detection System (PE Applied
Biosystems). An initial incubation step of 2 min at 50°C (to allow UNG mediated
elimination of carry-over PCR product contamination), and an enzyme heat activation
step of 12 min at 95°C were followed by 40 two-step amplification cycles of 20 sec at
95 °C for denaturation and 20 sec for 58°C for annealing and extension, and a final 5
minutes extension at 72°C. All PCR reactions were performed using 5-50 ng genomic
DNA in a total volume of20 ul.
NOS2A Haplotype Assignment
Several conserved haplotypes have been reported in Caucasian populations
(Table 6.2.5).19 Haplotypes in the present study were assigned per these previously
published descriptions."
Table 6.2.4. Primers used for genotyping the three single nucleotide polymorphism in the
promoter region of the NOS2A gene.
SNP Primerspecificity Primersequence
NOS2A -277
(A/G) forward common primer 5'-CTGGCTCCGTGGTGCC-3'
A-specific reverse primer 5'-CAGGGTGGCTGCTAAGAT-3'
G-specific reverse primer 5'-CAGGGTGGCTGCTAAGAC-3'
NOS2A -1026
(GfT) forward common primer 5'-GGCATTATAAGGAATGAAATTATAGGCC-3'
G-specific reverse primer 5'-GATTACAAGGGTTAGCCACC-3'
T-specific reverse primer 5'-GATTACAAGGGTTAGCCACA-3'
NOS2A -1659
(CIT) reverse common primer 5'-GGGATGGTATGGTGCTGATG-3'
T-specific forward primer 5'-CCTTGAACAAGGCAGAACT -3'
C-specific forward primer 5'-CCTTGAACAAGGCAGAACC-3'
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Table 6.2.5. Major Caucasian NOS2A haplotypes and their designations.
Designation -277 (AlG) -1026 (Grr) -1659 tern
Haplotype 1 A G C
Haplotype 2 G T C
Haplotype 3 G G C
Haplotype 4 G T T
Haplotype 5 A T C
Burgner D. et al. 18
Genotyping of CTLA4 allelic variants
Polymerase chain reaction with sequence specific primers (pCR-SSP) was used
to define the SNP in position 49 of exon 1 in the CTLA4 gene. Four PCR-SSP reactions
were used to type two CTLA4 SNPs at nucleotide positions 49 in exon 1 and -318 in
the promoter, with each reaction including a pair of SNP-specific primers (Table 6.2.6)
and a pair of control primers (CS, 5'-TgC CAA gTg gAg CAC CCA A-3') and (C3, 5'-
gCA TCT TgC TCT gTg CAg AT-3') specific for human DRBI intron 3, as described
by Olerup et al. The first two SSP reactions defined the 49A1G alleles when each of the
49A and 49G-specific primers was paired with the general primer SSPg. The second
two SSP reactions combined one of the -318C- and -318T -specific primers with
another general primer SSPf. The PCR mix (10 ~l each) consisted of lx buffer C (60
mM Tris-HCI, pH 8.5, 1S mM (NH4)2S04, 2.5 mM MgCI2), 50-70 ng of genomic DNA,
0.3 units 0 f AmpliTaq polymerase, 120 n M 0 f each control primer, 2 SO n Me ach 0 f
TAP/-specific primer (positive control), 0.4 mM each of dGTP, dCTP, dTTP and dATP,
10% (v/v) glycerol, and 0.02% cresol red. PCR cycling began with 10 higher-
stringency cycles of denaturing at 95°C for 25 sec, annealing at 62°C for 45 sec, and
extension at 72°C for 4S sec, followed by 22 additional lower-stringency cycles of
denaturing at 9SoC for 2S sec, annealing at S8°C for 40 sec, and extension at 72°C for 40
sec. Half of each PCR reaction product was loaded directly onto 1.5% agarose gels for
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electrophoresis, and the SSP-banding patterns were recorded on photographs of
ethidium bromide-stained gels. PCR-SSP-based typing of the -318CIT variants were
validated by 100% match with results from restriction fragment length polymorphisms
(RFLP) as -31ST contains an Msel site (TTAA). The strategy for typing -318CIT and
49NG was similar to procedures developed independently by another group of
investigators.i' except that the orientation of the 49NG-specific primers differed and
our PCR-SSP was done at a higher stringency as verified by close resemblance between
primer melting temperatures and PCR annealing temperatures. PCR-SSP-based
genotyping of ILIO variants was performed according to procedures reported
previously.62
Table 6.2.6. Oligonucleotides used to define CTLA4 polymorphisms by PCR-SSP
Oligo Oligo Annealing
Speci ficities name Oligo sequence (5' -+ 3')· positions b
CTLA4 49A (l7Tbr) SSPI gCT CAg CTg AAC CTg gCT A 1223 -+ 1241
CTLA4 490 (17Ala) SSP2 CTC AgC TgA ACC Tgg CTg 1224 -+ 1241
CfLA4 general SSPg ACA gAg CCA gCC Aag CCA 1424 -+ 1441
CfLA4 -318C c SSP3 CCA CTT AgT TAT CCA gAT CCT C 854 -+ 875
CTLA4 -31ST c SSP4 CCACTT AgTTATCCAgATCCTT S54 -+ 875
CTLA4 general C SSPf gCTTTgATCCAgATA TgT ATT ACAC 1056 -+ 1080
Statistical analyses:
Standard univariable analyses were conducted using contingency tables. Odds
Ratios (OR) and 95% confidence intervals (95%C.I.) were calculated along with
maximum likelihood and Fisher's exact p-values, as appropriate using the EpiStat
module of Epilnfo 2000 (Centres for Disease Control and Prevention, Atlanta, Georgia,
USA), or the STAT A® and SAS® statistical packages (see Chapter 3 for a detailed
discussion of the analytical methods).
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To analyse proportions of individuals carrying a variant, the number of patients
with that variant was divided by the total number of patients (N); SRs and NRs were
compared with Chi-square statistics for contingency tables. Odds ratios (ORs), 95%
confidence intervals and p-values (both maximum likelihood and Fisher's exact) were
calculated as appropriate.
Alleles at adjacent loci in linkage disequilibrium form haplotypes. To measure
the strength of linkage disequilibrium between variants at the promoter and exon 1 loci,
delta and X2 values were calculated according to standard methods.r' Haplotypes were
inferred from the relative values of these statistics for each allele combination. For the
study of CTLA4 variants, the putative promoter and exon-I haplotypes were verified by
comparison with previous studies.42•64
Comparisons of the effects of carriage of variants on baseline viral load levels
were tested using the Wilcoxon rank-sum method (2-tailed p-value) including all 158
Caucasian patients with all viral genotypes. Multiple logistic regression was used to
adjust for covariates thought to modify therapeutic response using the entire cohort of
158 Caucasian patients and then in those with genotype-I infections only. SRs to
IFN+R were compared with NRs as the referent group.
To assess the effects of genetic variants on viral dynamics during the course of
treatment, longitudinal analysis using mixed models was employed.f This time series
analysis method is analogous to the repeated measures procedure based on the analysis
of variance (ANOV A). This form of longitudinal analysis is more robust than the
conventional repeated measures procedure and allows for unequal measurement
intervals. The SAS' PROC MIXED procedure in SAS® software (Cary, NC) version 8.1
was used for longitudinal analysis, ensuring a parametric distribution appropriate for
this statistical procedure by taking natural log-transformed viral load measurements
(baseline, week 4 and week 12). For corroboration, the differences in viral load
measurements at three time points: baseline, week 4 and week 12 of therapy, were
compared using univariable techniques (Wilcoxon rank sum test).
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6.3 Results
Interferon-Stimulated Genes and Hepatitis C
Cohort characteristics
The present cohort was 52.8% male and 47.2% female. The average age at
infection among those with self-limiting infection was 26.8 years ± 14.6 years st. dev.,
and 32.6 years ± 14.7 years st. dev. among those with persistent infection. Viral
genotyping was available on 111 patients in the present study. 61.3% of those viral
genotyped had genotype-I infections, while 38.7% had non-l genotype infections.
Among the 638 Caucasian individuals included in the study, 94 had self-limiting HeV
infection and chronic (persistent) HeV infection. 166 individuals were treated with
interferon monotherapy and 93 achieved sustained response and 12 were relapsed-
responders (lOS initial responders), while 61 were non-responders.
Polymorph isms in the OAS. PKR and MxA genes
The following polymorphisms were identified: an AlG substitution at position -
545 of the }'lrA gene, a err substitution at position -168 and a Gff substitution at
position -180 of the PKR gene, an NG substitution in the 3' untranslated region (3'-
UTR) of OAS-I at position 347 of M11810 and a eGG trinucleotide repeat in the
promoter region of the PKR gene. Subsequent comparison of the -545MxA(NG) SNP
and the 3'-UTR OAS-I-(NG) SNP with known polymorphisms in the GenBank
database suggests that these SNPs correspond to the previously described
polymorphisms rs462903 and rs2660, respectively. The -88MxA polymorphism has
been taken form the literature.t" and the eCG repeat in the S'-UTR of the PKR gene has
subsequently been published.t" 67
MxA
The single nucleotide polymorphism (SNP) at position -88 with respect to the
transcription initiation site appeared to influence the natural outcome of HeV infection
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in addition to the response to interferon therapy (Table 6.3.1). The TT genotype was
found more frequently in patients who had self limiting infection (OR = 3.30, 95% Cl
0.80 - 14.15; P = 0.05) together with the GT genotype (OR = 1.59, 95% Cl 0.98- 2.59;
P = 0.05) indicating a gene dosage effect. The GT genotype was also found more
frequently in patients with an initial response and those with sustained response to
interferon compared to those with non-response (Initial Response: OR = 2.1, 95% Cl
1.05 - 4.07; P = 0.02. Sustained Response: OR = 1.8,95% Cl 0.85 - 3.82; P = 0.1). The
TT genotype was not detected in these groups. The SNP at position -545 was not found
to be associated with the outcome ofHCV infection or treatment response.
OAS-J
The Sr-..rpin the 3'UTR of the OAS-J gene shows evidence of association with
selflimiting HCV infection but not with the response to interferon therapy (Table 6.3.2).
The GG genotype at this locus was found in 9% of patients with self limiting infection
compared to 18.8% of patients with persistent infection (OR=0.43; 95%C.I.: 0.21 -
0.86; p=O.OI).
PKR
Polymorphisms in the PKR gene appear to influence both the natural outcome
and the response to interferon therapy in HCV infection (Table 6.3.3 for self-limiting
versus persistent HCV infection; Table 6.3.4 for initial response to interferon
monotherapy versus non-response; and Table 6.3.5 for sustained response compared to
non-response). Hctcrozygotes for the SNP at position -168 relative to the
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Table 6.3.1. Summary of univariable correlations between MxA polymorph isms and the outcome
of hepatitis C virus infection among Caucasian patients. Part A. presents the distributions for self-
limiting versus persistent infection. Part B. presents distributions for initial response (IR) versus non-
response (NR) to interferon mono therapy. Part C. presents the distributions for sustained responders
{SR} versus non-responders {NR} to interferon mono thera~~.
PART A.
locus Variant Self-limiting N Wo) Persistent N (%) OR 95%C.1. p-value
MxA ·88
GG 88 (65.2) 222 (77.1) 0.56 0.35 - 0.89 0.010
GT 41 (30.4) 62 (21.5) 1.59 0.98 - 2.59 0.048
TT 6 (4.4) 4(1.4) 3.30 0.80 -14.19 0.050*
·545
AA 14 (7.9) 42 (27.3) 0.58 0.54 - 3.27 0.120
AG 48 (61.5) 87 (56.5) 1.23 0.68 - 2.23 0.462
GG 16 (20.5) 25 (16.2) 1.33 0.63 - 2.82 0.420
PARTB.
locus Variant IR N ('Ie) NR N (DI,) OR 95%C.I. p-value
MxA ·88
GG 108 (73.5) 97 (85.1) 0.49 0.25 - 0.95 0.020
GT 39 (26.5) 17 (14.9) 2.06 1.05 - 4.07 0.023
TT 0(0.0) 0(0.0)
·545
AA 23 (30.3) 16(21.6) 1.57 0.71 - 3.52 0.230
AG 40 (52.6) 46 (62.2) 0.68 0.33 -1.36 0.238
GG 13(17.1) 12 (16.2) 1.07 0.42 - 2.73 0.880
PARTC.
locus Variant SR N ('t.) NR N (%) OR 95%C.I. p-value
MxA ·88
GG 73 (76.0) 97 (85.1) 0.56 0.26 -1.18 0.100
GT 23 (24.0) 17 (14.9) 1.80 0.85 - 3.82 0.096
TT 0(0.0) 0(0.0)
·545
AA 22 (30.1) 16(21.6) 1.56 0.7 - 3.53 0.238
AG 39 (53.4) 46 (62.2) 0.70 0.34 -1.42 0.238
GG 12 {16.4} 12 {16.2} 0.46 0.17-1.26 0.092
*Fisher's exact p-value. OR=Odds ratio; 95%C.I.= 95% Confidence Interval.
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Table 6.3.2. Summary of univariable correlations between OAS-1 3'-UTR polymorphism and the
outcome of hepatitis C virus infection among Caucasian patients. Part A. presents the distributions
for self-limiting versus persistent infection. Part B. presents distributions for initial response (IR)
versus non-response (NR) to interferon mono therapy. Part C. presents the distributions for sustained
responders (SR) versus non-responders (NR) to interferon mono therapy.
PART A.
Locus Variant Self-lImiting N <-I.) Persistent N (0/.) OR 95%C.I. p-value
OAS-1 3"UTR
AA 45 (36.9) 185 (35.9) 1.05 0.68 - 1.61 0.830
AG 66 (54.1) 234 (45.3) 1.42 0.94 - 2.15 0.082
GG 11 (9.0) 97 (18.8) 0.43 0.21 - 0.86 0.010
PARTB.
Locus Variant IR N <-I.) NR N (%) OR 95%C.I. p-value
OAS-1 3'-UTR
AA 97 (36.1) 51 (34.7) 1.06 0.68 - 1.65 0.780
AG 117 (43.5) 72 (49.0) 0.80 0.52 - 1.22 0.283
GG 55 (20.4) 24 (16.3) 1.32 0.75 - 2.31 0.310
PARTC.
Locus Variant SR N <-I.) NR N (%) OR 95·/.C.I. p-value
OAS-1 3'-UTR
AA 51 (35.7) 51 (34.7) 1.04 0.63 -1.74 0.860
AG 60(41.9) 72 (49.0) 0.75 0.46 -1.23 0.223
GG 32 (22.4) 24 (16.3) 1.48 0.79 - 2.77 0.190
Abbreviations: OR=Odds ratio; 95%C.I.= 95% Confidence Interval.
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Table 6.3.3. Summary of univariable correlations between PKR polymorph isms and self-limiting
versus persistent Infections.
Locus Variant Self-limiting N ('I.) Persistent N (Of.) OR 95%C.I. p-value
PKR -180
GG 2 (4.7) 8 (10.5) 0.41 0.06 - 2.27 0.226
GT 17 (39.5) 20 (26.3) 1.83 0.77 - 4.38 0.134
TT 24 (55.8) 48 (63.2) 0.74 0.32 -1.69 0.430
PKR ·168
CC 6 (9.8) 39 (19.2) 0.46 0.16 -1.21 0.090
CT 37 (60.7) 77 (37.9) 2.75 1.45 - 5.24 0.002
TT 18 (29.5) 87 (42.9) 0.56 0.29 -1.08 0.060
PKR eGG repeat
longllong 43 (70.5) 180 (78.9) 0.64 0.32 -1.26 0.162
Shortllong 18 (29.5) 39 (17.1) 2.03 1.01 - 4.07 0.030
Short/Short 0(0.0) 9 (3.9) 5.3 0.30 - 92.75 0.201
-Fisher's exact p-value. OR=Odds ratio; 95%C.I.= 95% Confidence Interval.
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Table 6.3.4. Summary of univariable correlations between PKR polymorphisms and initial response
(IR) to interferon mono therapy compared to those with non response (NR) to therapy.
Locus Variant IR N ('I,) NR N (%) OR 95%C.1. p-value
PKR -180
GG 2 (6.9) 6 (14.6) 0.43 0.06 - 2.68 0.320
GT 9 (31.0) 10 (24.4) 1.40 0.43 - 4.58 0.538
IT 18 (62.1) 25 (61.0) 1.05 0.35 - 3.12 0.930
PKR ·168
CC 19 (17.0) 18 (22.2) 0.72 0.33 -1.56 0.360
CT 43 (38.4) 27 (33.3) 1.25 0.66 - 2.37 0.471
IT 50 (44.6) 36 (44.4) 1.01 0.54 - 1.87 0.978
PKR eGO repeat
longllong 76 (85.4) 74 (71.8) 2.29 1.05 - 5.07 0.023
Short/long 12 (13.5) 22 (21.4) 0.57 0.25 -1.32 0.154
Short/Short 1 (1.1) 7 (6.8) 0.16 0.01 -1.30 0.050
Abbreviations: IR=initial response; NR=non-response; OR=Odds ratio;
95%C.I.= 95% Confidence Interval.
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Table 6.3.5. Summary of univariable correlations between PKR polymorphisms and sustained
response (SR) to interferon mono therapy compared to those with non response (NR) to therapy.
Locus Variant IR N (%) NR N (%) OR 95%C.1. p-value
PKR -180
GG 2 (7.4) 6 (14.6) 0.47 0.06 - 2.91 0.370
GT 9 (33.3) 10 (24.4) 1.55 0.47-5.16 0.421
TT 16 (59.3) 25 (61.0) 0.93 0.31 - 2.82 0.887
PKR -168
CC 12 (15.2) 18 (22.2) 0.63 0.26 -1.51 0.250
CT 31 (39.2) 27 (33.3) 1.29 0.64 - 2.59 0.437
TT 36 (45.6) 36 (44.4) 1.05 0.54 - 2.05 0.890
PKR eGG repeat
Long/Long 42 (89.4) 74 (71.8) 3.29 1.10 -10.52 0.017
Short/Long 5 (10.6) 22 (21.4) 0.44 0.13-1.34 0.113
Short/Short 0(0.0) 7 (6.8) 0.14 0.01 - 2.42 0.115
Abbreviations: IR=initial response; NR=non-response; OR=Odds ratio;
95%C.I.= 95% Confidence Interval.
transcription initiation site were more likely to have self limiting HCV infection
(OR=2.75; 95%C.I.; p=0.002) but this genotype had no significant influence on the
outcome of treatment. The SNP at position -180 had no significant influence on the
outcome ofHCV infection or treatment.
Associations were sought for individual alleles of the CGG repeat polymorphism
in the PKR promoter region. As trinucleotide repeats may influence gene transcription,
alleles were categorised as short « 9 repeats) or long (~ 9 repeats). Individuals with
two short alleles were found more frequently amongst those who had self limiting
infection (OR 18.8, P = 0.11) as were individuals with one short allele (OR = 2.03,95%
Cl 1.01 - 4.07; P = 0.03). Conversely, patients with two long alleles were found more
frequently in the initial responder group (OR= 2.29, 95% Cl 1.05 - 5.07; p = 0.02) and
sustained responder group (OR = 3.29, 95% CI1.10 - 10.52; p= 0.02). In a global test,
all polymorphic sites approximated to Hardy Weinberg Equilibrium.
NOS2A haplotypes and hepatitis C
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Cohort characteristics
The present cohort was 55.7% male and 44.3% female. The average age at
infection was 43.5 years ± 15.8 years st. dev. Viral genotyping was available on 177
patients in the present study. 66.7% of those viral genotyped had genotype-1 infections,
while 33.3% had non-l genotype infections. Among the 619 individuals included in the
study, 76 had self-limiting HCV infection and 543 chronic (persistent) HCV infection.
314 individuals were treated with interferon monotherapy and 112 achieved sustained
response and 102 were relapsed-responders (214 initial responders), while 100 were
non-responders.
NOS2A haplotypcs aml/ICV outcome
Five major NOS]A haplotypcs were observed with the following frequencies:
haplotype 1: 60.9%; haplotype 2: 16.2%; haplotype 3: 8.7%; haplotype 4: 12.8%; and
haplotype 5: 1.4%, and is comparable with frequencies reported in other Caucasian
cohorts.i" Homozygosity for haplotype 2 (Table 6.3.6) was associated with self-limiting
infection (OR=3.02; 9S%C.I.: 1.10-8.0; p=0.0206), while possession of the combination
of haplotypes 2 and 4 was also associated with self-limiting infection (OR=4.57;
95%C.I.: 1.32-14.32; p=0.OOI8).
The combination of haplotypes 1 and 4 were associated with the initial response
to interferon therapy (OR=2.32; 95%C.I.: 1.05-5.68; p=0.0275) (Table 6.3.7).
Marginally significant associations with non-response were observed with possession of
haplotypcs 1 and 5 (OR=0.09; 9S%C.I.: 0.01 - 1.93; p=0.0556) and homozygosity for
haplotype 3 (OR=O.27; 95%C.I.: 0.04 - 1.43; p=0.0594). No significant associations
were observed between NOS]A haplotypes and sustained response to interferon therapy
(Table 6.3.8).
The r dative infrequency 0 f these h aplotypes p recIuded m ultivariable analysis.
As an alternative, I stratified the observed haplotypic effects by patient gender and viral
genotype. Stratification of the association between haplotype 2 homozygous and self-
limiting infection yielded a stronger effect among men than women (OR=3.72; 95%C.I.:
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0.95 - 14.60; p=O.0790 for men, and OR=1.30; 95%C.I.: 0.26 - 6.39; p=0.6691 for
women). Stratification of the haplotype 2/4 combination by gender yielded similar
strength's of association for both males and females (OR=3.2; 95%C.I.: 0.32 - 31.34;
p=O.3335 for men, and OR=3.4; 95%C.I.: 1.05 - 11.06; p=0.0317 for women).
Stratification 0 fthe association between the combination 0 fh aplotype 114 and initial
response to therapy yielded a stronger effect among women than men (OR=0.99;
95%C.I.: 0.39 - 2.54; p=0.9854 for men, and OR=7.6; 9S%C.I.: 1.74 - 33.27; p=O.0015
for women). Stratification of the association of the combination of haplotypes 114and
initial response by viral genotype yielded a stronger effect among those with genotype-l
virus infections (OR=6.79; 95%C.I.: 1.51 - 30.52; p=0.0048 for genotype-l infections
and OR=1.8; 95%C.I.: 0.21 - 15.45; p=1.0 for non-l genotypes).
221
Chapter6
Table 6.3.6. Association of NOS2A haplotypes among 619 Caucasian individuals in the HENCORE
Study. 76 individuals have self limiting HeV infection, and 543 individuals have persistent infection.
Haplotype Self-limiting Persistent OR 9S%C.1. p-value
1/1 24 206 0.76 0.43 -1.29 0.2826
1/2 14 112 0.87 0.43 - 1.64 0.6548
1/3 5 53 0.65 0.20 -1.70 0.3727
1/4 12 90 0.94 0.45 - 1.86 0.8628
1/5 0 8 0.41 0.02 -7.21 0.5306
212 6 15 3.02 1.10 - 8.0 0.0206
213 3 12 1.82 0.32 - 6.95 0.3562
214 6 10 4.57 1.32 - 14.32 0.0018
215 0 2 1.42 0.07 - 29.77 0.8223
3/3 0 9 0.37 0.02 - 6.38 0.4745
3/4 4 13 2.26 0.52 - 7.58 0.1521*
4/4 1 8 0.89 0.02 - 6.81 1.0*
4/5 1 4 1.80 0.04 - 18.45 0.5973
515 0 1 2.36 0.10 - 58.55 0.5884
*Fisher's exact 2-tail.
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Table 6.3.7. Association of NOS2A haplotypes (as genotypes) with initial response (IR) and
non-response (NR) to therapy among 314 Caucasian patients in the HENCORE Study.
214 patients achieved initial response, while 100 were non-responders (NR) to interferon
monotherapy.
Haplotype IR NR OR 95%C.1. p-value
1/1 75 38 0.88 0.52 - 1.49 0.6155
1/2 42 25 0.73 0.40 -1.35 0.2789
1/3 21 15 0.62 0.29 - 1.35 0.1789
1/4 40 9 2.32 1.05 - 5.68 0.0275
1/5 0 2 0.09 0.01 - 1.93 0.0556
212 5 2 1.17 0.19 - 12.50 1.0*
213 5 1 2.37 0.26 - 113.12 0.4203
214 8 0 8.27 0.47 - 144.78 0.0853
215 1 0 1.41 0.06 - 34.97 0.8325
3/3 3 5 0.27 0.04 -1.43 0.0594
3/4 8 2 1.90 0.37 - 18.69 0.4138
4/4 3 1 1.41 0.11 -74.62 0.7674
4/5 2 0 2.36 0.11-49.71 0.5687
5/5 1 0 1.41 0.06 - 34.97 0.8325
*Fisher's exact 2-tail.
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Table 6.3.S. Association of NOS2A haplotypes (as genotypes) with initial response (SR) and
non-response (NR) to therapy among 314 Caucasian patients in the HENCORE Study. 112
were sustained responders (SR), while 100 were non-responders (NR) to interferon
monotherapy.
Haplotype SR NR OR 95%C.I. p-value
1/1 39 38 0.87 0.48 -1.59 0.6309
1/2 25 25 0.86 0.43 -1.71 0.6465
1/3 13 15 0.74 0.31 - 1.78 0.4664
1/4 16 9 1.69 0.66 - 4.55 0.2336
1/5 0 2 0.18 0.01 - 3.69 0.2078
212 4 2 1.81 0.25 - 20.42 0.6861*
213 2 1 1.80 0.09 - 107.24 1.0*
214 2 0 4.55 0.22 - 95.86 0.2872
215 0 0
3/3 1 5 0.17 0.003 -1.58 0.1024*
3/4 7 2 3.27 0.60 - 32.80 0.1716*
4/4 2 1 1.8 0.09 - 107.24 1.0·
4/5 0 0
5/5 1 0 2.70 0.11 - 67.13 0.5285
*Fisher's exact 2-tail.
CTLA4
Cohort characteristics
Patients in the present study were quite representative of the entire UAB cohort
in their characteristics at enrollment (Table 6.3.9). SRs and NRs differed as expected in
age, gender, viral load, viral genotype and ALT-all characteristics previously reported
to influence response to treatment. Among those with genotype 1 and non-1 infections,
39 and 40 were SRs while 73 and 6 were NRs, respectively. Only one individual who
was positive at week 12 achieved sustained response.
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Distribution of CTLA4 promoter and exon 1allelic variants and haplotypes
The frequencies of the CTLA4 promoter and exon 1 genotypes in Caucasians
approximated Hardy-Weinberg equilibrium and were comparable to those reported
elsewhere (for the promoter: C/C: 83.6%; CIT: 14.6%; TIT: 1.8%; for exon 1: GIG:
10.4%; G/A: 44.8%; NA: 44.8%).54, 64 This study observed strong linkage
disequilibrium between exon 1 position 49 and promoter -318 alleles, and the
haplotypes observed are comparable to those reported in other populations. 54,64
In univariate analysis of Caucasian SRs with genotype-l infections, 49G allele
carriers and 49G/G genotype homozygotes were significantly more frequent among SRs
{(OR=2.3; p=0.042) and (OR=5.2; p=0.049), respectively} (Table 6.3.10). Carriers of
the promoter -318C variant were frequent among both SRs and NRs, but more so
among SRs. As measured by allele frequency based on 2N chromosomes, a two-fold
higher likelihood of response was seen with both the 49G (OR=2.1, p=0.017) and the-
318C variant. Carriage of the tightly linked -318C-49G haplotype also conferred a two-
fold higher likelihood of response (OR=2.4; p=0.030). The magnitude of the association
of SR with homozygosity for the haplotype was even higher (OR=5.2; p=0.04). The
nearly exclusive haplotype pairing of 49G with -318C prevented separate analysis of
49G alone; every effect seen with 49G also occurred with the -318C-49G haplotype at
the same magnitude. The dimorphic nature of the -318 and 49 SNPs produced
reciprocal effects (inhibition of response) for the -318T and 49A variants and carrier
frequencies. Neither the 49G nor the haplotype effect was observed in patients infected
with non-l genotype viruses (p> 0.25 for all).
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Chapter6
Table 6.3.10. Differential distribution of allele frequency, allele carriage and genotype for the -318 SNP, the
49 S~P and the -31849 haplotype among 39 Caucasian sustained responders (SR) and 73 non-responders
(NR) infected with genotype-I virus infection.
SR(O/O) NR (0/0)"
I\IARKER !N-39~ !N=73~ OR 950/0C.I. P-VALUE
Allelelhaplotype (carriage l'
-3ISC 38 (97.4) 70 (95.9) 3.8 0.19-75.9 0.350
-318T 4 (10.3) 15 (20.5) 0.45 0.14-1.48 0.186
490 25(64.1) 32 (43.8) 2.3 1.0 - 5.1 0.042
49A 34 (87.2) 71 (97.2) 0.2 0.04 - 0.9 0.049
-318C49G 25 (64.1) 31 (20.5) 2.4 1.1 - 5.4 0.030
Genotype
49G!G 5 (12.8) 2 (2.7) 5.2 1.0 - 28.3 0.049
49AJA 14 (35.9) 41 (56.2) 0.4 0.2 -1.0 0.042
-318C-49G 1-318C-49G 5(12.8) 2 (2.7) 5.2 1.0·29.2 0.049
-318C-49A 1-318C-49A 12 (30.8) 33 (45.2) 0.5 0.3·1.3 0.139
• l"Rs served as the referent group for all calculations.
~Analyses performed using allele frequencies based on 2N chromosomes (SR=78 and NR = 146) showed
comparable ORs and p values).
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Multivariable analyses
The associations of the 490 variant and the corresponding -31SC+490 haplotype
persisted after multi variable adjustment for baseline characteristics {gender, age at
treatment, interaction between age at treatment and gender, baseline viral load, baseline
ALT and possession of the ILl 0 (10S) TCATA haplotype} (Table 6.3.11) in both the group
of ISS patients and in the subgroup with genotype 1 infections. Control for effect of
homozygosity for the ILJO (lOS) TCATA haplotype previously reported to be associated
with SR to IFN+R was precluded by the small number of individuals with this haplotype
(N=5).62 However, when considered jointly with the CTLA4 variant, carriage of a single
ILlO (lOS) TCATA haplotype, also previously associated with SR, actually demonstrated a
stronger association (OR=3.0 when adjusted for 490 carriage or -31SC+49G carriage;
p=0.02) than was originally reported (OR=1.6; p=0.30).62 High level (multiplicative)
interaction due to carriage of 490 or its haplotype plus carriage of ILlO (10S)TCATA was
not detected.
Longitudinal analyses of viral dynamics
In an analysis of the effect of these markers on viral dynamics during the initial 12
weeks of therapy among the entire group of ISS, 490 carriers and non-carriers showed
significant differences in viral load (Figure 6.3.1). Viral RNA concentration declined more
rapidly in 490 carriers (p=0.0095); lower levels were seen in carriers at each successive
point, with the greatest difference occurring by week 4 (p=0.0053) with the difference
being less pronounced by week 12 (p=O.0718) (Figure 6.3.1). Both the apparent
acceleration in response among 490 carriers and the interaction between 490 carriage and
time on viral dynamics were significant. Patients with the -31SC+490
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Table 6.3.11. Multivariable analyses of the effects of 49G allele and -318C-49G haplotype carriage
on sustained response to IFN+R in 158 Caucasian patients
A. MULTIVARIABLE MODEL FOR 49G OR 95%C.I. P-VALUE
49-(G) allele carriers 2.0 1.02 - 3.97 0.04
Baseline viral load 1.7 0.85 - 3.40 0.14
Baseline ALT 0.98 0.487 - 1.96 0.95
Gender 0.04 0.002·0.91 0.04
Age at treatment 0.27 0.03·2.7 0.26
IL-IO (10S)-TCATA allele carriage 3.0 1.2-7.4 0.02
Interaction between sex 4.1 0.77 - 22.2 0.1
and a e
B. MULTIV ARIABLE MODEL FOR -318C-49G OR 95% C.I. P-VALUE
-3IS-(C ) + 49-(G) haplotype carriers 2.0 1.0 - 3.9 0.04
Baseline viral load 1.7 0.87 - 3.5 0.12
Baseline ALT 1.0 0.49 - 2.0 0.95
Gender 0.04 0.002 - 0.9 0.04
Age at treatment 0.26 0.025 - 2.65 0.25
IL-I0 (108)- TCATA allele carriage 3.0 1.2 - 7.3 0.02
Interaction between sex 4.2 0.77 - 22.3 0.1
and a e
C. MULTIV ARIABLE MODEL FOR 49G AMONG OR 95% C.I. P-VALUE
THOSE WITH GENOTYPE-l INFECTIONS ONLY
49-(G) allele carriers 2.5 1.1 - 6.0 0.04
Baseline viral load 0.50 0.21 - 1.2 0.12
Baseline ALT 1.4 0.58 - 3.6 0.43
Gender 2.5 0.82 -7.6 0.11
Age at treatment 0.41 0.02 -7.0 0.54
IL-l 0 (108)- TCATA aileIe carriage 2.6 O.SI - S.5 0.11
Interaction between sex 1.1 0.18 - 6.4 0.94
and a e
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Chapter6
haplotype and with HCV genotype 1 only showed comparable longitudinal effects (data not
shown).
6.4 Conclusions
Interferon-stimulated genes
These observations suggest that polymorphisms in the interferon-induced genes may
be involved in determining the outcome of hepatitis C virus infection. With respect to the
MxA gene, the TT and the GT genotypes at the -88 locus were associated with self limiting
infection, suggesting that the T allele conferred an advantage in HCV infection.
Furthermore the GT genotype was found more frequently in those with an initial response
or sustained response to interferon therapy. This observation is consistent with a previous
report in a Japanese population in which the GG genotype was associated with non-
response to interferon.l'" 68 Interestingly the allele frequency of the T allele is much lower in
our Caucasian population than in the Japanese population (14.5% for Caucasians and 29%
for Japanese). The apparent effect of the T-allele is supported by in vitro functional work
suggesting that this variant has higher transcriptional activity than the T allele when
stimulated with interferon-u.f This is due to the fact that the polymorphism at position -88
lies within a sequence element similar to an interferon sensitivity response element (ISRE),
and the T-allele increases this similarity/" Consequently, patients with the GIG genotype at
position -88 may produce a sub-optimal MxA response when given interferon. Clinical
studies have also suggested that those who respond to interferon treatment express
increased amounts ofMxA mRNA during treatment.V
There is an association between the 3' -UTR OAS-(G/G) genotype with self-limiting
infection, but not with response to therapy. This observation may be explained by studies
suggesting that OAS levels do not change with the administration of interferon or that
levels may elevate and quickly dimish.69, 7°While levels of OAS protein expression have
been reported to be elevated in chronic HCV infection, administration of exogenous
interferon does not appear to have a modulatory effect on its expression.i" 71-73It is quite
possible that the natural induction of interferon by an infectious agent such as HCV is
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different from the administration of exogenous interferon or that persistent induction of
OAS through chronic HeV infection reduces sensitivity to exogenously supplied interferon.
Thus, it is possible that OAS plays a greater role in mediating self-limiting versus persistent
HeV infections rather than during the stage after viral persistence is established.
The length of the a lleles in the PKR promoter trinucleotide repeat polymorphism
influenced the outcome of infection. Patients who possessed one short allele were
approximately two fold more likely to spontaneously clear HeV whereas those with two
short alleles were estimated to have 18 fold increased chance of self limiting infection
although this fails to reach statistical significance. Variation of the number of repeats in
this PKR microsatellite may alter binding capabilities of transcriptional factors and affect
PKR expression during interferon therapy. Expansion of the number of trinucleotide repeats
in a promoter regions has been correlated with transcriptional silencing as in the FMRI
gene and Fragile X syndrome.i'' While the number of repeats in the FRMI gene expands
from 10-50 to 52-2000, the present study only found a maximum number of 10 repeats in
the S' untranslated region of the PKR gene, and the effect of the smaller number of repeats
remains unknown.
Our observed differences in the association between the longllong repeat and
response to therapy and lack of association between this genotype and self-limiting
infection may be due to, at least in part, differential effects from endogenously derived
interferon (as with self-limiting infection) and exogenous interferon (as with anti-viral
therapy) or differences in the level of interferon between natural infections and therapies.
While PKR expression occurs at a low level under most physiological conditions, its
expression is greatly enhanced within a few hours of interferon treatment. 6 The large dose
of interferon (3 million IV) given during interferon therapy may strongly increase PKR
expression and the increased quantity ofPKR may facilitate enhanced clearance of HeV.
Our study also suggests that the SNP at position -168 in the PKR gene may also be
important in the outcome of HeV. However, in this case it appears that heterozygosity
confers an advantage for spontaneous elimination. This observation may be explained in a
number of ways. Firstly, heterozygosity may in fact confer a beneficial effect. Such
observations have been reported initially for hemaglobinopathies in falciparum malaria and
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more recently for MHC class II genes for hepatitis B virus infection.i" 75 Second, the
association may have arisen through a systematic genotyping error. This is unlikely as the
genotyping was performed by sequence analysis and for the cohort as a whole the
genotypes conform to Hardy Weinberg equilibrium. Thirdly this may arise through latent
ethnic stratification as the cohort was recruited in nine different European centres. Again
this is explanation is not tenable as the allele frequencies of this polymorphisms did not
vary significantly between the centres. Finally, the difference in genotype frequencies may
have occurred by chance.
The present study highlights the important role of interferon-induced genes and the
outcome of HCY. In a ddition it identifies important polymorphisms that may be further
examined for potential use as genetic markers ofHCY disease outcome.
NOS2A haplotypes and hepatitis C
The observations suggest that NOS2A gene haplotypes may be involved in
determining the outcome ofHCY infection. Homozygosity for haplotype 2 and the
combination ofhaplotypes 2/4 were associated with self-limiting infection. Stratification by
gender suggested that the effect of the homozygous haplotype 4 was stronger among males
than females. These differences by gender are not surprising, as the natural history of HCY
has been observed to differ with respect to gender. Specifically, with respect to self-limiting
infection, some studies suggest that females are more likely to clear HCY viraemia
naturally than men.76• 77 It is plausible that NOS2A polymorphisms exert a differential
biologic effect in males and females.
There is also an association of the homozygous haplotype 3 with non-response (in a
comparison with initial responders). Unfortunately, the frequency of haplotype 3
homozygotes is low. Consequently stratified analysis was precluded. The combination of
haplotypes 1 and 4 was associated with initial response to interferon along with haplotypes
1 and 5. The relatively low numbers of individuals with these haplotypes also precluded
meaningful stratified analyses.
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Determination of whether effect underlying our observed associations are due to the
haplotype as a whole or the individual loci must await functional studies. It is also plausible
that these observed associations are due to linkage disequilibrium with another as yet
unidentified marker, and that the observed haplotypes merely reflect linkage with another
locus. Genes in this region include kinase suppressor of RAS (KSR) and NOS2c on the
centromeric side and 2 genes of unknown function on the telomeric side." Nevertheless,
these observations are important in highlighting the potential importance of the inducible
nitric oxide synthase pathway and the region surrounding the NOS2A gene, in the outcome
of HCV infection. Future studies should also address the functionality of NOS2A
haplotypes. In addition, future studies are needed to replicate these findings and it is
important that these studies also be sufficiently powered to not only accommodate
simultaneous adjustment for potential confounding variables through multivariate analyses,
but the analysis of host-pathogen interactions, such as the possible interaction of gender
with host genetics.
CTLA4 and HCV Therapy
Polymorphisms in CTLA4 may augment the current array of predictors of
therapeutic response to IFN+R. For genotype-l infection in Caucasians with sustained
response the present study observed associations of the allelic variants and the homozygous
genotypes consisting of the exon I 49G and the linked promoter SNP -3ISC. Tight linkage
disequilibrium of 49G with -3ISC accounted for the apparent advantage for SRs due to
each marker individually and to the corresponding -3ISC+49G haplotype; the 49G and the
haplotype effects could not be distinguished from each other. The relationships of carriage
of these markers were independent of previously described cofactors for response (e.g. age,
gender, baseline viral load and the ILIO (IOS)-TCATA polymorphism). The finding that
treated carriers of those CTLA4 variants reached lower levels of viraemia more rapidly than
treated persons not carrying them further attests to the likely biologic/clinical significance
of the association.
This study population, the apparent advantage of the one or both alleles, or the
corresponding haplotype, was confined to infection with genotype-l virus in Caucasians.
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Genotype-l viruses may differ intrinsically from the others in the magnitude or quality of
the T-cell response they elicit. In a study of the differential effect of interferon (IFN) on
antiviral T-cell responses, those infected with non-l virus had stronger IFN-induced T-cell
responses to HCV core antigen."
Any of several mechanisms may account for these observations. First, the
polymorphisms, either individually or as a haplotype, may confer a difference with respect
to gene expression. Carriage of the -318T allele has been associated with increased levels
of CTLA4 mRNA compared with -318C/-318C homozygotea" Similarly, 49G has been
shown to have a reduced effect on CTLA4 up-regulation. 55 Another study of the functional
effects of the haplotypes formed by these two loci demonstrated increased expression of
CTLA4 by the -318T -49A haplotype. 54 Thus, investigative efforts to date consistently
suggest that -318C, 49G, or the -318C-49G haplotype plays a role in down-regulating
CTLA4, presumably thereby amplifying the T-cell response in some individuals.
Alternatively, since CTLA4 ligands B7-1 (CD80) and B7-2 (CD86) may playa role in the
ThllTh2 developmental pathways, polymorphism in CTLA4 could shift the ThllTh2
balance.8o-82 A third possibility is that these SNPs are in linkage disequilibrium with an
adjacent marker that, by itself or as part 0 fthe haplotype, may alter CTLA4 expression
and/or function. Such a marker could instead account for the association by some other
mechanism that enhances the T-cell responses believed to govern both natural acute viral
clearance and equilibrium concentration of virus during IFN+R therapy.i" 83
This study had certain limitations. First, the small number of patients infected with
non-l HCV genotypes precluded meaningful analysis of associations between CTLA
polymorphisms and response to therapy in those individuals. Second, the study was
conducted before assays for plasma HCV concentration were standardized or results were
reported in international units (IU).84 An HCV-RNA copy has not been officially defined,
measurement variability between assays still exists, and the correlation of RNA copies with
IUsis uncertain. 84-90The factor used to convert m easured levels 0 f H CV-RNA into IUs
only approximates the true value. Future studies attempting to replicate our observed
epidemiologic associations may be more informative if they measure viral loads directly in
IUs. Third, this study was conducted in a single Caucasian population; the associations of
235
Chapter6
CTLA4 polymorphism with response to interferon therapy should be examined in other
ethnic groups and populations.
In summary, successful viral clearance during therapy for HCV infection appears to
depend on robust T-cell responses facilitated by the reduction of CTLA4 levels, and
diminished in vitro expression of CTLA4 has been found in the presence of CTLA4
polymorphisms associated with improved viral clearance. 53, 54 With further clinical
validation of this phenomenon, it will remain to be determined precisely how the CTLA4
alleles/haplotype, along with the fLlO (108)-TCATA haplotype, influence the pathogenesis
of H CV infection and its prognosis following antiviral therapy. Meanwhile, beyond the
implication that the co-stimulatory pathway involving CTLA4 affects the outcome of
therapy for HCV infection, there is the prospect that the CTLA4 gene or its product might
represent a separate target for therapeutic intervention.
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Conclusions, Public Health Impact and Future Directions
7.1 Summary
In this thesis, I have addressed several important aspects relating to chronic hepatitis
C virus (HCV) infection: co-morbid conditions in HCV infection (namely the formation of
anti-nuclear autoantibodies) and the identification of genetic polymorphisms that may
affect HCV natural history. Below, I will summarise the major findings and discuss their
implications, as well as offer some ideas for future research directions.
7.2 Host Genetics
Host genetic factors that may affect HCV outcome have been recognised as an
important aspect of HCV research.' While there has been a substantial body of literature
produced aimed at identifying genetic markers for HCV outcome, there have been mixed
results. A more positive example is the reproduced association of DQB1 *0301 with self-
limiting infection. In contrast, studies such as those of the haemochromatosis gene (HFE)
and the progression ofliver fibrosis have been inconsistent.
The present study used the candidate gene approach to study correlations between
several genes and the outcome of HCV infection. The study examined whether
polymorphisms in several interferon-stimulated genes (PKR, OAS, and MxA) are associated
with HCV outcome. Several associations were observed. UnforturIately, the relative
frequency of these variants in the Caucasian population studied would preclude its
successful and cost-effective use as a screening marker to assist in determining an
individual's chances of responding to therapy. Nevertheless, this study implicates the
importance of the interferon-stimulated genes pathway in the outcome of HCV infection.
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Similarly, we examined whether haplotypes in the NOS2A gene were associated with Hey
outcome. Although we observed several relationships, the relative frequency of these
haplotypes in the Caucasian population precludes its effective use as a screening marker for
prognostic tests of disease outcome. However, our study highlights the importance of the
inducible nitric oxide synthase pathway in HCY infection. The identification of these
pathways also may be a target for future therapeutic strategies. We also observed a variant
of the CTLA4 gene, and its corresponding haplotype associated with responsiveness to
interferon+ribavirin therapy. The frequency of the variants in this gene occur at a relatively
high frequency. If future larger-scale studies confirm the associations reported in the
present study, then research should explore combining these, along with other genetic
variants that may be associated with therapeutic outcome in HCY, with existing factors
known to be predictive of response such as viral genotypes and patient race and gender. By
"screening" for those individuals who would most likely not ultimately response to
interferon therapy, needless suffering from the multiple and often debilitating side effects
of interferon therapy may be avoided. In addition, the costs of interferon therapy may be
better spent on an individual who would have a higher chance of responding. Future
research will be needed exploring new combinations of algorithms that incorporate genetic
markers with existing prognosticators of response.
Another future direction for drug therapy concerns the custom tailoring of drug
regiments to a person' s specific genetic makeup.i For example if a person has variant A at a
specific locus that is known to be highly correlated with response to a specific regimen, that
person will be given a drug cocktail that includes the specific drug, while those with variant
B are given another?
The public health impact of genetic prognosticators is high. Identification of
successful markers for screening of individuals who would likely not benefit from
expensive and debilitating therapies like those involving interferon will prevent needless
suffering in patients who will ultimately not benefit from these therapies, as well as direct
limited financial resources towards those who will more likely benefit from these expensive
therapies.
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There is also an urgent need for large-scale, properly-designed epidemiologic
studies to allow for the systematic study of genetic factors in Hev. As mentioned in
chapter 2 (systematic review of genetic factors and HeV natural history), it is important for
future studies to be sufficiently powered to detect meaningful relationships with respect to
genetic factors and HeV outcome.
7.3 Autoimmunity in HeV: Antinuclear antibodies
/
In the study of antinuclear antibodies (ANA) and HeV outcome, no adverse effects
of ANA positivity on the response to interferon therapy was detected. This observation has
important ramifications with respect to HeV treatment, as its uggests that the estimated
4%-41% of individuals with low titre ANA should not be precluded from treatment with
interferon. Interestingly, we detected an almost two-fold higher association of ANA
positivity with faster progression of HeV-related fibrosis. Although this association did not
reach statistical significance, the strength of association suggests that it may be worthwhile
to explore this relationship further. If future larger studies, are able to replicate this
association, then it may warrant the further exploration of the biological mechanisms
behind this epidemiologic observation. Such studies may facilitate the understanding of
fibrogenesis in general as well.
The present study identified an association between female gender and a higher
likelihood of developing ANA, which is consistent with the association of female gender
with autoimmunity in general. I also observed an association between latitude and
increased prevalence of ANA, similar to the reports of increased cryoglobulins in southern
Europe compared to northern Europe. Further research employing ANA positivity in HeV
as a paradigm for autoimmunity may lead to abetter understanding 0 f a utoimmunity in
general.
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7.4 Concluding thoughts
In this dissertation I have addressed several important aspects concerning the
clinical 0 utcomes 0 f H CV infection. I n addition toe xploring genetic predictors 0 f H CV
outcome, I have also examined the effect of comorbidities on the clinical outcome of
hepatitis C. In addition to identifying important clinical observations such as the important
lack of a negative effect of ANA positivity on HCV outcome, I have identified important
avenues for future research, such as the identification of genetic associations to be
replicated in further studies as well as pathways that may be further explored in basic
research. Collectively, the research included in this thesis offers a piece to the hepatitis C
puzzle.
247
Chapter 7 References
1. Hoofnagle 111.Course and outcome of hepatitis C. Hepatology 2002;36:S21-9.
2. Constans E. Making Medicine Personal. TIle Scientist 2002; 16:44-46.
248
Chapter 7
Appendices
Appendices
249
Appendix 1
List of key demographic variables in the St. Mary's
HospitallHENCORE database
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List of key demographic variables in the St. Mary's
HospitallHENCORE database
.Patient ID
.DNA ID Number
.1lENCORE Study number (if part of HEN CORE)
.Centre (if part of HEN CORE)
.Ethnic Origin
.Gender
.Route oflnfection, ifknown
.Year ofHCV infection, ifknown
.Did they receive anti-viral therapy
.Anti-viral therapy regimen type
.Response to anti-viral treatment
.HCV viral genotype
.Date of first liver biopsy
.Fibrosis of biopsy #1 (Metavir)
.Fibrosis of biopsy #1 (HAl)
.Inflamamtory score biopsy #1
.Date of biopsy #2, if done
.Fibrosis of biopsy #2 (Metavir)
.Fibrosis of biopsy #2 (HAl)
.Inflamamtory score biopsy #2
.Current alcohol intake
.Previous alcohol intake
.HBV co-infection
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List of key demographic and clinical variables
in the Alabama hepatitis C cohort database
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List of key demographic and clinical variables in the Alabama hepatitis C cohort
database:
.PatientID
.DNA ID Number
.Centre (Birmingham or Mobile)
.Race
.Gender
.Level of education
.Route oflnfection, ifknown
•Year of infection, if known
.HCV viral genotype
• Baseline viral load
•Week 4 viral load
•Week 12 viral load
•Week 24 viral load
•Week 48 viral load
.6 month follow-up viral load
• Baseline liver function tests (ALT and AST)
•Week 4 liver function tests (ALT and AST)
.Week 12liver function tests (ALT and AST)
.Week 24liver function tests (ALT and AST)
•Week 48 liver function tests (ALT and AST)
.6 month follow-up liver function tests (ALT and AST)
• Baseline platelet
•Week 4 platelet
.Week 12 platelet
•Week 24 platelet
•Week 48 platelet
.6 month follow-up platelet
• Baseline neutrophils
.Week 4 neutrophils
.Week 12 neutrophils
•Week 24 neutrophils
.Week 48 neutrophils
.6 month follow-up neutrophils
.Previous alcohol intake
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Appendix 3
Laboratory Protocol for Antinuclear Antibody (ANA)
Detection by Indirect Immunofluorescence
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ANA Laboratory Protocol:
Detection of antinuclear autoantibodies (ANA)
by indirect immunofluorescence on Hep-2 cell substrates
Prepared by LJY on 21 February 2002
Reagents needed:
Reagent
Hep-2 substrate slides
Goat anti-human Ig FITC-conjugate
Catalogue number
FSOO1.2
FA003
Company
Binding Site
Binding Site
(at working dilution 1:100 or 1:50-see manufactuer's recommendations)
DABCO (1,4-diazabicyc1o-(2,2,2) octane) D 2522
PBS Tablets P4417
Glycerol G5516
Clear Nail varnish (polish)
Positive and Negative control sera Pooled patient sera
Sigma
Sigma
Sigma
Any store
Immunology Lab
Other supplies needed:
Serum samples
3 plastic boxes (for washes and staining slides)
curvettes or microfuge tubes (for dilution of samples)
box or rack to hold samples and curvettes during dilution stage
cotton swabs ("Q-tips")
slide cover slips
towels for drying backs of slides
Pasteur (serologic) pipettes
Pipettors with corresponding tips
Preparation of Solutions needed:
1) As usual.
Mounting solution:
1) Dissolve 5g of DAB CO in 20mL PBS using a stirrer (will take a while to dissolve).
2) Add this 20mL solution to 380 mL of glycerol.
3) Mix well.
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Brief Theory
Hep-2 cells are used to express substrate antigen for binding of anti-nuclear
autoantibodies (ANA) present in positive sera. Excess sera is then washed off. Anti-Ig
with FITe (fluorescein isothyocyanate) is then applied to bind to any human antibodies
that may have bound to the substrate and excess washed off. Samples with positive
ANA will then bind this secondary antibody. If positive, the wells wi11light up in a
green colour when examined under a fluorescent microscope. The pattern of
immunofluorescence can then be read as well.
Procedure:
Part A: Preparation of samples:
1) Place samples in a rack, along with empty curvettes in front.
2) Label curvettes with appropriate number for identification of patient number.
3) First 6 wells on the first slide in each batch are for controls (WeIll for neg
control and 2-6 for positive control dilutions)
NOTE: dilutions are done at 1:40, 1:80, 1:160, 1:320, and 1:640.
4) Last 5 tubes are for dilutions of previous positive samples (although this set-up
may vary)
5) Place serum samples in tray analogous to slide set-up illustration on the
accompanying page, skipping rows. Place the curvettes in front of the respective
serum. Typically a 3-slide configuration is used; however, more may be added-
but be sure to include the first slide as is, as it has all the controls.
SUMMARY OF SERUM QUANTITIES NEEDED:
1O~L serum + 390 ~L PBS for samples and 1:40 dilution
200 ~L of the previous dilution (Le. 1:40) + 200~L PBS for subsequent ones
6) Add 390 ~L PBS to all curvettes for the following samples: negative control,
positive control I :40 dilution only, samples, and 1:40 sample of dilutions only.
7) Add 200 ~L PBS to the curvettes for the following dilutions on the positive
controls as well as the samples undergoing dilution: 1:80, 1:160, 1:320, 1:640.
8) Place 10~L negative control sera in appropriate (first) curvette.
9) Place 1O~L sera into the 1:40 dilution curvettes and patient samples only.
10) Do doubling dilutions by taking 200~L 1:40 mixture and adding to the 1:80
mixture.
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11) After mixing well, take 200 J.lLof this mixture and add to the 1:160 mixture and
so forth, so do sequential doubling dilutions.
Part B: Sample substrate binding:
1) Remove slides with pre-fixed Hep-2 cells from freezer, remembering to log the
batch number down onto sample sheets and filling in the other appropriate
information, such as sample identification numbers.
2) Label each slide at the top with "ANA" and slide number. Number wells, place
the date at bottom of slide.
3) Place slides in the "damp box." This is a box with wet towels at the bottom.
Make sure they are level.
4) Apply 20J.lLof each sample to the appropriate well. Be careful to be neat and
make sure the edge of the meniscus reaches the borders of the well.
5) Stand in the damp box for 30 minutes to bind at room temperature.
6) THAW CONJUGATE at this time.
Part C: First wash to remove unbound antibodies:
1) Prepare the wash basin by filling about 2 cm deep with PBS.
2) Take slides and a wash bottle with PBS and tilt the slide to the side and
carefully spray off the sample over the catch basin, being careful not to let
samples run over other wells and contaminate.
3) Place slides in wash basin, submerging it in the PBS.
4) Repeat for all slides.
5) Place at room temperature for 20 minutes. It is not necessary to have it shaking.
6) Centrifuge conjugate for a couple of minutes at this time to shoot particulates to
the bottom of the tube.
Part D: Application of FITC-conjugate:
I) Remove slide from PBS solution and give a few good flicks to remove
excess PBS.
2) Since the slide is already wet, add just 10 J.lLconjugate to each well.
3) Incubate in the wet box for 30 minutes at room temperature.
4) NEVER let the wells dry-out.
NEVER EVER USE THE REMAINING DREGS OF CONJUGATE!!!
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This contains particulates that might ruin your final product or even appear like
speckled pattern ANA!
Part E: Final wash of conjue;ate:
1) Over the catch basin, squirt PBS over the slide. Since all wells are
covered by the same conjugate, you don't have to be as careful with run-
over this time.
2) Place slides in wash basin with the PBS (can use same PBS from
previous wash) for 20 minutes at room temperature.
Add Chlorox bleach to the solution in the basin when finished and mix and
sit for a while. Then dispose of as you would normal contaminated waste.
Part F: Mounting of slides:
1) Flick the slides a few times to rid it of excess PBS.
2) Put a drop of the DABCOIPBS solution over each well.
3) Place the cover slip on a towel.
4) Invert the slide and gently touch to cover slip starting from one side, to
not catch any bubbles.
5) After making sure there are no bubbles in the wells.
6) Seal the cover slip to the slide using fingernail varnish along the sides,
being careful not to put too much or cover the wells to obscure reading.
7) Wipe any excess glycerol solution off, especially from the back side so
that it doesn't stain the microscope.
Slides are now ready for scoring. They should be kept in the refrigerator at
4°C and should be read within 48-72 hours.
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Appendix4
Antinuclear Antibody (ANA) Data Collection/Entry Sheet
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Data Entry Completed: 0 Double Entry Completed: 0
ANA Slide Set-Up Record Sheet
Date Run: __ , __ , __ Slide No.:----
Slide Batch No.: _
ID: Q 0 ID:Pos. Neg Titre: Pos. Neg Titre:HMG Speck. Nucl Other HMG Speck. Nuc} Other
ID: 0 0 ID:Pos. Neg Titre: Pos. Neg Titre:HMG Speck. Nucl Other HMG Speck. Nuc1 Other
ID: G C0 ID:Pos. Neg Titre: Pos. Neg Titre:HMG Speck. Nucl Other HMG Speck. Nuc1 Other
ID: 0) 8 ID:Pos. Neg Titre: Pos. Neg Titre:
HMG Speck. Nucl Other HMG Speck. Nucl Other
ID: G 0 ID:Pos. Neg Titre: Pos. Neg Titre:
HMG Speck. Nucl Other HMG Speck. Nucl Other
Label
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Appendix 5
Data Dictionary for Antinuclear antibodies (ANA) in
Hepatitis C Study Dataset
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DATA DICTIONARY
Anti-nuclear antibody (ANA) dataset
Variable name Explanation Coding
ID Unique ID number for each patient 6-digit number
DNAID Unique ID number to identify the l-digit alpha followed
DNA sample in the laboratory by a 1-3 digit number
CENTRE The study center the patient is from 1= London, United Kingdom
2= Padova, Italy
3= Lund, Sweden
SERUM Unique ID number of serum 5-digit number
YOB Year of the patient's birth 4-digit number
RACE Patient's race 1=Northern European
2=Southern European
3=IndianlIndian subcontinent
4=B1ack African
5=North African
6=Eastern European
7=Afro-Caribbean
8=Oriental
9=South American
10=Middle eastern
AGE Age of patient in 2003 2-digit number
YOI Estimated year of acquisition 4-digit number
ofHCV infection, ifknown
DUR Estimated duration of infection as
of2003. Based on YOI variable
as above
1 to 2-digit number
AGEINF Estimated age at infection
Based on variables above
(AGEINF= YOI - YOB). For
individuals infected during their
first year of life, 1 is entered rather
than O.
1 to 2-digit number
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ROUTE most probable route ofHCY 1= injection drug use
acquisition 2= blood products
3=sex
4= occupational exposure
GENDER Patient's gender 1= male
2= female
POS Whether sample is ANA positive 0= negative
I=positive
PATIERN For positive samples, the 1= homogenous
pattern of ANA staining 2= speckled
3= nucleolar
4= other undefined pattern
COMMENTS Comments about the pattern, alpha characters
(for unusual patterns, if any)
TITRE For positive samples, the 1= 1: 40
highest positive titre 2= 1: 80
3= 1: 160
4= 1: 320
5= 1: 640
YRBXl The year of the patient's first 4-digit numberic
liver biopsy
BXNI necro-inflammatory score for 1-8 ordinal categorical
the biopsy
FSCORE The Knodell fibrosis score for 1-6 ordinal
the biopsy
RESP The patient's response to 1= non-responder
anti-viral therapy 2= sustained responder
3= relapsed responder
RXYEAR Year of anti-viral therapy 4-digit
ETOH Level of previous alcohol use 1= none
2=minimal
3= moderate
4=heavy
YGENO HCY viral genotype 1= genotype 1
2= genotype 2
3= genotype 3
4= genotype 4
88= mixed genotypes 1 and 2
263
Appendices
Appendix 6
List of Thesis-Related Publications
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Appendix 6
Thesis-Related Publications
1. Thursz MR and Vee LJ. Immunogenetics ofHCV Chronicity and Response to
Therapy. (in press: to be published in the Supplement for the 2003 Annual
Meeting of the European Association for the Study of the Liver (EASL)).
2. Vee U and Thursz MT. Genetic diversity in the major histocompatability complex
and the immune response to infectious diseases. In: Susceptibility to infectious
diseases: the importance of host genetics. Richard Bellamy, editor. (in press)
3. Vee U, Hall AJ, and Thursz MR. Comorbid conditions in chronic hepatitis C virus
infection: the role of autoimmunity. (In press: Proceedings of the 11th
International Symposium on Viral Hepatitis and Liver Disease)
4. Vee U, Perez KJ, Tang J. et a1.Association of CTLA4 polymorphisms with sustained
response to interferon + ribavirin therapy for chronic hepatitis C virus infection.
Journal of Infectious Diseases (2003) 187 (8); 1264-1271.
5. Knapp S, Vee LJ, Frodsham AJ, et a1.Polymorphisms in interferon-induced genes
and the outcome of hepatitis C virus infection: roles of MxA, OAS-J and PKR.
Genes and Immunity (in press).
6. Yee LJ, Kelleher PK, Goldin RD, et a1.Antinuclear antibody positivity in chronic
hepatitis C virus infection: correlates of positivity and clinical relevance (in
review)
7. Vee LJ, Knapp S, Burgner D, et a1. Inducible nitric oxide synthase (NOS2A)
haplotypes and the outcome of hepatitis C virus infection (in review)
8. Vee L1. Host genetic diversity and the outcome of hepatitis C virus infection: a
systematic review and meta-analysis. (in preparation)
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